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RÉSUMÉ
De plus en plus d’études démontrent que l’hyperglycémie et
l’activation du système rénine-angiotensin (RAS) sont des facteurs de
risque majeurs dans la pathogénèse de la néphropathie diabétique (DN).
L’existence d’un RAS local intrarénal est maintenant bien acceptée. Toutes
les composantes du RAS sont exprimées dans les cellules du tubule
proximal du rein. L’angiotensinogène est le seul substrat du RAS et est
exprimé principalement dans les RPTC; il est ensuite converti en Ang li
(forme biologiquement active), par la rénine rénale et l’enzyme convertrice
d’angiotensine (ACE). Les niveaux d’Ang li et l’expression génique du RAS
sont augmentés dans le diabète, indiquant que le RAS intrarénal joue un
rôle important dans la progression de DN. Le(s) mécanisme(s) de
régulation de l’expression génique d’AGT dans le rein par un milieu élevé
en glucose ainsi que l’insuline, demeurent cependant mal compris.
Afin d’identifier et des cloner ces protéines ainsi que définir leur action
sur l’expression génique d’AGT, les protéines nucléaires extraites des
IRPTC ont été séparées par électrophorèse en deux dimensions. Les
protéines positives ont été hybridées par Southwestern Blot, identifiées par
spectrométrie de masse et enfin confirmées par Western Blot. Nous avons
identifé deux protéines nucléaires de 48-kD et de 70-kD identiques aux
ribonucléoprotéines hétérogènes F (46-kDa hnRNP F) et hnRNP K (65-kDa
hnRNP K). Les cDNA de hnRNP F et hnRNP K ont été clonés des IRPTC
par RT-PCR et ensuite exprimés dans des clones bactériens. Les
recombinants bactériens de hnRNP F et hnRNP K sont liés à l’élément de
réponse à l’insuline (IRE)-AGT du rat, comme démontré par essai de
retardement sur gel (GMSA) et immunoprécipitation de la chromatine
iv
(ChIP). L’addition d’anticorps polyclonaux contre hnRNP F résulte en un
supershift dans le GMSA. La transfection transitoire de cDNA de hnRNP F
ou hnRNP Kdans des IRPTC a inhibé l’expression AGT au niveau mRMA
et protéine. D’autre part, le knockdown de hnRNP F ou hnRNP K par small
interference RNA augmente l’expression de AGT au niveau mRNA (et
protéine?) dans les IRPTC. De plus, hnRNP F interagit avec hnRNP F dans
les essais de pulldown et de Co-IP La co-transfection de hnRNP F et
hnRNP K inhibent l’expression génique d’AGT au niveau mRNA et protéine.
Un mileu élevé en glucose stimule hnRNP F ou hnRNP K tandis que
l’insuline inhibe leur expression dans les IRPTC in vitro et des RPTC de rat
in vivo. Nous avons établi des tranfectants stables d’IRPTC surexprimants
hnRNP F et des souris transgéniques surexprimant hnRNP F de façon
spécifique dans les RPIC in vitro et in vivo. Nous avons démontré que la
surexpression de hnRNP dans les RPTC peut prévenir la stimulation par le
glucose (25mM) d’AGI ainsi que de growth factor-31 (TGF-31) au niveau
mRNA et protéine, ainsi que l’hypertrophie cellulaire (ie: contenu total en
protéine de la cellule, incorporation [3H]-Leucine et expression protéique
de p27kinf) De plus, les souris transgéniques surexprimants HnRNP F
démontrent une atténuation de l’expression d’AGT et du récepteur TGF-31
Il au niveau mRNA ainsi qu’une diminution de l’expression de la protéine
p27’) et du ratio protéine/ADN dans les RPTC de souris diabétiques
induite au streptozotocin. Ces observatioms suggèrent qu’AGT est
modulée par HnRNP F et HnRNP K via la liaison avec l’IRE, action aussi
régulée par le glucose et l’insuline. Nous résultats démontrent aussi que
HnRNP F ou K pourrait jouer un rôle protecteur ou modulateur dans la
prévention de l’hypertrophie des RPTC dans le diabète et ses mécanismes
Vsont médiés via l’atténuation de l’expression génique d’AGT intrarénal et
de la voie de signalisation TGF-E31 in vitro and in vivo.
Mots-clé: angiotensinogène, hnRNP F, hnRNP K, glucose, Insuline,
élément de réponse à l’insuline, souris transgéniques, rein, hypertrophie
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ABSTRACT
Accumulating evidence has demonstrated that hyperglycemia and
renin-angiotensin system (RAS) activation are major risk factors in the
pathogenesis of diabetic nephropathy (DN). The existence of a local
intrarenal RAS has now been well accepted. AIl components of the RAS
are expressed in renal proximal tubular cells (RPTCs). Angiotensinogen
(AGT) is the sole substrate in the RAS and is expressed predominantly in
RPTCs and converts into biologically-active Ang II by renal renin and
angiotensin converting enzyme (ACE). Intrarenal Ang Il levels and RAS
gene expression are elevated in diabetes, strongly indicating that intrarenal
RAS activation plays an important role in the progression of DN. The
mechanism(s) of regulation of intrarenal AGT gene expression by high
glucose and insulin remain, however, incompletely understood. Previously,
our lab has demonstrated that an insulin-responsive element (IRE) in rat
AGT gene promoter that binds to two nuclear proteins with apparent
molecular weights of 48 and 70 kD from rat immortalized RPTCs (IRPTC).
The expression of two nuclear proteins in IRPTCs was up-regulated and
down-regulated by high glucose and insulin, respectively. To identify and
clone these proteins and to define their action on AGT gene expression,
nuclear proteins from IRPTC were separated by 2-dimentional gel
electrophresis, positive proteins were detected by Southwestern blotting
and identified by mass spectrometry and subsequently confirmed by
Western blotting. We identified that the 48-kD and 70-kD nuclear protein
were identical to 46-kD and 65-kD heterogenous ribonucleoprotein F
(hnRNP F) and hnRNP K. HnRNP F and K cDNAs were then cloned from
IRPTC by reverse transcriptase-PCR and expressed in bacteria. Bacterially
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expressed recombinant hnRNP F and K bound to rat AGT-IRE, as revealed
by gel mobility shift assay (GMSA) and chromatin immunoprecipitation
assay. The addifion of polyclonal antibodies against hnRNP F yielded a
supershift in GMSA. Transient transfection of hnRNP F or hnRNP K cDNA
in IRPTC inhibited AGT mRNA and protein expression. In contrast,
knockdown hnRNP F or hnRNP K gene expression by small interference
RNA enhanced AGT mRNA expression in IRPTC. Moreover, hnRNP F
interacted with hnRNP F in pulldown and co-immunoprecipiation assays.
Co-transfection of hnRNP F and hnRNP K further suppressed AGT mRNA
expression. Hyperglycemia stimulated and insulin inhibited hnRNP F and
hnRNP K expression in IRPTCs in vitro and rat RPTCs in vivo. We have
established stable IRPTC transfectants overexpressing hnRNP F and
transgenic mice overexpressing hnRNP F specifically in RPTCs in vitro and
in vivo. We demonstrated that overexpression of the hnRNP F in RPTCs
prevented the high-glucose stimulation of AGT and transforming growth
factor-f31 (TGF-1) mRNA and protein expression as well as cellular
hypertrophy, i.e., total cellular protein contents, [3H]-Leucine incorporation
and p27kIPl protein expression). HnRNP F transgenic mice displayed an
attenuation of AGT and TGF-31-receptor II mRNA expression as well as a
decrease of celi and nuclear volume, 27kiP1 protein expression and
protein/DNA ratio in RPTCs in streptozotocin-induced diabetic mice. Taken
together, these data suggest that AGI was modulated by hnRNP F and
hnRNP K through the binging with IRE and this was also regulated by
glucose and insulin. Our findings demonstrate that hnRNP F or K may play
a protective or modulatory role in preventing RPTC hypertrophy in diabetes
and its underlying mechanism is mediated via attenuation of intrarenal AGI
expression and TGF-131 signaling in vitro and in vivo.
Key words: Angiotensinogen, hnRNP F, hnRNP K, glucose, Insulin,
insuli n-responsive element, transgenic mice, kidney, hypertrophy.
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Chapter 1: Introduction
21.1 Anatomy and Function of the Kidneys
In humans, the kidneys are two bean-shaped organs, each about the
size of a fist and Iocated in the posterior part of the abdomen, on each side
of the spine. The right kidney sits just below the liver, and the Ieft kidney,
below the diaphragm, adjacent to the spleen. In a normal human aduit,
each kidney weighs 150 grams and is about 10 cm long, 5.5 cm wide and 3
cm thick (1; 2).
Both kidneys are surrounded by 3 layers. 1. The renal capsule covers
the outer surface of the entire organ. 2. Fat keeps them in place and
surrounds the renal capsule. 3. The renal fascia is a dense, fibrous outer
layer that also secures the kidneys to the posterior abdominal wall and
surrounding structures (3). The kidneys themselves are made up of 2
layers, the cortex and the medulla. The cortex is the outer layer, and the
medulla, the inner layer. Wthin the medulla are 8-18 triangular structures,
the renal pyramids. The tips of the pyramids are referred ta as renal
papillae. The renal cortex and the pyramids together make up the
parenchyma, which consists of approximately 1.25 million nephrons, the
functional units cf the kidneys that produce urine and help regulate blood
composition (1; 4).
The kidneys filter wastes (such as urea) from the blood and exctete
them, along with water, as urine. The nephrons consist of renal tubules and
renal corpuscles. The tubules are approximately 50 mm in length and
comprise the convoluted tubules (proximal and distal) and loop 0f Henle (4).
The proximal tubule, as a part of the nephron, can be divided into an initial
convoluted portion and a following straight (descending) portion. Fluid in
3filtrates entering the proximai convoluted tubule is reabsorbed into the
peritubular capillaries, inciuding approximateiy two-thirds of filtered sait and
water (65%) and ail (100%) filtered, organic solutes (primarily glucose and
amino acids). These functions of the renal tubules are performed by a
number of transporters and channels expressed at the apical and
basolateral membranes of the tubular cells (5).
1.2 End-Stage Renai Disease (ESRD)
ESRD (or kidney failure) is a slow, progressive loss of kidney functions
caused by inherited disorders, prolonged medical conditions or the
long-term use of medications (6; 7). If untreated, it is irreversible and fatal.
Renal replacement therapy (RRT), which includes hemodialysis, peritoneal
dialysis and renal transplantation, is the major treatment available since the
1960s for ESRD patients (8). ESRD has become a serious medical and
economic health problem in developed countries, including Canada (9; 10).
1.2.1 Epidemiology of ESRD
The Canadian lnstitute for Health Information (CIHI) is the national
information system that provides timely, accurate and comparable health
information on ESRD and other diseases in Canada.
1.2.1.1 Incidence of ESRD
The incidence of ESRD represents the number cf persons newly
diagnosed with the disease in a specific population in a given time period. It
is useful in medicai and epidemiological research examining the causes of
disease and the differences in subpopulations affected by these causes.
The incidence of ESRD in Canada and other countries during 1998 to 2003
is shown in Figure 1. Over 150 new cases have been reported since 1999,
4and this number continues to tise every year. If we examine the data in
more detail by age group, the rate among persons aged 19 years or
younger was relatively stable, and decreased by 5% in young adults (20 to
39 years old). However, it increased by 32% among those between the
ages of 40 to 59 years, and by 17% in people over 60 years (11).
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Figure 1. Incident ESRD RRT patients, selected countries, from 199$-2003(Crude Rate PMP)
1.2.1.2 Prevalence of ESRD
ESRD prevalence represents the number of persons in a specific
population who have ESRD at a given time point. Figure 2 shows that
ESRD prevalence increased dramatically, by almost 2-fold from 1990 to
2004 in Canada. At the end of 2004, 18,827 patients were on dialysis and
12,099 were living with a functioning kidney transplant, for a total of 30,924
Canadians with kidney failure registered in the CIHI (11).
5Source Canadian Organ Replacement Register, Canadian Institute for Health Information Ç2OŒ)
Figure 2. Prevalent ESRD patients at year-end, Canada,1990-2004 (Number)
1.2.2 Health Care Costs of ESRD
The health care costs incurred by dialysis and transplantation are
enormous. The average cost of peritoneal or hemodialysis is
$50,000-75,000 per patient year(12; 13). At least 1 billion Canadian dollars
were spent to maintain the quality of life of ESRD patients in last 5 years.
Since its incidence and prevalence have increased every year in Canada,
the economic burden of ESRD in Canada has become a serious probtem.
Effective and economic treatment as well as prevention of ESRD onset are
major ways of reducing its clinical incidence and could resuit in
considerable cost savings for the Canadian public healthcare system.
1.2.3 Causes of ESRD
According to the CIHI, there are several major causes of ESRD
(Figure 3). Diabetes and hypertension are the number J and 2 causes cf
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6kidney disease, respectively, in the USA and Canada. Besides this, kidney
failure patients aged 65 and older had the highest overali rate of diabetes
between 1995 and 2004, more than doubling from 124 per million in 1995
to 270 per million in 2004.
Unknin
Other
Diibetes
Diabetes is the leading cause of ESRD, accounting for more than 40%
of ail registered ESRD patients in Canada, up from 25% 10 years ago, a
paftern that is also being encountered in the USA. In addition, it is
noteworthy that diabetes types account for these increases. While the
number of ESRD patients with type 1 diabetes declined from 526 in 1995 to
303 in 2004 (down 42% in 10 years), the number of patients with type 2
diabetes more than tripied over the same period, from 540 to 1,836.
Investigating effective ways of reducing the prevalence of diabetes couid
Vascular disease
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Source: Canadian Organ Reptacement Register, Canadian Institute for Health Information (2006)
Figure 3. Distribution of incident ESRD patients by primary diagnosis,
Canada, 1993-2004
7heip decrease the devastating health consequences associated with it and
ESRD.
1.2.4 Diabetes and the Renin-Angiotensin System (RAS)
Diabetes is a chronic disease characterized by hypergiycemia and
complications 0f multiorgan dysfunction, i.e. the kidneys, heart, brain and
eyes. In Canada, ovet 2 miflion people have diabetes, of which there are 3
main types: type 1 (insulin-dependent diabetes mellitus, IDDM), type 2
(non-insulin-dependent diabetes mellitus, NIDDM), and gestational
diabetes (caused by the hormones of pregnancy). The most common types
are type 1 and type 2, with 10 to 21% of diabetes patients developing
kidney disease (11).
Considerabie evidence suggests that the intrarenal RAS plays an
important role in diabetic nephropathy (DN). Landmark studies by
Anderson et al. (14) have revealed the superiority of
angiotensin-converting enzyme (ACE) inhibitors (ACEi) in haiting the
progression of renai disease. Conversely, chronic infusion of angiotensin
(Ang) II produces marked giomerular and tubulointerstitial injury in the
kidneys (15-17). These studies suggest that Ang II is pivotai in the
pathophysiology of chronic renai disease. However, it is difficuit to separate
the effects of blood pressure (BP) reduction from these agents in whole
animais and humans. This is because patients with overt DN generaily
develop systemic hypertension, an adverse factor in ail progressive renai
diseases and especially SO in DN. b elucidate the non-hemodynamic
effects of Ang il on DN, finding relevant animai models has become a
$challenge for researchers. Furthermore, there is close interaction between
the RAS and transforming growth factor-beta (TGF-3) signaling (18-20). In
fact, many profibrotic effects ofAng Il are mediated by TGF-3 stimulation.
1.2.5 Diabetic Nephropathy
DN, a chronic renal disease characterized by glomerulosclerosis,
fibrosis of the tubulointerstitial microenvironment, and tubular atrophy (21),
is due to Iongstanding DM. The deposition and decreased turnover of
extracellular matrix (ECM) proteins, including fibronectin, collagen types I,
III, and IV, are important components of the scarring observed during the
evolution of glomerulosclerosis and tubulointerstitial fibrosis (22). TGF-f3
serves as a paradigm of profibrogenic cytokines (23). Its function in the
renal pathophysiological process has been investigated by Border et al.
(24).
DN is one of the most significant long-term complications in terms of
morbidity and mortality for individual patients with diabetes. Although both
type 1 and type 2 DM lead to ESRD, the majority of patients are those with
NIDDM. In a prospective study in Germany, the 5-year survival rate was
less than 10% in the elderly population with type 2 diabetes, and no more
than 40% in the younger age group with type 1 diabetes. The exact cause
of DN is unknown, but various postulated mechanisms are hyperglycemia
(causing hyperfiltration and renal injury), advanced glycosylation products,
and the activation of cytokines (8; 25; 26).
1.2.6 CeIlular Hypertropathy in Diabetic Nephropathy
9Diabetic nephropathy is typified by renal hypertrophy, increased
glomerular filtration rate (GFR), and increased urinary albumin excretion
(27; 28). It has been presumed that early hypertrophic changes in the renal
ceNs are integral to the subsequent development of more severe renal
histopathologic changes. Nevertheless, the mechanisms initiating and
regulating the functionai changes in renal ceNs remain incompietely
characterized. The proximal tubuie is uniquely susceptible to a variety of
metabolïc and hemodynamic factors associated with diabetes. Renal
function and prognosis correlate better with structural lesions in the tubuB
and cortical interstitium than with classical glomerular changes of diabetic
nephropathy (29). The proximal tubules show a variety of poorly
characterized changes, which have Ied to the notion that tubular injury
represents a “final common pathway” for proteinuric renai injury. However,
tubular hypertrophy, reduced organic ion transport, and other tubular
changes are already apparent before the onset of proteinuria in diabetes. It
seems reasonable to assume that cytokines and polypeptide growth
factors including inhibitory factors such as TGF-beta induce in concert,
rather than as single factors, tubular hypertrophy (30).
Tubuiar celis can undergo hyperplasia or hypertrophy, two totally
different growth responses. Hyperplasia with mitogenesis of tubular cells
plays a central role in the regeneration of functional tubular epithelium
subsequent to acute tubular necrosis. The molecular mechanisms how
mitogenic signais are transduced to the nucleus are relatively welI
characterized. In contrast to the hyperplasia, celiular hypertrophy is less
well understood. Hypertrophic celis are arrested in the Gi-phase of the cell
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cycle and increase their size, protein and RNA content, but do not replicate
their DNA normally. Such an eniargement of tubular cefls often occurs in
more chronic situations of renal damage in which remnant nephrons adapt
their function to the increasing need. However, evidence exists that
hypertrophic tubules are finaliy joined into the process of maladaptation of
renai function leading to tubular atrophy, interstitial scarring, and
progression of renai disease (31).
1.2.7 Hyperglycemia and Kidney lnjury
Ihe critical role of hyperglycemia in the genesis of DN has been
established by ceil culture studies, experimental animal models, and clinicai
triais. Certain cytokines and growth factors have been identified as likely
mediators of the effects of high ambient glucose on the kidneys, and
prominent among them is TGF-, a prototypical hypertrophic and fibrogenic
cytokine. TGF-p overexpression has been demonstrated in the glomerular
and tubuiointerstitial compartments of experimental diabetic animais (32).
The TGF- receptor signaling system is also triggered, as evidenced by the
upregulation of TGF-f3 type 2 receptors and activation of the downstream
Smad signaling pathway (33). Treatment of diabetic mice with neutralizing
anti-TGF-13 antibodies prevents the development of renal hypertrophy,
mesangial matrix expansion, and the decline in renal function. Antibody
therapy also reverses the estabiished lesions of diabetic glomerulopathy
(34). TGF-3 may also contribute to the cellular hypertrophy found in
petsons with DN. Ceil culture studies suggest that high-glucose
concentrations stimulatethe hypertrophy of proximal tubular and mesangial
celis (35; 36) as weIl as the production of matrix moiecules, such as
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fibronectin and collagens in these ceNs, and even in epithelial, endothelial,
and interstitial-fibroblastic cells (37-39). Such investigations strongly
support the hypothesis that overactivity of the TGF-3 system in the kidneys
is a crucial mediator of diabetic renal hypertrophy and mesangial matrix
expansion.
Hyperglycemia may activate protein kinase C (PKC) (40; 41), which
may contribute to renal disease and other vascular complications of
diabetes. Hyperglycemia may also activate Ang II, which is the bioactive
peptide of the RAS, and has hemodynamic and non-hemodymic effects in
the kidneys, as shown in Table 1.
Table 1. Proposed mechanisms ofAng II effects in DN
Hemodynarnic effects Non-hemodynamic effects
Systemic hypertension Induction of renal hypertrophy and ceil proliferation
Systemic and renal vasoconstriction Stimulation ofextracellular maffix synthesis
lncreased glomerular capillaiy pressure Inhibition of extracellular matrix degradation
and pemieal,ility Stimulation ofcytokine (e.g., TGF- , VEGF)Mesangial celi contraction leading to production
reduction of tue filtration surface area Stimulation of superoxide production
Modited from Ref. 21
1.3 The RAS
Ihe RAS, or the renin-angiotensin-aldosterone system, is an
extracellular hormonal system that plays an important role in regulating
blood volume and systemic vascular resistance, which together influence
cardiac output, arterial pressure, and electrolyte homeostasis (42). In this
tightly-regulated system, physiological regulators of BP and fluid balance
induce the production of potent vasoactive Ang peptides by the sequential
proteolysis of angiotensinogen (AGT) prohormone. AGI is the only known
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precursor of Ang peptides, whose circulating concentrations influence the
tonic activity of the RAS (43). AGI abundance is controlled at the
transcriptional level by hormonal and celi type-specific regulators (44; 45).
AGI has been identified as a non-inhibitory member cf the serine
proteinase inhibitor (serpin) family. Although the most abundant source of
plasma AGT is the liver, Northern blotting and reverse
transcription-polymerase chain reaction (RT-PCR) techniques have
confirmed AGT mRNA expression in a wide range of tissues, including the
kidneys, brain, vascular tissue, adrenai glands, placenta, and leucocytes
(46; 47). The sequencing of rat (r) and human (h) AGI genes has
increased our understanding of this protein and its role in the physiology
and pathogenesis of human disease (48; 49). Early observations on the
reguiation of AGI are now explicable at the molecular level, with
identification of the core promoter, the hormone, acute phase responsive
elements and tissue-specific enhancers (45). The role of AGI in DN has
been studied.
Ang li, the most important biologically-active end product of the RAS,
is an extremeiy potent vasoconstrictor and a major determinant of sait and
water homeostasis. lt is thought to act as both a circulating hormone and
paracrine factor. However, the physiological significance of paracrine Ang
II is stiil flot weii-understood.
1.3.1 Biosynthesis of RAS Members
The RAS is composed of the precursor moiecule AGT a peptide
related to the family of serpins. A unique substrate for the circulating
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protease renin (EC 3.4.23.15), AGT is derived mainiy from juxtagiomerular
celis of the kidneys, and aiso from many other tissues and organs (46; 47;
50). Figure 4 illustrates the biosynthesis pathway of the RAS.
Prorenin, the inactive precursor of renin, circulates in human plasma in
excess of renin, at up to 100 times higher concentrations (51). Studies in
transgenic (1g) animais displaying prorenin expression show that prorenin
activation at tissue sites might invoive proteolytic removal of its prosegment
(52-54). Alternativeiy, activation could occur in a non-proteoiytic manner, for
instance, through binding to a receptor. lndeed, Ichihara et ai. have
proposed recentiy that human prorenin has so-called gate and handie
regions for non-proteolytic activation through its putative receptors (55).
Nguyen et ai. have cloned a prorenin receptor, as prorenin binding to it
aiiows prorenin to become fuiiy active enzymatically in a non-proteolytic
manner (56). It has been reported recently that prorenin binding to the
prorenin receptor plays a pivotai role in the deveiopment of DN by a
mechanism that involves the receptor-associated prorenin system (55; 57).
AGT hydrolysis by renin is rate-limiting for the whole system and resuits in
production of the peptide Ang I, which is converted to the peptides Ang Il
and Ang III by ACE (EC 3.4.15.1) and aminopeptidase A (APA) (EC
3.4.11.7), respectiveiy. These peptides act on 2 membrane-bound Ang II
receptors (AT1 and AT2) belonging to the 7-transmembrane
G-protein-coupled receptor family.
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Figure 4. Enzymetic pathway of bioactive angiotensins generation.
Besîdes the circulating renin of renal origin, there are at least 2
categories of tissue renin-like enzymes (isorenins) (58). Ihe first category
is represented by tissue cathepsins (G, D, and E), which are lysosome
serine-proteases, ensuring local capacity for the lysis of AGI to Ang I, as
the common precursor of bioactive Angs. While cathepsin G is present in
human neurotrophils and activates circulating prorenin (59; 60), cathepsin
D has been found in the heart and vascular smooth muscle and stimulates
myocyte growth (61). In turn, cathepsin E is involved in Ang I and
endothelin biosynthesis (62). Ihe second category of tissue renin-like
enzymes is represented by tonin (59), a cytosolic serine-protease that
allows direct Ang II synthesis from tissue AGI.
Classical ACE 1, a zinc metallopeptidase Iocated predominantly at the
luminal surface of the pulmonary vascular endothelium, cleaves the
histidylleucine dipeptide from inactive Ang I, producing active Ang 11(63).
Being a dipeptidylcarboxypeptidase, ACE1 is rather nonspecific in the way
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it hydrolyzes several substrates, including bradykinin and opioid peptides
(64; 65).
Ang II is detected in plasma and tissues, even when ACE1 is inhibited,
indicating a role for other enzymes in the conversion of Ang I to Ang II. In
the human heart, for instance, chymase is the major Ang Il-forming enzyme
(66). It belongs to the family of myocardial cathepsins with Ang-forming
activity. Unlike the converting enzyme present mainly in the atria and
endothelial cells, chymase has a predominantly ventricular Iocalization and
does not inactivate bradykinin (67).
Recently, a new homologous ACE, ACE2, has been discovered in the
heart, kidneys, liver, and intestine (68). This new converting enzyme
induces hydrolysis of the Iast amino acid of Ang I, producing Ang 1-9, an
inhibitor ofclassicalACEl and a precursor of vasodilating Ang 1-7. Ang 1-9
thus limits the formation and actions of Ang II, contributing to
autoregulation of the local circulation (69). In addition, the proteolytic
activity ofACE2 is 400 times higher with Ang II as substrate than Ang 1(70).
ACE2 may function as a tissue-specific, negative feedback regulator 0f the
activated RAS, e.g. by vasodilation mediated by Ang 1-7 and bradykinin
(71). The actions of both ACE1 and its homologue ACE2 seem to be more
complex than originally believed. The precise interplay between ACEI,
ACE2 and their substrates and by-products is stili unclear.
Angiotensinases are peptidases that generate active or inactive Ang
peptides, altering the ratio between their bioactive forms. Ang II is
converted to Ang III by APA, whereas Ang III is inactivated by
aminopeptidase N (APN) (72; 73). Endopeptidases use Ang I as a
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substrate to form Ang 1-7 (74; 75). Tissue carboxypeptidases and
proteolytic enzymes (pepsin, trypsin, chymotrypsin, etc.) also contribute to
the degradation of bioactive Angs to inactive fragments (76).
The major biological actions of Ang Il are mediated by 2
weII-characterized receptors, type 1 (AT1) and type 2 (AT2) (Table 2) (77).
In aduit tissues, the Ail receptor is widely distributed in the vasculature,
kidneys, adrenal glands, heart, liver, and brain (50; 78). The AT2 receptor is
widely distributed in the fetus and then expressed minimally in adults. In
healthy aduits, the AT2 receptor is present only in the adrenal medulla,
uterus, ovaries, vascular endothelium, and distinct brain areas (50; 78).
Table 2. Receptors for angiotensin related peptÏdes
Type Ligand Distribution Function
Ail Ang Il Widespread, Sait and water
(kidneys, blood homeostasis,
vessels, etc.) blood pressure
AT2 Ang li Fetal tissue, Apoptosis,
adrenal, ovaries, growth inhibition,
brain, endothelium vasodilation
Mas Ang l-7 Kid neys, heart Blood flow,
renai Na
AT4 Ang III Brain, heart, Blood 110w,
Ang IV adrenal, kidneys, renal Na,
blood vessels memory
Ang receptors share several similarities. They are both G-coupled
polypeptides that contain approximately 360 amino acids with 7 ceIl
membrane-spanning regions (79; 80). Both genes share sequence
homology of approximately 30% (Figure 5) (81). As a resuit, they are
functionally distinct and employ different signal transduction pathways (80;
82). For example, the Ail receptor mediates the hemodynamic actions,
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endocrine functions, and mitogenic effects of Ang ii in the kidneys (82; 83),
whereas the AT2 receptot regulates fetal organ deveiopment and exerts
both vasodiiatory and antiproliferative effects (84; 85). The AT2 receptor
ïnteracts with and modulates the actions perpetuated by the Ail receptor,
likely antagonizing many of them. For instance, AT2 receptor deletion in
mice treated with a nitric oxide synthase inhibitor is associated with
hypertension as well as reduced sodium and water excretion (86). In
contrast, mice with intact AT2 receptors remain normotensive and maintain
normai sait and water homeostasis.
AT1 1 7-transmembrane domain 35g
NP_œ0677. 1
AT2 1
_____7-transmembrane
domai n 363
NP_œœ77.2
Figure 5. Structure of ATI and AT2 receptors.
1.3.2 Historical View of the RAS
After 1898, when Tigerstedt and Bergman discovered a substance in
both watery and alcoholic extracts of the rabbit renal cortex, renin was
found. ihis is seen as one of the great advances in physiology, although it
had liftle impact at that time (87). Now, more than a century later, the fuii
physiological and pathoiogical significance of renin or even the whoie RAS
is no longer doubted by medical scientists.
Ciassically, the RAS has been considered to be a hormonal circulating
system. Through vasoconstriction and aldosterone secretion, Ang Ii plays
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an important role in the maintenance of BP and electrolyte balance. Since
the identification of the classical enzyme cascade that produces active Ang
Il in circulating blood, experimental support has accumulated in favour of
renin-like activity within many tissues and organs (88). Thus, the notion of
the extrarenal RAS was established, leading to the concept of the RAS as
a unitary hormonal system, with circulating and tissue components.
During the last decade, it has been established that, apart from its
classical actions, Ang Il has various other effects induced by direct impact
on its receptors or via the local actions 0f Ang metabolites. Ihus, the RAS
has been postulated to be a complex humoral system with endocrine,
paracrine, autocrine and intracrine properties (89).
1.3.3 General Properties of RAS Members
The contributions cf the RAS to the reg ulation cf arterial pressure and
the physiopathology of hypertension have long been recognized. It is
important to understand that circulating AGT concentrations are generally
quite high, being more than 1,000 times greater than plasma Ang I and Il
concentrations (90-92). Figure 6 depicts the representative plasma AGT
concentrations in rats, expressed as pmol/ml, while Ang I and Ang li
concentrations are expressed as fmol/mI, indicating that active Ang Il
concentrations in plasma are a small fraction of Ang Il available in the form
of AGI (91). Therefore, even small relative changes in the rates of Ang I
and Ang Il generation may make large absolute differences in circulating
concentrations. Nevertheless, changes in AGI synthesis and release
occur slowly and, thus, their effects are flot as dynamic as the effects cf
changes in plasma renin concentration (44; 93).
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Figure 6. Tubular and interstitial formation, secretion and uptake 0f
angiotensin (Ref. 91).
As discussed above, Ang Il exerts its effects via Ang receptors, which
trigger intracellular signaling processes. In response to Ang II stimulation,
the Ail receptor interacts with various heterotrimeric G proteins, inducing
the phosphorylation of tyrosine kinase (94). ihe intracellular signaling
processes are multiphasic, leading to various biological actions. AT1
receptor activation results in increased protein tyrosine phosphorylation
and mitogen-activated protein kinase (MAPK) Activation. ihese processes
are associated with growth factors, cytokines, and inflammatory agents.
ihus, in addition to its potent vasoconstrictor actions, Ang Il has
proliferative and pro-inflammatory properties (95).
One of the earliest detectable events arising from Ang Il stimulation is
Ail signaling through phospholipids with the involvement of
phospholipase C (PLC), PLD and PLA2. While the stimulation of PLC
induces rapid 1 ,4,5-inositol triphosphate production and diacylglycerol
(DAG) release, PLD hydrolyzes phosphatydylcholine to phosphatidic acid
and choline. PLA2 is responsible for arachidonic acid release from celi
Interstjtium
AGT ANG I 1 pmol/mI * ANG II 3 pmollml
(from Circulation) f
ACE
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membrane phospholipids (94). ihe phospholipid-derived second
messengers produced by Ang ll-activated PLs induce multiple subsequent
events (Ca2+ release from the sarcoplasmic reticulum, PKC activation by
DAG, eicosanoid generation, etc.).
The Ai2 receptor may counteract some of the actions of the Ail
receptor. Found in large amounts in fetal tissues, the Ai2 receptor is
considered to be a factor that stimulates growth and development.
Preferentially expressed by various secretary celis, it is activated by both
circutating and locally-generated Angs (96). As already noted, AT2 has
antagonistic properties, being involved in local blood flow control as a
vasodilating mechanism (97).
It has been demonstrated that Ang Il exerts opposite effects on the
growth cf certain ceils within blood vessels by binding to either the Ail or
Ai2 receptor. Ang li induces celi proliferation by activating its Ail receptor
and inhibits cell growth by stimulating the A12 receptor in different cell
types (98). ihe growth-suppressing effects mediated by the AT2 receptor
do flot involve repression cf fos and c-jun gene expression, but are evoked
through the inhibition of cyclin Dl expression and cyclin Dl-associated
kinase activity (99). Furthermore, Ai2 receptor stimulation modulates Ail
receptor-mediated vasoconstriction, and altered Ai2 receptor function may
contribute to an exaggerated vasoconstrictor action of Ang lI (97).
Apoptosis is another biological phenomenon which seems to be triggered
by the stimulation cf Ai2 teceptors. Elevated A12 receptor levels have
been observed in the brain of rats after global ischemia, eventually leading
to delayed neuronal cell death (100).
In addition te its multiple actions, Ang Il also functions as a precursor
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of its active fragments, represented by Ang III [2-8], Ang IV [3-8], Ang V
[3-7] and Ang l-7 (Figure 4). ihe heptapeptide Ang III has
physio-pharmacological effects similar to those of Ang Il (58; 89; 101-104),
mediated by their common receptors, Ail and Ai2 (103). Ang IV is
involved in blood flow regulation, exploratory behavior, learning, memory,
and neuronal development (103). It has been demonstrated that the
inhibitory influence of Ang li via Ail, and a facilitory role of Ang IV via its
receptor Ai4, in the neuronal firing rate, associative and spatial learning
(105).
Ang l-7 produces vasodilation, diuresis and antiproliferative reactions
through a specific receptor (Mas). The vasodilating effects of Ang 1-7,
more intense in vessels with an intact endothelium than in those with the
endothelium removed, are accompanied by the release of nitric oxide (NO),
kinins, and prostaglandins (76). ihrough inhibition of the pressor and
proliferative actions of Ang Il, Ang 1-7 behaves like e true counteracting
factor. In agreement with these data, possible balance has been
hypothesized between the vasoconstrictor and hypertensive properties of
Ang Il and the actions of Ang 1-7 (69). Ang 1-7, one of the active
components of the RAS, is involved as a possible counter-regulatory factor
in the vasoconstrictor effects ofAng II.
1.4 The Local RAS
Over the last 3 decades, it has become increasingly clear that
bioactive Ang peptides can be generated, not only in the systemic
circulation, but also as local hormones in several tissues and organs. Since
aIl components of the RAS have been detected in many tissues and organs,
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numerous investigations have shifted their focus from its endocrine to its
autocrine/paracrine role in specific tissue functions, such as tissue growth
and differentiation.
The localization and expression of key RAS components, notably AGT
and renin, which are mandatory for the presence of tissue RAS, have been
reported in a wide range of tissues (47; 106; 107). The expression of local
RAS components in tissues such as the brain, heart, kidneys, adrenals,
and gonads has led to the proposition that these components may either
potentiate systemic functions, or have entirely separate activities meeting
the specific needs of individual tissues (107-109). There is accumulating
evidence that changes in tissue/organ-specific RAS may be associated
with the pathophysiology of respective tissue/organ functions, giving rise to
the possibility that drugs acting on tissue RAS could ameliorate some of
these disorders (110).
1.4.1 Discovery of the Local RAS
Evidence accumulated over decades has expanded significantly by
more recent findings that have increased the complexity of the RAS.
Different Ang receptors and signal transduction pathways have been
characterized. Moreover, additional truncated peptides, such as Ang 1-7,
have been identified, and alternative Ang Il formation by non-renin and
non-ACE pathways has been reported. These resuits have modified our
view of the RAS to the concept of “local” or “tissue” RASs. This concept is
based on flndings of RAS components in “unlikely” places (such as “kidney
enzyme” renin in the brain), where endocrine actions of the system cannot
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be explained (111-113). This, in turn, has leU to new hypotheses and
functional concepts of local RAS actions based on the tissue synthesis of
Ang Il.
The overexpression of RAS genes in Tg mice and rats as well as the
knockout of these genes in mice have fostered detailed studies on
functions of the local RAS (113). It has also become increasingly clear that
these systems are flot isolated entities, but can interactwith the endocrine
RAS as well as other peptide systems (such as the endothelin system) at
multiple levels.
Early controversies surrounding the novel concept of tissue RAS arose
from the question of local synthesis versus uptake from the circulation. A
case in point is the controversy between investigators after the
demonstration 0f renin expression in the heart (75; 114) and those
questioning local renin synthesis. This controversy was aftributed to the
fact that renin mRNA in the heart could only be demonstrated
inconsistently, suggesting that studies measuring cardiac reninwere biased
by artifacts from contamination with plasma renin or active renin uptake
from the circulation. The issue should not threaten the concept of the local
RAS, since either mechanism could contribute to local AGT synthesis and
actions. Modem concepts of the tissue RAS are therefore
function-oriented.
1.4.2 The Local RAS in the Kidneys and Its Function
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The multiple intrarenal actions of Ang Il are based on its predomînantly
local synthesis and the presence of Ail receptors within glomerular
vessels and various tubular segments. A density gradient of these
receptors has been demonstrated by their much higher amounts in
superficial than in juxtamedullary glomeruli. Ang receptors can be found
mostly in the basal membrane of the tubular epithelium and mesangial cells.
ihis distribution provides the contractile effect of the peptide on mesangial
cells and the control of proximal sodium and water reabsorption. Proximal
tubular sodium transport is stimulated by enhanced sodium/hydrogen ion
antiporter activity on luminal membranes (115). lncreased
sodium/potassium pumps and sodium/bicarbonate co-transporters on the
basolateral membranes of proximal tubular celis (PiCs) also enhance
sodium reabsorption (116; 117). Ang Il augments sodium reabsorption
through actions on sodium/potassium pumps in the medullary thick
ascending limb and epithelial sodium channel of cortical collecting tubules
(117; 118). At the functional level, Ang li contributes to control of the
glomerular filtration rate (GFR).
Aside from its hemodynamic effects, Ang Il promotes other processes
in the kidneys. It perpetuates the production of nephrotoxic reactive oxygen
species (ROS), and stimulates celI proliferation as well as tissue
remodeling by enhancing the synthesis of profibrotic cytokines and growth
factors. ihe overexpression of chemokines, chemotactic factors, and celi
adhesion molecules contributes to abnormal cellular proliferation and renal
fibrosis. Collagen deposition is also enhanced through the inhibition of
proteases that normally function to degrade abnormal tissue proteins (119).
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Together, these effects increase the development of glomerulosclerosis
and tubulointerstftial fibrosis (119; 120).
At the same time, the vasa recta and peritubullary capillaries, being
most sensitive to the vasoconstricting action of Ang Il, contribute to both
tubulo-glomerular feedback and the control of water and ion elimination.
Ang II participates in the long-term regulation of arterial BP through such
volume regulatory mechanisms.
1.5 Activation of the Local Renal RAS in DN
Sustained interest in dissecting the pathophysiology of DN has leU
many to focus on renal hemodynamics. One factor that has fueled this
interest is the unequivocal benefit derived from ACE inhibition in DN.
Baseline plasma renin activity is found to be reduced in type 2 diabetic
patients. The renovascular response to an Ang antagonist is substantially
greater than normal, indicating intrarenal RAS activation flot reflected in
plasma levels (121). Thus, investigators are searching for factors that
evoke RAS activation in diabetes. Hyperglycemia is a logical candidate
(122-124).
1.5.1 AnginDN
The beneficial effects of ACEi or Ang receptor blockade in the
prevention of diabetic renai disease suggest that Ang Il is a major mediator
of progressive renal injury (25; 125-127). However, measurement of the
activity of circulating RAS components largely points to suppression in DN
(121). These observations indicate local renal tissue activation of the RAS
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or increased intrarenal sensitivity to Ang II, especially at Ail receptors, in
DN.
mRNA and protein levels of renin are elevated at the onset of DN in
spontaneously or streptozotocin (SIZ)-induced diabetic rats (128). In early
DN, proximal tubule renin mRNA is signiflcantly upregulated, with no
change in AGT or ACE mRNA (129). Ihis process is reversed by insulin
therapy. In addition, an increase in intrarenal AGI mRNA has been
reported in diabetic rats, implying heightened AGI synthesis by proximal
tubules (128; 130). In our Iab, we have discovered that hyperglycemia
stimulates AGI synthesis in a concentration-dependent manner in
association with augmented AGT mRNA expression (131). A
glucose-response element has been located on the AGI gene promoter
that might mediate this effect (129). Recently, we also found that
hyperglycemia increases AGT gene expression via ROS in rat proximal
tubules, providing evidence of intrarenal RAS activation in DN (132).
In diabetic rat and human kidneys, ACE1 is redistributed towards
glomeruli and the renal vasculature but away from the proximal tubules
(130; 133). These studies suggest that glomerular ACE mediates nephron
injury, possibly by increasing local intraglomerular Ang II formation. In
cultured rat mesangial cells, high-glucose levels stimulate Ang II production
in a concentration-dependent manner in association with augmented
IGF-13 production (134). Nevertheless, whole-kidney Ang II levels in
diabetic animal models have been reported to be elevated, decreased or
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unchanged (128; 135-137). Howevet, whole-kidney levels probably do flot
reflect Ang II at specific nephron sites.
1.5.2 Ang Receptors in DN
Several studies have documented the expression of renal ATI and
AT2 receptors in DN. Reduced renal expression of the Ail receptor has
been reported in rats after 3 weeks of STZ-induced diabetes and also in
diabetic patients (138). However, another investigation found no significant
change in AT1 receptor expression, but reduced A12 receptor expression
in the kidneys of rats with early (2-week) STZ-induced diabetes (139).
Recently, an experiment was performed on spontaneously hypertensive
rats (SHR) after 32 weeks of STZ-induced diabetes. In Iong-term DN in the
context of hypertension, increased albuminuria and renal structural injury
were accompanied by the decreased expression of genes encoding Ail
and Ai2 receptors and respective proteins in the kidneys (140). The
downregulation of receptor expression implied reduced receptor synthesis,
as opposed to the inability of Ang II to internalize and desensitize the AT2
receptor. The decline in renal AT2 receptor expression in diabetic
Wistar-Kyoto (WKY) rats without systemic hypertension and with less
prominent renal injury was consistent with a glucose-dependent mode cf
AT2 receptor regulation.
1.5.3 Ang Il-induced DN
Ang Il has many actions that might cause or contribute to DN (Table 1).
It is produced by mesangial ceils, in which its biosynthesis is increased by
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glucose (134). ihus, mesangial ceils might have their own self-contained
RAS, and hyperglycemia could stimulate its activity, leading to celiular
contraction with reduced filtration surface area (141). Both glucose and
Ang Il stimulate ECM formation, and collagen accumulation in mesangial
ceHs is blocked by ATI receptor inhibition (134; 141). iGF-3 is an
important mediator of coilagen accumulation and fibrosis. Because
glomeruli from diabetic animais and humans have increased mRNA
encoding TGF-13, iGF-3 contributes to the pathogenesis of DN (142). Ang
Ii stimulates mesangial celi matrix biosynthesis via the Ail receptor, and
this is mediated by TGF-3 (16). in rat mesangiai cells, glucose-induced
TGF-13 secretion is abrogated by Ail receptor blockade (134). in humans,
the progression of DN is elicited, at least in part, by Ang il action via iGF-3
(143). These observations suggestthat glucose stimulates Ang li synthesis,
leading to increased TGF-3-induced matrix accumulation.
Several studies have reported Ai2 receptor downregulation in diabetic
animai modeis (139; 140). if intrarenal Ang II production is augmented in
diabetes, Ai2 receptor downregulation could create an imbaiance in which
Ail receptor stimulation is unopposed. A reduction of renai nitric oxide
(NO) in diabetes could occur because of diminished NO synthesis,
decreased availability of the substrate L-arginine, or failure of the Ai2
receptorto generate NO (25; 139; 144).
in summary, these data and other investigations indicate that
intrarenal RAS activation might piay an important role in DN.
1.6 Clinical irials of RAS Blockade in Diabetic Patients
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Because intrarenal RAS activity contributes to DN, many clinical trials
have explored the effects of RAS blockade and obtained surprising resuits
in hypertensive patients with or without diabetes. Since the mid-1980s,
numerous clinical studies have assessed the metabolic effects of ACEI or
Ang receptor blockers (ARBs). Besides these inhibitors, a novel direct
renin inhibitor, Aliskiren, has just become available in the USA, Switzerland,
and Europe. The Iong-term potential of Aliskiren and direct renin inhibition
is being investigated in a clinical program known as ASPIRE HIGHER,
focusing on the benefits of the drug in hypertensive patients with heart
failure (HF) or kidney failure. Preliminary data from this program indicate
that BP is reduced in these patients (145).
16.1 Clinical Trails ofACEi in Diabetic Patients
Six clinical studies in which ACEi were given to patients with
hypertension or other risk factors for cardiovascular disease (CVD) indeed
suggest that they decrease the risk cf ESRD (Table 3).
The Heart Outcomes Prevention Evaluation (HOPE) trial found a 34%
reduction (P < 0.001) in the relative risk of new-onset diabetes in patients
treated daily with up to 10 mg of the ACEi ramipril (146). Similarly, the
effect cf enalapril on the incidence of new-onset diabetes was assessed in
a subgroup of patients from studies cf left ventricular dysfunction (SOLVD).
A significant 78% reduction (P< 0.0001) in the incidence of new-onset
diabetes was noted in comparison to placebo (147). Together with the
small number of patients included in the sub-analysis, this limited wider
interpretation cf the findings. Nevertheless, the data from both HOPE and
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SOLVD suggested that ACEi prevent the development cf diabetes in
subjects with CVD, meriting further investigation in prospective trials.
Table 3. Clin ical evidence for prevention cf diabetes with ACE inhibitors
Clinical study Comparison Reduction in ESRD risk
HOPE Ramipril vs. placebo 34% (15-49%, P< 0.001)
SOLVD Enalapril vs. placebo 78% (54-90%, P < 0.0001)
CAPPP Captopril vs. beta blockers/diuretics 22% (6-33%, P = 0.039)
ALLHAT Lisinopril vs. amlodipine 17 % (8.1% vs. 9.8%, p < 0.46)
Lisinopril vs. diuretics 30% (8.1% vs. 11.6%, p < 0.001)
AScOT—BPLA Amlodipine ± perindopril vs. 34% (22-37% P < 0.001)atenolol ± bendroflumethiazide
DREAM Ramipril vs. placebo 7 % (18.1% vs. 19.5%)
The Captopril Prevention Project (CAPPP), which compared the
effects of captopril and conventional therapy (diuretics or beta-blockers) on
cardiovascular morbidity and mortality in more than 10,000 patients with
hypertension (diastolic BP> 100 mmHg on 2 occasions), included
new-onset diabetes as a secondary endpoint. After a mean foHow-up of 6.1
years, the incidence of new-onset diabetes was reduced by 14% overall in
the captopril group (P = 0.039) and by 22% in the subgroup of patients
previously untreated for hypertension (P = 0.041) (148).
The Antihypertensive and Lipid-Lowering treatment to prevent Heart
Attack Trial (ALLHAT) was a large randomized study designed to
determine whether newer classes of anti-hypertensive agents lowered the
incidence cf coronary heart disease or other CVD events better than the
diuretic chlorthalidone (149). After a mean cf 4.9 years, no differences
were seen between the treatment groups in terms cf primary outcomes.
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However, analysis of a sub-group of individuals who were non-diabetic at
the start of the study found that the relative risk of developing diabetes in
patients treated with the ACEi lisinopril was reduced by 30% compared
with the diuretic, and by 17% compared with the calcium antagonist
amiodipine.
Similarly, in the Blood Pressure-Lowering Arm of the
Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT-BPLA), hypertensive
patients assigned to treatment with amlodipine ± perindopril were 34% less
likely to develop new-onset diabetes than those randomized to
atenolol ± bendroflumethiazide (P < 0.001) (150). At the outset,
approximately 75% of patients did flot have diabetes. During the 5-year
study, 8% of patients in the amiodipine group, the majority 0f whom also
received perindopril, developed diabetes, compared with 11.4% of those
on atenolol-based therapy. These flndings may be the resuit of the
diabetogenic effect of the diuretic-beta-blocker combination and the
positive effect of the ACE1 (151).
The Diabetes REduction Approaches with ramipril and rosiglitazone
Medications (DREAM) Trial was a large-scale study specifically designed
to investigate drug therapies for the prevention of diabetes. A total of 5,269
patients without CVD but with impaired fasting glucose or impaired glucose
tolerance were recruited. Patients were randomized to receive up to 15 mg
ramipril daily or placebo and followed for 3 years. Treatment with ramipril
did not significantly reduce the incidence 0f diabetes or death over this
period (ramipril 18.1% versus placebo 19.5%), although the Kaplan-Meier
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survival curves tended to diverge by the end of the trial. However, there
was a significant benefit versus placebo for the secondary endpoint of
regression to normoglycemia (152). Regardless of the reasons for ramipril
failure to reduce new-onset diabetes in the DREAM trial population,
considerable evidence supports the use of ACEi in patients with
hypertension and/or CVD, with the additional purpose of normalizing
glucose homeostasis and decreasing the incidence of diabetes, especially
when compared to many other antihypertensive drugs.
The resuits of a new clinical study, Action in Diabetes and Vascular
Disease: Preterax and Diamicron MR Controlled Evaluation (ADVANCE),
were published in September 2007. ADVANCE is the largest-ever trial to
assess the treatment of type 2 diabetes patients with a fixed-dose
combination of an ACEi, perindopril, and a thiazide-type diuretic,
indapamide, versus placebo in a population of 11,140 patients with a mean
age of 66 years, recruited from 22 countries in Asia, Australia, Europe, and
North America. Over a mean foliow-up duration 0f 4.3 years, the results
showed that a composite of major macrovascular and microvascular
events was reduced by 9% with active treatment vs placebo (P 0.041).
The relative risk of death from CVD was decreased by 16% (P = 0.027) and
ail-cause mortaiity by 14% (P = 0.025) in the active treatment arm, with
significant declines also seen in total coronary events (14%) and total renal
events (21%) with active treatment (153; 154). ADVANCE is a very
important triai because it provides further confirmatory evidence that
reducing BP is important in diabetic patients, and combination treatment
with ACEi affords significant kidney protection in type 2 diabetes patients.
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1.6.2 Clinical Trails of ARBs in Diabetic Patients
Like ACEi, AREs are known to exert positive metabolic effects.
However, only recent clinical studies of AREs have been prospectively
designed to include new-onset diabetes as an endpoint (Table 4). As with
ACEi, initial evidence of the effects of ARBs on new-onset diabetes came
from trials in which they were compared with conventional therapies. In the
Losartan Intervention For Endpoint reduction in hypertension (LIFE) trial,
patients with hypertension were randomized to receive either Iosartan- or
atenolol-based treatment and were followed for at Ieast 4 years. At the end
ot the study, 25% risk reduction in new-onset diabetes was observed in the
ARB group compared to the beta-blocker group (155).
Table 4. Cli nical evidence for prevention 0f diabetes with ARBs
Clinical study Comparison Reduction in ESRD risk
LIFE Losartan vs. atenolol 25% (6.0% vs. 8.0%, P < 0.001)
LAPINE Candesartan vs. HCTZ 78% (0.5% vs. 4.1%, P < 0.05)
VALUE Valsartan vs. amlodipine 88% (13.1% vs. 16.4%, P < 0.001)
CHARM Candesartan vs. placebo 19 % (6% vs. 7.4%, P = 0.02)
SCOPE Candesartan vs. placebo 18 % (4.9% vs. 6%, P = 0.09)
The Antihypertensive Treatment and Lipid Profile In a North of
Sweden Evaluation (ALPINE) study investigated metabolic outcomes in
392 patients with hypertension (156). Patients were randomized to either
candesartan or hydrochlorothiazide (HCTZ) and were followed for 1 year.
Significantly more patients in the HCTZ group were diagnosed with
diabetes during follow-up.
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Additional evidence of the antidiabetic effects cf ARB therapy came
from the Valsartan Antihypertensive Long-term Use Evaluation (VALUE)
study, which compared valsartan with amlodipine in more than 15,000
patients with hypertension. After a mean follow-up of 4.2 years, new-onset
diabetes was diagnosed in significantly fewer patients in the valsartan
group (13.1%) than in the amlodipine group (16.4%, P< 0.001) (157).
Ihe Candesartan in Heart failure — Assessment of Reduction in
Mortality and Morbidity (CHARM) program included the reduction of
new-onset diabetes in HF patients treated with candesartan compared to
placebo as a pre-specified secondary endpoint (158). The investigators
concluded that candesartan decreased the risk of new-onset diabetes in
HF patients, and that this benefit was in addition to diminutions in the
primary endpoint of mortality and hospitalizations for HF.
The Study on COgnition and Prognosis in the Elderly (SCOPE) also
reported an 18% relative risk reduction in new-onset diabetes with
candesartan compared to placebo (159). Although this finding did not
achieve statistical significance, it does further support that ARBs can help
to decrease the risk of diabetes in high-risk patients, such as those with
hypertension
1.7 Gene Regulation 0f AGI
Plasma and tissue AGI concentrations both contribute directly to
circulating Ang I and Ang II levels. Ihus, changes inthese concentrations
are important, as they can influence thedegree of RAS activation. AGT is
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regulated by severai hormonal factors, and some of the cis- and
trans-regulatory elements involved in the control cf its transcription have
been identified.
1.7.7 AGT Regulation by Hormonal Factors
Many in vivo and in vitro studies have demonstrated that
glucocorticoids (i.e. dexamethasone), estrogens, Ang Il, and thyroid
hormones ail stimulate AGI synthesis and release (160; 161). These
hormones increase AGI mRNA levels in the rat liver (47; 162; 163). Ihe
hormonal regulation of AGI mRNA has also been investigated in
hepatocytes and othercell unes, such as PICs and adipocytes (164). The
effects of steroids are neutrahzed by antiglucocorticoids and antiestrogens.
Ihyroidectomy decreases plasma AGI concentration, and T3 restores it.
Ang Il has been consistently found to stimulate AGT synthesis, and insulin
inhibits its expression in PTCs in culture (131; 165). However, it has also
been suggested that insulin downregulates AGI expression in adipocytes
(166). The fail in plasma AGI that occurs during chronic ACE inhibition is
probably due to decreased positive feedback by Ang Il, or to increased
cleavage by plasma renin and its reduced synthesis (167), although other
mechanisms are possible since ACE inhibition does not block only the
RAS.
Plasma AGT and estrogen concentrations rise in parallel during
pregnancy. Oral contraceptive puis containing synthetic estrogens cause a
dose-dependent elevation cf plasma AGI (168), but thereseems to be no
direct relationship between the increase in plasma AGI and BP. Ihe
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estrogen-induced increase in AGT is tissue-dependent. The effect of
estrogen on the liver is important, but it does flot stimulate AGT production
in adipose tissue, and contradictory results have been reported in the brain
(169). Bilateral nephrectomy leads to heightened hepatic synthesis and
plasma concentrations of AGT (170), but the manner in which it does so îs
thus far unknown. The additive effects of these various stimuli suggest that
they trigger AGT synthesis through different transcription pathways.
Ihese observations indicate that a chronic increase in plasma AGI
might modulate RAS activity, and may also cause an abnormally short
feedback loop between Ang Il and renin release. The rise in plasma Ang Il
after plasma AGT elevation exerts a short negative feedback loop on renin
release in the normal physiological state, and this limits the direct effect of
changes in plasma AGT on BP.
1.7.2 AGI Expression in Diseases
Several pathological conditions lead to augmented AGI production,
which contributes to local Ang Il generation. The medial layer of an injured
aorta contains increased amounts of AGT mRNA, as might be expected for
a member of the serpin family, which suggests that AGI is involved in
myointimal proliferation in response to vascular injury (171). Enhanced
ACE activity and AGI synthesis also occur after experimental left
ventricular hypertrophy (172), indicating, along with other studies, that the
cardiac renin system may help modulate heart growth and hypertrophy.
Ihe change in renal hemodynamics caused by experimental HF leads to a
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specific increase in renai AGT mRNA, suggesting that it contributes to
activation of the intrarenal renin system (173).
1.7.3 Iranscriptional Reg ulation cf AGI
AGT production is mainly reguiated by gene transcription, although
there is evidence of post-transcriptional regulation, as when Ang II
increases the stability of AGI mRNA (174). Recent studies in mice indicate
that the proximal promoter region of the mouse AGI gene (-96 to +22) is
sufficient for AGT gene expression in mouse fibroblast ceHs during their
differentiation into adipocytes (175). A liver-specific factor (AGF2) binds to
the proximal promoter element (-96 to +52), and a ubiquitous nuclear factor
(AGF3) binds te the core promoter element (-6 to +22). These 2 factors
seem to act synergisticaiiy (175). The core promoter region of the human
AGI gene in HepG2 ceNs has been analyzed (176). Electrophoretic
mobility shift assays have demonstrated that a ubiquitously-expressed
nuciear factor (AGI cote promoter-binding factor 1) binds te a region
between positions -25 to -1, denoted as AGCE1 (AGI cote promoter
element 1), iocated between the IAIA box and the transcription initiation
site. AGCE1 appears to play a major rote in activating AGI transcription,
particularly by downstream cote elements. Ihis region is probably more
compiex with severai nuclear factors binding te its 5- or 3’-side (177),
which may be important for the general rate cf transcription initiation and
aise for determining the paftern cf AGI gene expression. These studies
point to the importance of reguiatory regions where several naturai variants
of the AGT gene have been detected.
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1.8 Insulin and AGI
As discussed above, insulin could modulate AGT gene expression in
adipocytes and PICs. However, the resuits are contradictory in 2 different
ceil types. In this section, I wiIl discuss in more detail the gene regulation
effects of insulin, for a clear hypothesis on how it inhibits AGT expression in
PICs.
Insulin, the most important hormone implicated in blood glucose
control and energy metabolism, acts by stimulating glucose influx and
metabolism in adipocytes and muscles, and by inhibiting gluconeogenesis
in the liver. Since its discovery, insulin has been subjected to extensive
research to elucidate its activity in various metabolic processes, including
glucose homeostasis, substrate metabolism, gene regulation, protein
synthesis, and protein degradation (178). This hormone is secreted by
3-cells of the pancreatic islets of Langerhans in response to increased
circulating glucose levels after a meal. lmpaired insulin actions, either due
to insulin hyposecretion or defects in insulin signaling, cause serious
problems in glucose homeostasis, and subsequently lead to DM.
1.8.1 lnsulin Signaling
Insulin acts through a ceil surface receptor that belongs to a subfamily
of growth factor receptor tyrosine kinases. Ihis subfamily is comprised of 3
members: insulin receptor (IR), type J insulin-like growth factor (IGF)
receptor, and lR-related receptor (179). Ihe IR consists of a heterodimeric
2, F32 structure. Insulin-binding to the IR a-subunit results in conformational
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changes, leading to enhanced intrinsic protein tyrosine kinase activities of
the t3-subunit by multi-site tyrosine phosphorylation. Phosphorylated IR can
phosphorylate several cytosolic IR substrates, including insulin receptor
substrates (IRSs), Src homology collagen (Shc), and adaptor protein with
pleckstrin homology, Src homology 2 (SH2) domains, and Casitas
B-lineage lymphoma. The phosphorylated proteins dock downstream
affector molecules that contain the SH2 domain (180), which are then able
to activate 2 key signaling pathways. These pathways are the
phosphatidylinositol 3-kinase f PI3K)-AKT/PKB pathway (181), which is
responsible for most of the metabolic actions of insulin, and the Ras-MAPK
pathway (180), which regulates the expression of some genes and
cooperates with the PI3K pathway to control celi growth and differentiation
(Figure 7) (182).
The Ras-MAPK pathway goes through the formation of complexes
between the exchange factor mammalian son of 7 less (mSOS) and growth
factor receptor binder-2 (Grb2) (183). Grb2 can be activated by IRS or Shc,
2 direct substrates of IR kinase. Activation of the IRS-Grb2-mSOS complex
resuits in subsequent activation of the Ras, Raf, MEK, and extracellular
signal-regulated kinase (ERK) pathway. Activated ERKJ/2 phosphorylates
a downstream ribosomal protein kinase, pg0rsk Both ERK1/2 and p9O
can be translocated to the nucleus where they phosphorylate transiocation
factors, and contribute to the mitogenic and growth-promoting effects of
insulin.
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FIgure 7. Insulln signallng pathway and Its cellular function.
The second pathway that mediates insulin signalling through the IRS
complex involves PI3K activation (178; 181). PI3K phosphorylates
phosphatidylinositol (PI) Iipids at position 3 of the inositol ring, and
generates 3 phosphorylated forms of PI, such as phosphatidylinositol 3,4,5
triphosphate (PIP3) (184), which is implicated in activation of the
mammalian target of Rapamycin (mTOR) and phosphoinositide-dependent
kinase (PDK). mTOR has been found to phosphorylate eIF4E-binding
protein (4EBPJ). PDK is related to serine/threonine protein kinases
responsible for the phosphorylation and stimulation of several downstream
signaling protein kinases, such as PKB/AKT, p70 ribosomal S6 kinase
(p70s6k)
and PKC-zeta. PKB phosphorylates glycogen synthase kinase 3
(GSK3), cGMP-inhibitable phosphodiesterase 3b, BAD, and FOXO
transcription factors, leading to the stimulation of glycogen synthesis and
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inhibition of lipolysis, apoptosis and gene expression, respectively (185;
186). Activation of these serine/threonine protein kinases has been
hypothesized to mediate the metabolic effects of insulin at the level cf
glucose transport, GLUT4 translocation, and protein synthesis (187).
lnterest in the PKC family has been rekindled by observations that the
addition of inhibitors of its atypical isoforms results in partial suppression of
glucose uptake in adipocytes and that heightened PKC activity is
associated with increased intramyocellular triglycerides, a hallmark of
insulin resistance (188).
1.8.2 Insulin Effect on Gene Regulation
While insulin has long been known to modulate intracellular
metabolism by altering the activity or intracellular location of various
enzymes, it has also been recognized that regulation cf gene transcription
is a major action of this hormone. Insulin has been reported to regulate the
expression at least 100 genes (189). A recent report revealed changes in
the mRNA levels of about 800 genes during 3-hour insulin infusion in the
skeletal muscles of healthy individuals (190). Many metabolic effects are
mediated by the regulation of gene expression with positive actions on
glycolytic and lipogenic enzymes and negative impacts on gluconeogenic
enzymes. Furthermore, insulin affects the mRNA stability of specific genes
(PEPCK, GLUT4, and CYP45O 2BIE), promotes translation by the
activation of 70s6k 4EBP1, and eIF4E, stimulates the phosphorylation and
dephosphorylation of many metabolic enzymes, and plays a role in hepatic
growth and regeneration. These are aIl mechanisms of protein regulation
by insulin.
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Table 5. Insulln response sequenceslelements.
Eflect ot
IREÎIRS type Genes IREflRS sequence Insulin
GAPDH4RE GAPDH; Apo A-l CCCGCCTC Positive
SRE motif FAS; HK Il; SREBP-lc; TCACCCC Positive
ACC2
API motif Collagenase-1 TGA(GIC)TCA Positive
Ets motif Prolactin; somatostatin (CIA)GGA(Aft) Positive
E-Iox motif Pyruvate kinase CANNTG Positive
SREBP motit Glucokinase ATCACCCCAC Positive
TTF-2 motif Thyrogbbulin C(T/A)(NG)A(NG)(CIA)MACA Positive
CIAICIE motif Glucagon CACGCCTCTG Negative
PEPCK4Ike motit PEPCK; G6Pase; IGFBP-1; T(G/A)UT(T1G)(Gff) Negative
TAT; êpo CIII
NF-1-lIke motit GLUT4 TflGGAflG4AGCAAT Negative
GC-box4lke motif ANG CCTTCCCGCCCTTCA Negative
Regarding gene regulation, an important question is: how does
insulin’s signal pass from the IR on the plasma membrane to a specific
trans-acting element and bind to its cis-acting element? The promoter
elements that mediate the effect of insulin on gene transcription are
referred to as insulin-response elements or insulin-response sequences
(IREs/IRSs). Unfortunately, while no single consensus on IRE is apparent
in multiple insulin-regulated genes (191), there is some consensus on IREs
in a small number of genes, such as TGTTTTT in PEPCK, G6Pase, TAT
Apo CIII, and IGFBP-1, although their mechanisms of regulation by insulin
are different (192). Seven distinct IREs that mediate the positive effects of
insulin on gene transcription have been characterized. Several reports
have identified potentially novel stimulatory IREs in other genes that do not
match any of these sequences (192; 193). In contrast, only 4 negative IREs
have been identified, and 2 of them have been weII-characterized. Table 5
Iists 11 distinct classes of IRSs/IREs that have been defined.
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Although the cis-acting elements that mediate the actions ofinsulin on
gene transcription have been defined for a significant number of genes, the
transcription factors responsible for the transactivation of these target
sequences remain unknown. Because there is no consensus IRE in many
insulin-regulated genes, no common insulin-responsive factor (IRE) could
mediate ail the insulin effects on gene regulation. it is possible, however, to
identify more trans-acting elements by DNA-protein interaction technology.
Data published during the past 10 years provide evidence that insulin
mediates its action on gene transcription through the insulin-signaling
pathway that directly modifies the phosphorylation/dephoshorylation of
some transcription factors, such as c-Fos/c-Jun, thyroid transcription
factor-2, hepatic nuclear factors 1 and 3, and forkhead transcription factor
box 01 (FOXOI, previously known as Fkhr). Then, it regulates its targeted
gene expression on the promoter region (192-195), or perhaps an
intraceHular receptor interacts directly with insulin-like steroid hormone
receptor, and performs its gene regulation function through the receptor.
However, this has flot yet been identified.
Two major pathways, PI3KIAKT and ERK, are known to play a major
role in transcription regulation. Insulin stimulates sterol response
element-binding protein-1 (SREBP-1) gene transcription through
sterol-response element (SRE). Studies of the promoter regions of
insulin-regulated genes suggest that SRE 15 also a responsive motif of fafty
acid synthesis, acetyl-Co-ACarboxylase-2, and hexokinase II (196; 197). It
has been suggested that insulin modulates these genes through
phosphorylated GSK3 by PI3K/AKT which resuits in reduced GSK3 activity
and may thus stabilize SREBP-lc nuclear content by inhibiting its
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degradation (198; 199).
Insulin controls glucose production by inhibiting the expression of 2
rate-limiting enzymes in gluconeogenesis and glycogenolysis,
phosphoenolpyruvate carboxykinase (PEPCK), and
glucose-6-phosphatase (G6Pase) (195; 200; 201). Interestingly, both have
the same IRE, but in different copy numbers. One IRE is located between
-425 and -399 in the mouse PEPCK promoter, with 3 IREs between -198
and -159 (region B of its insulin response region) in the mouse G6Pase
promoter. The signaling pathways for these effects are flot completely
understood, but are thought to require activation of the Iipid kinase P13K.
Among the PI3Ks, AKT has been implicated as a mediator of insulin’s
inhibition of a reporter gene driven by a PEPCK promoter spanning the
putative IRE. FOXO1 (202) is phosphorylated in an insulin-responsive
manner by PIP3-dependent kinases, such as AKI and Sgk.
Phosphorylation leads to nuclear exclusion and inhibition of
FOXO1-dependent transcription (203; 204). Studies in hepatoma celis
suggest that FOXO1 and its closely-related isoform FOXO3 possess the
ability to regulate the transcription of reporter genes containing IRE from
G6Pase and PEPCK promoters in an insulin-dependent manner (201).
These data indicate that FOXO1 is a positive transcription factor of PEPCK
and G6Pase. Insulin inhibits the expression of these genes by
phosphorylating FOXO1, leading to its transiocation.
Although these experiments support the hypothesis that FOXOJ and
its orthologs are the IRFs that bind the PEPCK-like IRE motif and mediate
the inhibitory effect of insulin on gene transcription through this element,
other results do not concur wfth this model. Several studies suggest that
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PKB is either flot required or flot sufficient for insulin-regulated PEPCK and
G6Pase gene expression (205). In addition, a detailed base-by-base
analysis of the PEPCK IRE indicated that the effect of insulin mediated
through this element on heterologous gene transcription does flot correlate
with FOXO1-binding (206). This raises another question: are there other
unknown IRFs with different roles in gene regulation?
Because the PEPCK, G6Pase, IGFBP-1, tyrosine aminotransferase
(TAT), and apolipoprotein CIII genes share the same IRE (Table 1), it has
been assumed that the same trans-acting element mediates the effect cf
insulin on the transcription of ail these genes. However, the resuits suggest
that these IREs might function differently. Such findings also taise the
question of whether a different mechanism modulates specific gene
transcription.
We have previously reported from Dt. John S.D. Chan’s lab that insulin
inhibits rAng expression in PTCs, and that a putative IRE is Iocated in the
rAGT promoter region between -882 and -855 (165; 207). Wth
Southwestern blolling, we found 2 nuclear proteins that bind this element of
AGT and the binding profile was modulated by glucose and insulin
stimulation. However, furthet expetiments are required to acquire more
detailed information.
1.9 The Heterogenous Nuclear Ribonucleoprotein Family (hnRNP)
The hnRNP family of more than 20 different proteins shares common
structural domains, and extensive research has shown that they play
central roles not only in mRNA processing, metabolism and transport but
also in DNA repair, telomere biogenesis, ceil signaling and the regulation of
gene expression at both the transcriptional and translational levels (208).
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Through these key celiular functions, individual hnRNPs have a variety of
potential roles in tumor development and progression, inciuding the
inhibition of apoptosis, angiogenesis and celi invasion.
1.9.1 Structure of the hnRNP Family
As RNA polymerase Il (RNA poly Il) transcripts are synthesized, they
associate with proteins to form hnRNP complexes. It is within these hnRNP
complexes that pre-mRNAs are processed to form mature mRNA
transcripts before being exported from the nucieus (209). lmmunopurified
hnRNP complexes from human HeLa ceiis contain more than 20 individuai
proteins designated as hnRNP Ai (34 kD) through hnRNP U (120 kD)
(210).
Ail hnRNPs share some structural motifs (Figure 8). The most
common is the RNA-binding domain (RBD), also known as the RNA
recognition motif (RRM), which is generaliy located at the N-terminus. RNA
appears to bind to the surface of the RBD and, therefore, remains exposed
and accessible for interaction with other factors (211). Binding studies have
shown that sequence-specific eiements of DNA or RNA are bound by
hnRNPs through the RRM (209). In addition to binding to nucieic acids, the
RRM of certain hnRNPs, i.e. hnRNP Ai, is involved in protein-protein
interactions. Indeed, hnRNP Ai, through its N-terminal RBD, interacts with
IKBQ, resuiting in nuclear factor kappa-B (NF-KB) activation (212).
47
Proe:n-procm IntcnCtiŒ,.
RNA
RNA,DNA RNAfD0-A npnI
ftcooi
I t......_[.......] I
R)A £indjng K hoIogy Mo,fs
Domn (RHO) KNA (KH) 20-25 r.rno cid
Mof(RR2I stchcs Ûtn,rg
- I-3 (H Arg-GIyG(
.3 p p hRNP mppji ftpLs
Figure 8. General structurai domains of the hnRNP famlly(Ref. 211).
hnRNPs also have auxiiiary regions, for exampie, RGG and KH (K
homology) motifs. However, such regions are found in oniy some but flot ail
hnRNP proteins. RGG motifs are 25-amino-acid stretches with Arg-Gly-Gly
tripepetide repeats. Besides being invoived in RNA-binding, they are aiso
implicated in protein-protein interactions, transcriptional activation, and
nuclear Iocalization (209). The KH domain, first described in hnRNP K
(213), is 50 amino acids long, and contains conserved octapeptide repeats
of lle-Giy-X2-Gly-X2-Iie (X being any amino acid). hnRNP K has 3 KH
domains, and mutational analysis studies have confirmed that the
octapeptide repeats are essentiai for RNA-binding.
1.9.2 Transcriptionai Function of the hnRNP Famiiy
hnRNPs are involved in different ceilular functions, and through such
functions, this family of ptoteins could potentiaily regulate celi physiology
via various mechanisms. In my thesis, I focus on the transcriptionai effects
of hnRNPs.
The genome is tightly packed into DNNprotein structures, referred to
as chromatin. These DNNprotein structures are modified by various
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mechanisms such as acetylation or methylation (214). Using tormaldehyde
cross-linking on HeLa celis, hnRNP U was demonstrated to bind directly ta
chromosomal DNA (215). Subsequently, yeast 2 hybrid and
co-immunoprecipitation assays revealed that hnRNP U interacts with p300,
a protein known ta acetylate histones. Contact between this protein
complex and DNA results in the local hyperacetylation of histones (216),
providing a connection between hnRNPs and chromatin remodeling. In
addition ta hnRNP U, the chromatin-remodeling role of other hnRNP
members is beginning to emerge. For exampte, hnRNP K has been shown
ta interact with the chromatin-remodeling enzyme histone
methyltransferase, but the resultant effect on chromatin remains unknown
(217).
Transcription factors can either function as activators or repressors of
gene expression, and hnRNP members have been identified as
transcription factors. hnRNP K, which wilI be described later, and hnRNP U
have been the most extensively studied. hnRNP U represses transcription
by acting as a RNA poly Il elongation inhibitor (218), hnRNP U associates
with the general transcription factor TFII H in vivo and prevents
phosphorylation of the C-terminal domain (CTD) of RNA poly II by TFII H, a
process required for elongation (218). A recent report described hnRNP U
associating directly with RNA poly II, and antibodies against hnRNP U
inhibited RNA poly II transcription. Therefore, hnRNP U association with
co-factors dictates whether it functions as an inducer or inhibitor of
transcription (219). Interestingly, hnRNP P2 also interacts with RNA poly Il
through its N-terminal domain and associates with SR proteins (which
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mediate mRNA-splicing) through the C-terminus (220). Ihese interesting
observations suggest that hnRNP P2 may function as an adaptor molecule
Iinking transcription to RNA-splicing.
hnRNP Al is another family member which has been shown to
mediate transcription and DNA-binding in an independent manner. The
transcriptional activation and DNA-binding activities of N F-KB protein are
inhibited by IKBO-binding. Previously, I reported that hnRNP Al interacts
with and leads te IKBQ-degradation. Ceils lacking hnRNP Al expression
are defective in N F-KB-dependent transcriptional activation. However,
hnRNP Al overexpression increases IKBG-degradation and
NF-KB-dependent transcription (212).
Besides the direct effects of hnRNPs on transcription, the
post-translational modification cf certain hnRNPs also affects their ability to
function as transcription factors. hnRNP D mediates transcription by
interacting with TATA-binding protein (ISP) and p300, and is therefore a
transcription factor (221). hnRNP D phosphorylation by PKA enhances
whereas GSK3 phosphorylation inhibits the transcriptional activity cf this
family member (221). Stimulation cf hnRNP D by the PKA pathway
increases its DNA-binding, yet t remains unclear if GSK33 inhibits
transcription by decreasing DNA affinity or preventing co-factor interaction
(p300 or TBP) cf hnRNP D (222). Nevertheless, another post-translational
modification process cf hnRNP Cl decreases its interaction with
single-stranded DNA (223).
1.9.3 hnRNP F
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hnRNP F belongs to the hnRNP H family that is involved in the
regulation of alternative spiicing and polyadenylation, specifically
recognizing poly(G) sequences (G-tracts). The hnRNP H family consists of
4 highly homologous proteins: hnRNP H, hnRNP H’, hnRNP F and hnRNP
2H9.
Members of the hnRNP H family specifically recognize G-tracts that
are abundant in both DNA and RNA. These G-tracts are known to form a
specific structure, the G-quadruplex, that consists of 4 guanine bases
arranged in a square planar conformation and stabilized by hydrogen
bonds (224; 225). In DNA, these structures are mainly located in telomeres
and in some promoter regions. In RNA, G-tracts are frequent splicing
recognition elementsfound in both introns, and exons, and are crucial for 5’
splice site recognition (226-228). They are also abundant downstream of
mammalian polyadenylation signaIs (229). hnRNP F and H, through
binding to these G-tracts, are responsible for the regulation of
polyadenylation (230) and the splicing regulation of numerous pre-mRNA5,
such as Bd-x (231), rat 3-tropomyosin (232), Rous sarcoma virus NRS
(233), HIV type 1 TAT (234), I-11V-1 tev (235), HIV-1 pl7gag instability (236),
and c-src (237) pre-mRNAs. Furthermore, mutations in G-tract splice sites
correlate with many diseases (238). In some cases, such as
neurofibromatosis type 1 disease involving the NF1 gene (239), congenital
hypothyroidism involving the TSH-13 subunit gene (240), or cystic fibrosis
through theCFTR gene (241), mutations directly affect (disrupt orenhance)
hnRNP H/F-binding to pre-mRNA (241; 242).
1.9.4 hnRNP K
hnRNP K is an evolutionarily-conserved factor (243) in multiple
51
subcellular compartments, including the nucleus (226), cytoplasm (244)
and mitochondria (245). The finding that hnRNP K is involved in gene
expression through chromatin-remodeling (243), transcription (246),
pre-mRNA-splicing (247), mRNA export (248) and translation (249) has
generated great interest in thisfactor (250). hnRNP K involvement in these
many processes probably reflects the interactions of its multiple domains
(250) with a diversity of molecular partners, including DNA, RNA, protein
kinases, the GTP/GDP exchange factor Vav, and proteins involved in
chromatin-remodeling, transcription, mRNA-splicing and translation (251).
Many of these interactions have been shown to be regulated by hnRNP K
phosphorylation, induced either by changes in the extracellular
environment or by the activity of specific ligands. hnRNP K is not only a
kinase substrate but it also regulates the activity of kinases (252). These
flndings are consistent with a model where hnRNP K bridges signal
transduction pathways to sites of nucleic acid-directed processes.
hnRNP K has been found to bind DNA in a sequence-specific manner.
The protein binds CT elements located in promoters of the human
proto-oncogenes c-Src (253) and c-myc (246). Moreover, analysis of the
immediate early gene egr-1 in serum-induced rat hepatoma ceils reported
by Ostrowski et al. supports the observation that hnRNP K is a transcription
factor. egr-1 expression is associated with transient hnRNP K recruitment
to multiple sites within this gene, including promoter and transcribed
regions (251). This protein-DNA interaction is specific as constitutively
active 3-actin loci fail to recruit hnRNP K (251). Their experiments revealed
that hnRNP K binds DNA. Subsequently, its transcriptional activity was
demonstrated by introducing mutations within the CI element. hnRNP K
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was unable to bind this DNA element, resulting in reduced transcriptional
activation (251). Furthermore, hnRNP K was able to stimulate transcription
in vitro and interact with TBP, a protein required for the recruitment of RNA
poly II. When TBP and hnRNP K were co-overexpressed in celis, a CT-rich
element reporter gene was activated synergistically (246). Interestingly,
hnRNP K-mediated gene activation was shown to increase the level of
transcription without altering the decay rate of mRNA (254), suggesting
that transcriptional activation by hnRNP K is independent of its
mRNA-processing role. hnRNP K, therefore, appears to be a bona fide
transcription activator, but it has also been documented as a functional
repressor. C/EBP- is a transcription factor that has been demonstrated to
regulate genes involved in acute phase responses. In liver nuclear extracts,
hnRNP K was reported to be present in a complex containing C/EBP-, an
interaction that repressed C/EBP-E3 transcriptional activation (255).
Surprisingly, hnRNP K was found to elicit repression of C/EBP-13
transcriptional activity in a manner that did not require hnRNP K to bind
DNA, but rather through protein-protein interaction. The effect of hnRNPs
affecting transcription independently of DNA-binding has also been
described for additional members, e.g. hnRNP U.
1.10 Mouse Models in Diabetes Research
Several clinical studies have demonstrated significant renoprotection
through blockade of the RAS compared with the effects other
antihypertensive drugs, suggesting a crucial role of the intrarenal RAS
activation in human kidney diseases. Despite the enthusiasm for ACEis
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and ARBs in patients with kidney disease, direct evidence of augmentation
of the intrarenal RAS in human is relatively sparse. In human subjects,
direct measurements of the intrarenal RAS components, microperfusion
studies, or micropuncture investigations are flot available. However,
accumulating evidence including functional investigations and studies 0f
human biopsy samples emphasize augmentation of the intrarenal RAS in
human patients. Therefore, mouse models have played a major role in
shaping our current understanding of diabetes. Two major purposes of
mouse models are to improve understanding the physiology of diabetes
and promote development of new therapeutic compounds. Important
contributions have corne from both classical laboratory animal models and
new ones made using advanced methods of genetic manipulation.
1.10.1 Characterization of Diabetic Nephropathy in Humans and Mice
In humans, DN manifests as a clinical syndrome that is composed 0f
albuminuria, progressively declining GFR, and increased risk for
cardiovascular disease (256; 257). The occurrence of cardiovascular
disease is an integral component of DN and underscores the systemic
nature of this disorder, of which nephropathy is only one aspect. Another
key aspect of DN in humans is that it is a Iate complication of diabetes,
occurring progressively in susceptible people only after 15 to 25 years of
diabetes (258; 259). Because of issues of cost and convenience, most
studies of DN in mice have focused on the earlier harbingers of DN,
including the development of albuminuria and histopathologic changes, and
have not explicitly used renal insufficiency as an end point (260; 261).
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Diabetic albuminuria in humans is associated with the development of
characteristic histopathologic features, including thickening of the
glomerular basement membrane (GBM) and mesangial expansion. As
albuminuria progresses and renal insufficiency ensues, glomerulosclerosis,
arteriolar hyalinosis, and tubulointerstitial fibrosis develop (262). These
pathologie features correlate well with GFR in humans with diabetes and
kidney disease and would be important features in a robust mouse model
of DN (263; 264).
The major deficiency in animal models of DN is the absence of renal
failure. Whereas animal models of diabetic kidney disease exhibit
albuminuria and some of the characteristic pathologie changes, reports of
renal failure resulting from diabetes in mice or rats are lacking. Furthermore,
associated increased risk for cardiovascular disease, neuropathy, and
retinopathy has been poorly characterized. Whether the inability to detect
renal failure in mice is simply a consequence of studying mice with
established diabetes for an insufficient time period orthe absence of renal
failure reflects an intrinsic resistance to nephropathy of the strains studied
thus far remains uncertain.
In contrast to the absence of renal failure, several of the more
short-term consequences, including the development of glomerular
hyperfiltration, increased albuminuria, and some cf the characteristic
histopathologic changes, can be detected in animal models. Human DN
proceeds through several distinct pathophysiologic stages, including an
early stage cf glomerular hyperfiltration, followed by the so-called silent
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phase in which GFR returns to normal (265). This is followed by the
sequential development of microalbuminuria, dipstick-positive proteinuria,
and then a progressive decline in GFR leading to ESRD. An optimistic view
is thatthe detection of the early functional and histopathologic changes in
mouse models of diabetes reflects inadequate duration of hyperglycemia
before the study of these models (264).
1.10.2 Advantages and Disadvantages of Mouse Models in Research of
Diabetic Nephropathy
The ideal animal model is simple to describe. It should be easy to produce,
maintain, and study while accurately reproducing the human phenotype.
Breyer et al. have summarized the advantages and disadvantages of
different mouse models in diabetes research (Table 6, Ref. 264). The most
frequently used 16-cell injuring chemicals are streptozotocin (STZ) and
alloxan. Alloxan is a pyrimidine that is given as a single dose. It is rapidlly
taken up by ,8 -ceil, causes the production of hydroxyl rad icals, and
produces irreversible b-cell damage within minutes to hours. The
permanent insulinopenia with hyperglycemia and ketoacidosis typically
starts after 12 hours and insulïn therapy is required to keep the animais
alive. The severity and lack of titratability of alloxan make it Iess frequently
used than STZ.
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Table 6. Some mouse modeis of diabetes studied for DN.
Mouse Modal Diabetic Type Advantages Disadvantages
Streptazok,cin Type 1 Well established, raproducible Potentiel for nonspecific toxicity;
timrng; may be established i strain-dependent dosing
strains bath resistant and necessaiy; biohezard: potentiel
susceptible to DN mutagen
lns2 Aldta Type j Commercially available (JAX); Presently only C57BL16
autosomal dominant mutation commercially available; C57BLi
relatively resistant ta
nephropathy; hyperglycemia in
females is mild
Dbldb Type 2 Available on multiple stiains; Infertile; autosomal recessive;
commercially available mutation in leptin receptor is a
vety rare cause or obesity and
type 2 diabetes in humans
High-fat diet Type 2 Oriset can be determined by Only C57BU6 reported as
the investigator susceptible; hyperglycamia flot
prominent
Modited from Re 259
STZ is a fungal fermentation product that seiectively damages
pancreatic 3-cell, possibly via oxidant damage (266). In many species, a
signal injection of a large dose of STZ (requiring approximately l5Oto 200
mg/kg to obtain chronic hyperglycemia) is sufficient to cause
insulin-deficient diabetes. A regimen using multiple injections of Iow dose of
STZ has also been devised. This regimen typically cails for daily
intraperitoneally injections of 40 to 50 mg/kg STZ for 5 days (267). This
model of type 1 diabetes typically develops albuminurïa (268), even on the
relatively scierosis-resistant C57BU6J background (269); however, the
potential for coliateral tissue toxicity complicates the interpretation of the
cause of this aibuminuria. The multiple dose technique more consistently
produces animais with sufficient beta-ceil ioss to cause diabetes, whiIe at
the same time leaving enough residual insulin secretary capacity to avoid
ketoacidosis and the need for treatment with insulin. This is a major
practicai advantage.
To circumvent the potentiai nonspecific tissue toxicity that occurs in the
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SIZ model of type 1 diabetes, one may use the recently described insulin-2
Akita (Ifl52Ita) mouse mutant model of type 1 diabetes (270). Akita mouse
is severely deficient in insulin production, but with enough residual insulin
to allow the animal to ive. The C57BU6-Ins2Akita/+ mouse has small islet
and greatly reduced insulin production. The Akita mutation is a cysteine to
yrosine change at position 7 of the A chain of the Ins2 gene. Since mice
have 2 insulin loci, the phenotype of heterozygous mice might have been
predicted to be an asymptomatic —25% reduction in insulin levels. However,
the Akita insulin molecular has severe folding problems, causing toxicity to
b-cells making the protein, a dominant phenotype, and the reduction in 9
-ceIl mass (271).
In type 2 diabetes researches, the db/db mutation on the C57BLKS
background has been investigated intensively and exhibits many features
similar to human DN. The diabetic gene (db) is transmitted as an autosomal
recessive trait. The db gene encodes for a G-to-T point mutation of the
leptin receptor, leading to abnormal spiicing and defective signaling cf the
adipocyte-derived hormone leptin (272). In the C57BLKS/J db/db mouse,
hyperinsulinemia is noted by 10 day of age, and blood glucose levels are
slightly elevated at 1 mo of age (7.2 ± 2.3 mM) (273). Progressive
hyperglycemia is noted with mean levels of glucoseof 28.6 ± 13.2 mM at
16 wk of age (273). By 2 to 4 mo cf age, diabetic mice have a 20 to 30%
increase in glomerular size. Glomerular hypertrophy at the onset of
diabetes may be due to alteration of glomerular hemodynamics as there is
evidence of glomerular hyperfiltration in db/db mice during the early stages
of diabetes (274).
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Ihe progression ot diabetes in db/db mice on the C57BU6
background in the diabetic phenotype is less severe than that in
C57BLKS/J, and as these mice age, plasma glucose seems ta normalize.
More recently, some investigators have reported observing that a subset 0f
approximately 50% of C57BL/6J db/db mice develop more persistent
hyperglycemia. In these mice, more robust albuminuria and renal
histopathologic diabetic changes have been reported. Unfortunately, the
factors that cause this subgroup of C57BL/6] db/db mice to develop
persistent hyperglycemia remain to be elucidated. Nevertheless, although
the leptin mutation may flot produce as robust a model for DN on the
C57BU6 background as it does on the C57BLkS/J background, it does
provide a clear advantage for genetic studies because most transgenic and
knockout strains are available on this background and can cleanly
introgressed onto this strain (264).
1.11 Hypothesis and Aims of Ihese Studies
Rationale: DN is the major cause of ESRD. Hyperglycemia and RAS
activation play major roles in the progression of DN. Ihe existence of a
local intrarenal RAS has now been welI-accepted. AGI is the sole
substrate of the RAS. The regulation of renal AGI gene expression,
however, is not well-understood. During the last several years, our lab has
focused on the mechanism(s) of regulation of rAGI gene expression in
renal proximal tubular cells (RPICs) under high glucose conditions. In
previous studies, we showed that high glucose stimulates and insulin
inhibits AGI gene expression and celi hypertrophy in immortalized RPICs
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(IRPTCs). Moreover, we identified a novel IRE motif that contains
nucleotides N-878 to N-864 (5’-CCI 1CC CGC CCI TCA-3’) upstream of
the transcription start site of the rAGI gene promoter. Ihis AGT-IRE binds
to 2 major nuclear proteins with apparent molecular weights (MW) cf
approximateiy 48 and 70 kD in IRPTCs, as revealed by Southwestern
blotting. It appears that high glucose and insulin enhance and inhibit the
expression of 48- and 70-kD nuclear protein expression in IRPTCs,
respectively. Ihese data suggest that 48- and 70-kD nuclear proteins might
mediate the effect cf high glucose and insulin on AGT gene expression in
IRPTCs. However, these 2 nuclear proteins have flot been identified, and
the molecular events that link them to hyperglycemia and the
transcriptional regulation of rAGI are iargely unknown. The main goal cf
the present studies is te identify and clone the 2 nuclear proteins and to
investigate their actions on AGI gene expression.
Hypothesis: We hypothesize that the 48- and 70-kD nuclear proteins
speciflcally bind to IRE and that both have transcriptional activity on the
rAGT promoter. Subsequently, both exert their effects on the regulation of
rAGI expression, could be modulated by its IRE, and interact with other
cis- and trans-element factors at the gene transcription level.
AIM 1: la clone and identify the 48-kD nuclear protein and investigate
its role in AGT gene expression.
AIM 2: b clone and identify the 70-kD nuclear protein and investigate
its raie in AGT gene expression.
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AIM 3: To elucidate the essential roles of these 2 nuclear proteins in
AGT regulation and their subsequent influence on RAS activation and the
progression of renopathology in hyperglycemia, i.e. RPTC hypertrophy.
HYPOTH ESIS
Hyperglycemia insulin signal
__________
(MEKI/2) I PD98059
TFIID TEIIA.
TBP
AGT
Li J’Lfî
Chapter 2 : Article I
Heterogenous nuclear ribonucleoprotein F
modulates angîotensïnogen gene expression ïn
rat kïdney proximal tubular celis.
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ABSTRACT
We previously identified an insuhn-responsive element (IRE) in the rat
angiotensinogen (ANG) gene promoter that binds to 2 nuclear proteins with
apparent molecular weights of 48 and 70 kiloDalton (kDa) from rat
immortalized renal proximal tubular cells (IRPTCs). The present studies
aimed to identify and clone the 48 kDa nuclear protein and to define its action
on ANG gene expression. Nuclear proteins were isolated from IRPTCs and
subjected to 2-dimensional electrophoresis. The 48 kDa nuclear protein was
detected by Southwestern bloffing and subsequently identified by mass
spectrometry, revealing that it was identical to 46 kDa heterogeneous nuclear
ribonucleoprotein F (hnRNP F), a nuclear protein that binds to TATA-binding
protein and associates with RNA polymerase Il and also interacts with nuclear
cap-binding complex. We cloned the hnRNP F cDNA from IRPTCs by reverse
transcriptase-polymerase chain reaction. Bacterially-expressed recombinant
hnRNP F bound to the rat ANG-IRE, as revealed by gel mobility shift assay.
The addition of polyclonal antibodies against hnRNP F yielded a supershift in
gel mobility. Transient transfer of sense and antisense hnRNP F cDNA in
IRPTCs inhibited and enhanced angiotensinogen gene expression,
respectively. High glucose stimulated and insulin inhibited hnRNP F
expression in IRPTCs. Expression studies indicated that hnRNP F is present
in the kidney, testis, liver, lung and brain but flot in the spleen. In conclusion,
our studies demonstrate that hnRNP F binds to rANG-IRE and modulates
renal ANG gene expression, implicating that dysregulation of hnRNP F might
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affect renin-angiotensin system activation and, subsequently, kidney injury in
diabetes.
Abstract: 249 words; Text: 5,131
INTRODUCTION
insulin regulates the expression of over 100 genes by affecting the
transcription, mRNA stabiiity or mRNA translation (1, 2). The underiying
mechanism(s) of insulin regulation of gene transcription and mRNA stability
are poorly understood. One major obstacle in hampering the progress at the
transcriptional level is that there is no consensus insulin response element
(IRE) that can be account for the regulation of ail insulin responsive genes.
This is in contrast with consensus-responsive elements that have been
described for other hormones, i.e., the steroid hormone receptors. However,
some genes whose transcription is inhibited by insulin appears to share a
common IRE (T(G/A)Tfl(T/G)(GIT)) core sequence including
phosphoenolpyruvate carboxykinase (PEPCK), insulin-like growth factor
binding protein-J (1GFBP-1), tyrosine aminotransferase, glucose-6-
phosphatase, apolipoprotein C III, and aspartate aminotransferase (3-8).
Iransacting factors that interact with the above common IRE have been
tentativeiy identifled, but none have been directly shown to mediate an insulin
response. Moreover, other genes contain a weil-deflned IRE but its sequence
is substantially different from the common IRE (2), thus it has been postulated
that no single common transacting factor could be associated with ail IREs of
different genes.
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Angiotensinongen (ANG) s a glycoprotein consisting of 452 amino
acid residues with an apparent molecular weight of 62-65 kiloDalton (kDa) (9,
10). ANG is principally expressed in the iiver and is the sole substrate in the
renin-angiotensin system (RAS). In addition to the weii-characterized
systemic RAS, the presence of a local intrarenal RAS has now been
generally accepted (11,12). The mRNA and protein for ail RAS components,
including ANG, renin, angiotensin-converting enzyme (ACE) and
angiotensin il (Ang li) receptors (AT1R and AT2R subtypes), are expressed in
murine and rat immortalized renal proximal tubular ceils (IRPTCs) (13-20).
Several studies have reported that Ang li levels, ANG and renin mRNA
expression are eveivated in early diabetic kidney (16, 21, 22), suggesting that
hyperglycemia and/or augmented intrarenal Ang Il may be directly or
indirectiy responsible for renal proximal tubuiar hypertrophy and
tubuiointerstitiai fibrosis in diabetes.
in previous studies, we showed that high glucose stimuiates and
insuiin inhibits ANG gene expression and cell hypertrophy in IRPTCs (23-31).
Moreovet, we identifled a putative insulin tesponsive element (IRE) motif
containing nucleotides N-878 to N-864 (5’ CCI TCC CGC CCT TCA 3’)
upstream of the transcription start site of the rat ANG gene promoter (32).
This ANG-IRE binds to 2 major nuciear proteins with apparent molecular
weights of approximately 48 and 70 kiloDaltons (kDa) from IRPTCs, as
revealed by Southwestern blouing (31). it appears that high glucose and
insulin enhanced and inhibited the expression of 48 and 70 kDa nuciear
protein expression in 1RPTCs, respectively. These data suggest that 48 and
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70 kDa nuclear protein might mediate the effect of high glucose and insulin
on ANG gene expression in IRPICs.
The present studies aimed to identify and clone the 48 kDa nuclear
protein and to investigate its action on ANG gene expression. We have
identifled the 48 kDa nuclear protein as 46 kDa heterogenous nuclear
ribonucleoprotein F (hnRNP F) by 2-dimensional (2-D) electrophoresis and
mass spectrometry. We demonstrated that hnRNP F binds to ANG-IRE and
modulates ANG gene expression in IRPTCs. Finally, high glucose stimulated
and insulin inhibited hnRNP F expression in IRPTCs. These studies
demonstrate that 46 kDa hnRNP F is one of the IRE-binding proteins (BPs)
that binds to the rat ANG gene promoter and modulates ANG gene
expression in IRPTCs.
MATERIALS AND METHODS
D(+)-glucose, D-mannitol and insulin were purchased from Sigma
Aldrich Canada Ltd. (Oakville, ON, Canada). Gamma-[32P-ATP] (3000 Ci/mol)
and D-threo-[J,2 14CJchoramphenicol were obtained from Amersham
Pharmacia Biotech (Baie dijrfé, QC, Canada). Rabbit polyclonal antiserum
raised against the full-length human hnRNP F and antiserum predominantly
recognizing hnRNP F (CTARRYIGIVKQAGLER corresponding to amino acids
215 to 230 of human hnRNP F (33)) was a gift from Dr. Taka-aki Tamura
(Chiba University, Chiba, Japan) and Dr. Christine Milcarek (University of
Pittsburgh School of Medicine, Piftsburgh, PA, USA), respectively. The
characteristics of these antisera have been reported (34, 35). The bacterial
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expression vector pGex 4T-3, and mammalian expression vector pcDNA 3.1,
were purchased from Amersham-Pharmacia Biotech and inVitrogen inc.
(Buriington, ON, Canada), respectiveiy. Restriction modified enzymes were
acquired from either InVitrogen Inc., Amersham-Pharmacia Biotech or Roche
Diagnostics (Lavai, QC, Canada).
Oiigonucieotides for rat ANG-IRE N-882 to N-855 (5’ CCI CCC TIC
CCG CCC TTC ACT TIC TAG T 3’) (32), mutants cf ANG N-882 to N-885
(Ml, 5’ CCI CCC TIC CAT TAC TIC ACT TIC TAG T 3’, M2, 5’ CCI CCC
lIA AAT AAG ACC ACI ITC TAG T 3’, M3, 5 CCI CCC TIC CCI TCC
TIC ACT TIC TAG T 3, M4, 5 CCT CCC TIC CCL CCC TIC ACT TIC
TAG 1 3, rANG-IRE motif N-878 to N-864 (5’ CCI TCC CGC CCI TCA 3’),
concanmeric rANG-iRE motif (3 X N-878 to N-864, 5 CCT TCC CGC CCT
TCA CCI TCC CGC CCI TCA CCI TCC CGC CCI TCA 3), iRE of human
giyceraidehyde phosphate dehydrogenase gene (hGAPDH-IRE, N-473 to N-
477, 5’ CCA ACT TIC CCG CCI CTC AGC CU TGA A 3) (36), IRE of rat
giucagon gene (N-267 te N-242, 5’ AGI ITT CAC GCC IGA CTG AGA 11G
A 3’) (37) were synthesized by InVitrogen inc. The oiigonucleotide containing
the consensus SPI-binding site (5 -TCG CCC CGC CCC CGA ICG AAI-3)
(38) was purchased from Promega (Fisher-Scientific Inc., Montreai, QC,
Canada).
The plasmid containing the concatameric rANG-IRE motif DNA was
constructed by inserting the double-stranded concatameric rANG-iRE motif
oligonucieotide with the Not-l enzyme restriction site added on both termini
into the polyclonal site cf pcDNA 3.1 by conventionai methodology. The
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double-stranded concatameric rANG-IRE motif DNA fragment was then
incised from the plasmid and used for labeling as probe.
The expression vectors, plasmid containing the coding sequence for
chloramphenicol acetyltransferase (CAT) without the promoter (pOCAT) or
with Rous sarcoma virus enhancer/promoter sequence (pRSV/CAT) fused to
the 5 -end of the CAl coding sequence, respectively, were a gift from Dr. Joel
F. Habener (Massachusetts General Hospital, Boston, MA). Thin-layer
chromatography plates were purchased from Fisher Scientific (Montreal,
Quebec, Canada).
Celi Culture
IRPTCs at passages 12 to 16 were used in the present studies. The
characteristics of IRPTCs, which express the mRNA and protein of ANG,
renin, ACE, and Ang Il receptors, have been described previously (39).
Cellular and Tissue Nuclear Extract Preparation
Nuclear extracts from 10 plates (150 x 20 mm) each of confluent
IRPTCs previously incubated in DMEM with 5 mM glucose and 20 mM D
mannitol, 25 mM glucose or 25 mM glucose plus insulin (10v M) for 24 h, and
rat tissues (liver, kidney, testis, lung, brain and spleen) were prepared
according to the method of Henninghausen and Lubon (40) with slight
modifications, as we have described elsewhere (31, 41).
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2-D Electrophoresis
2-D electrophoresis was carried out with the IPGphor Isoelectric
Focusing Unit (Amersham-Pharmacia Biotech). For isoelectrofocusing fIEF),
precast 13 cm IPG strips (pH 3-10, non-linear, Immobiline DryStrips,
Amersham-Pharmacia Biotech) were pre-equilibrated with 750 tg of nuclear
extracts in 250 tl rehydration buffer (8 M urea, I M thiourea, 4% CHAPS, 2%
IPG buffer, 1%NP-40, 0.1 M DTT, and 0.0001% of bromophenol blue (BPB))
for more than 12 h according to the supplieris manual. IEF was run for 90
kilovoit-hours at 25°C. After IEF separation, the IPG strips were immediately
equilibrated for 15 min with a buffer containing 50 mM Tris-HCI, pH 6.8, 6 M
urea, 30% glycerol, 2% sodium dedocyl sulfate (SDS), 2% Dfl and 0.0001%
of BPB. Then, the strips were re-equilibrated with another buffer containing
50 mM Tris-HCI, pH 6.8, 6 M urea, 30% glycerol, 2% SDS, 2%
iodoacetamide and 0.0001% BPB for an additional 15 min. For 2-D
separation, the IPG strips were placed above 10% polyacrylamide gel (PAGE)
containing SDS and electrophoresed. Amershams rainbow markers served
as molecular weight markers. IRPTC nuclear extracts (100 tg) were run on
the same 10% PAGE-SDS as controls. Each sample was divided in 2 strips
for 2-D electrophoresis. One gel was stained with Coomassie Brilliant Blue R
250 (Amresco Inc., Solon, OH, USA) to visualize proteins. The other was
electrotransferred to a Hybond C-extra membrane (AmershamPharmacia
Biotech) for Southwestern blotting.
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Southwestern Bloffing
Southwestern bioffing was performed according to the procedure of
Kwast-Welfeld et al. (42) with slight modifications (31,41). Briefly, IRPTC
nuclear proteins (200 tg) were resolved on a 4 to 20% PAGE-SDS gradïent
or on 10% PAGE-SDS (43), then electrotransferred to a Hybond C-extra
membrane, which was incubated with 10% (WN) non-fat miik proteins in a
binding buffer containing 10 mM Hepes, pH 7.0, 10 mM MgCI2, 50 mM NaCI,
0.25 mM EDTA and 2.5% glycerol (VN) for 24 h at 4°C. The membrane was
washed at least twice with binding buffer containing 0.25% non-fat milk
proteins. Subsequently, it was hybridized overnight with 32P-labelled
concanmeric ANG-IRE motif DNA (approx. 1.0 to 2.0 pmol; 106 cp/ml) in
binding buffer containing 0.25% non-fat milk proteins and 300 tg/ml non
denatured herring sperm DNA at 4°C. The membrane was finally washed,
air-dried and exposed for autoradiography.
MALDI-Mass Sjectrometry
Spots on the gel corresponding to positive signais of the Southwestern
blot membrane were picked up for MALDI-Mass Spectrometry (MALDI-MS).
Ail MALDI-MS analyses were performed at the Quebec Genome Centre
(McGill University, Montreal, QC, Canada). Briefly, protein samples were first
cleaved by trypsin and then subjected to MALDI-MS. MALDI-MS analysis was
conducted at 20 kV accelerating voltage and 23 kV reflecting voltage. For
protein identification, peptide mass fingerprints were searched by the Mascot
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program developed by Mattix Science Ltd. (freely accessible on
hftp:\\www.matrixscience.com).
Cloning of hnRNP F
hnRNP F was cloned from IRPTCs by conventional RT-PCR. Sense
and antisense primers corresponding to nucleotides N+1 to N÷19 (5 ATG
ATG CTG GGC CCT GAG G 3) and N+1228 to Ni-1245 (5 TCG TAC CCA
CCT ATA CTA ATC 3) of rat hnRNP F cDNA (35) were used in PCR. In
addition, the Not I enzyme restriction site was added on the 5 and 3 end of
sense and antisense primers, respectively. hnRNP F cDNA was then
subcloned in sense and antisense orientation at the polyclonal site (Not 1) of
the bacterial expression vector pGex 4T-3, or mammalian expression vector
pcDNA 3.1, by conventional methodology.
Purification of Recombinant hnRNP F from Bacteria
E.CoIi BL-21 celis (Amersham-Pharmacia Biotech) were transformed
by pGex 4T-3 containing rat hnRNP F cDNA. Expression of the fusion protein
[GST fused with hnRNP F (GST-hnRNP F)] in BL-21 celis was induced by the
addition of 0.5 mM isopropylthiogalactoside (IPTG) into the culture medium
with incubation for 4 h. The bacteria were then harvested, and GST-hnRNP F
fusion proteins were purified from the bacterial extracts by GST affinity
column chromatography according to the manufactureris protocol
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(Amersham-Pharmacia Biotech). The purified GST-hnRNP F fusion ptoteins
were used in gel mobility shift assays.
GMSAs
Gel mobility shift assays (GMSAs) were performed according ta
methodology described elsewhere (31, 41), employing the labeled monomeric
ANG-IRE motif DNA as probe. Briefly, the rANG-IRE DNA fragment was 5’
end labeled with [y-32PJ-ATP by T4 polynucleotide kinase. Purifed GST
hnRNP F fusion proteins (1 tg) or GST (5 gig) or IRPTC nuclear proteins (5
jtg) in the presence of 0.3 units of poly(dl/dC) in 20 mM Hepes (pH 7.6), 1
mM EDTA, 50 mM KCI, 2 mM spermidine, 1 mM Dfl, 0.5 mM PMSF and
10% glycerol (VN) were incubated for 30 min at room temperature. Then, the
5’-labelled probe (—0.1 pmol) was added and further incubated for 30 min at
room temperature. After being chilled on ice, the mixture was run on 5%
(WN) non-denaturing PAGE and exposed for autoradiography.
In competition assays, 100- ta 300-fold molar excess of unlabeled DNA
fragments was added ta the reaction mixture and incubated for 30 min at
room temperature before incubation with the Iabeled probe. In super-shiif
assays, 0.5 ta 2 pi of polyclonal antibodies against hnRNP F was added in
the reaction mixture and incubated for 30 min on ice before incubation with
the labeled probe.
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Mammalian ExDression of Recombinant hnRNP F
Mammalian expression vector pcDNA 3.1 containing rat hnRNP F
cDNA in sense (pcDNA 3.1/hnRNP F (+)) or antisense (pcDNA 3.1/hnRNP F
(-)) orientation was transfected into IRPICs with Fugene 6 reagent according
to the instruction manual provided by the supplier (Roche Diagnostics). We
optimized the DNA concentration for gene transfection at 2 ig per 0.5 to I x
106 cells. Forty-eight h after transfection, the celis were either harvested and
assayed for hnRNP F protein and ANG mRNA by Western blolling and RT
PCR, respectively.
Western Blotting for hnRNP F
Briefly, the cellular proteins and nuclear extracts were dissolved in 700
tl lysis buffer [62.5 mM Tris-HCI, pH 6.8, containing 2% (WN) SDS, 10%
glycerol, 50 mM DIT, 1 mM PMSF, 1 ig/mI leupeptin, I ig/ml aprotinin, and
0.1% (WN) BPB], sonicated for 15 sec, heated at 95°C for 5 mm, and
centrifuged at 12,000 x g for 5 min. Thirty-five pi cf the supernatants were
subjected to 10% PAGE-SDS gel and then transferred onto a polyvinylidene
difluoride membrane (Hybond-P, Amersham-Pharmacia Biotech). The
membrane was initially blotted for anti-hnRNP F antibody (1 :30,000 dilution)
and then reblofted for anti-f-actin antibody (1:10,000 dilutions) using
chemiluminescent developing reagent (Roche Diagnostics). The relative
densities of the hnRNP F and F3-actin bands were quantified by computerized
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laser densitometry (ImageQuant software (version 5.1), Molecular Dynamics,
Amersham-Pharmacia Biotech).
RT-PCR for Quantification of ANG mRNA in IRPTCs
Total RNA, isolated with TRizol reagent (InVitrogen Inc.) according ta
the supplier[s protocol and quantified by its absorbance at 260 nm, was
deployed in RT-PCR ta quantify the amaunt of ANG mRNA expressed in
IRPTCs as described previously (25, 26). The sense and antisense rat ANG
primers were 5’-CCT CGC TCT CIG GAC TTA TC-3’ and 5’-CAG ACA CTG
AGG TGC TGT TG-3’, corresponding ta N+729 ta N+748 of exan 2 and
N+1 11 to N+1 30 of exon 3 af rANG gene (9), respectively. The sense and
antisense rat 3-actin primers were 5’-ATG CCA 1CC TGC GIC TGG ACC
TGG C-3’ and 5’-AGC AH TGC GGT GCA CGA TGG AGG G-3’,
corresponding to the nucleotide
sequences cf +155 ta +179 of exan 3, and nucleotide sequences af +115 ta
+139 cf exon 5 af the rat f3-actin gene (44), respectively.
To identify rANG and 3-actin cDNA fragments, 10 pI cf the PCR
praduct were electrophoresed an 1.2% agarase gels and transferred onto a
Hyband XL nylon membrane (Amersham-Pharmacia Biotech). Digoxigenin
labeled aliganucleatide 5’-GAG GGG GTC AGC ACG GAC AGC ACC-3’,
correspanding ta nucleotide +775 ta +798 of rANG cDNA (9) (i.e., nucleatide
+828 ta +851 cf exan 2 cf rANG gene (44)) prepared with a digoxigenin
aligonucleatide 3’ end labeling kit (Roche Diagnastics), was used ta hybridize
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the PCR products on the membrane. After stringentwashing, the membrane
was detected with a digoxigenin luminescence kit (Roche Diagnostics) and
exposed to Kodak BMR film (Eastman Kodak Co., Rochester, NY). After
rANG mRNA analysis, the same membrane was stripped and rehybridized
with a 3-actin oligonucleotide probe (sequence: 5-TCC TGT GGC ATC CAl
GAA ACI ACA TTC-3’, corresponding to nucleotides +9 to +35 of exon 4 of
the rat -actin gene (44)). ANG mRNA levels were normalized by
corresponding J3-actin mRNA levels.
Chloramrhenical Acetvl Transferase (CAl) assay
The method of construction of the rANG-CAT fusion gene,
pOCATIrANG N-1498/+18 and mutant pOCAT/rANG N-14981+18 with
mutated IRE has been described previously (31, 32). Control plasmid or
ANG-CAI fusion gene were transfected into IRPTCs using lipofectamine
(InVitrogen, Inc.). We have optimized the DNA concentration for gene
transfection at 2-3 pg per 0.5 to I x 106 cells. Thus, in the present studies, a
total of 2 j.g of supercoiled DNA (i.e., 2 ig of pRSV/CAT, 1 .tg of pOCAT
/rANG N-14981+18 or mutant pOCAT/rANG N-1498/+18 plus I jtg of pcDNA
3.1 or pcDNA 3.1/hnRNP F) was used routinely in celi transfection. 24 h after
the transfection, the media were ceplaced with fresh 5 mM D-glucose DMEM
and incubated for another 24 h. The ceils were then harvested and assayed
for CAT activity (30).
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To normalize the efficiency of transfection, 0.5 jtg 0f pTKIhGH [a vector
with the thymidine kinase (TK) enhancerlpromoter fused to the 5 -human
growth hormone (hGH) gene] was co-transfected with pRSV/CAT or
pOCAT/rANG N-14981+18 as described previously (30). The plasmid
pRSV/CAT served as a positive control to monitor the efficiency of
transfection of rANG-CAl fusion gene. The level of transfection efficiency for
pRSVICAT in IRPTCs ranged from 60 to 90%, i.e., the percentage of
conversion of 14C chloramphenicol to mono- and di-acetyl chloramphenicol.
The transfection efficiency of pOCAT/rANG N-14981+18 in IRPTCs ranged
from 25% to 35% compared with pRSV-CAT. The inter- and intra-assay
coefficient variation of transfection for pOCAT/rANG N-1498/+18 in IRPTCs
are 25% and 12% (N = 10), respectively. The method for chloramphenicol
acetyltransferase (CAT) assay has been described previously (30).
Statistical analysis
Three to 5 separate independent experiments were performed per
protocol, and each treatment group was run in duplicate. The data were
analyzed by one-way ANOVA and the Bonferroni test. A probability tevel of
p0.05 was regarded as statistically significant.
RESU LTS
Identification of Rat IRE-BPs in IRPTCs
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Figure lA shows the staining of nuclear proteins aftet 2-D
electrophoresis. Southwestern blotting of IRE-BPs affer 2-D electrophoresis is
displayed in Figure lB. It is apparent that 2 positive spots with an apparent
molecular weight of 46-48 kDa were identified, and these spots were cut out
and subjected to MALDI-MS. The MS resuits are displayed in Figure 2. The 2
spots identified a common protein designated as RIKEN (Accession number
4833420120 (Mus musculus)). Database analysis revealed that RIKEN is
identical to the rat hnRNP F cDNA sequence reported by Yoshida et al. (34).
To confirm the authencity of rat hnRNP F revealed by Southwestern
bloffing, we stripped the radioactivity from the membrane and reblofted with
rabbit polyclonal antiserum against hnRNP F, as shown in Figure IC. It is
apparent that the proteins interacting with anti-hnRNP F were superimposabte
with positive signais detected by Southwestern blolling, as seen in Figure lB.
These data confirm that the proteins that interact with rat ANG-IRE are
identical to hnRNP F.
Gel Mobility Shift Assay
Bacterially expressed recombinant hnRNP F was employed ta study
the interaction of putative rANG-IRE (N-878 ta N-864) with hnRNP F. Figure
3 illustrates the analysis of GST-hnRNP F fusion proteins by 10% PAGE-SDS
gel. Three major bands with apparent molecular weights of 26, 44 and 69-72
kDa were induced by isopropylthiogalactosidase (IPTG) (Figure 3A). The 44
and 69-72 kDa species interacted with rabbit antiserum against hnRNP F, but
flot the 26 kDa species (Figure 3B). The 26 kDa molecular species was the
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induced GST protein, according to information provided by the supplier
(Amersham-Pharmacia Biotech). The 69-72 kDa molecular species had the
molecular weight cf hnRNP F (46 kDa) fused with GST (26 kDa), whereas the
44 kDa molecular species was Iikely partially-degraded GST-hnRNP F fusion
proteins. Partially-purifed GST-hnRNP F (lane 7 in Figure 3A and 35) was
used in subsequent GMSAs.
When the labeled rANG-IRE DNA was incubated with GST-hnRNP F,
1 major band consisting of 2 species appeared with retarded mobility (Figure
4A). No slowly-migrating band was observed when the Iabeled DNA was
incubated with GST (bacterial extract of empty vector pGex 4T-3). The
addition of an unlabeled rANG-IRE was effective in competing with the
binding of Iabeled rANG-IRE DNA to the fusion proteins(s) (100- and 300-fold
molar excess of unlabeled DNA fragment), but not the unlabeled DNA
fragment of hGAPDH-IRE, rat glucagon-IRE, and the SPi consensus
sequence (Figure 45). Unlabeled mutants (M3 and M4) of rANG-IRE (N-878
to N-864) were effective in competing with the binding of labeled rANG-IRE
DNA but not the unlabeled mutants (Ml and M2) of rANG N-882 to N-855 in
competing with the bïnding of Iabeled rANG-IRE DNA (Figure 5). These
studies showed that the mutation of 4 nucleotides in N-878 to N-864 was
sufficient to completely abolish binding with hnRNP F, indicating that the
rANG N-874 to N-867 sequence Iocalized within nucleotides N-878 to N-864
is important for binding to hnRNP F.
The addition of rabbit antiserum against hnRNP F induced a supershift
cf rANG-IRE binding with GST-hnRNP F fusion protein in a dose-dependent
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manner (Figure 6). These data further conflrm that rat ANG-IRE binds to
hnRNP F.
Figure 7 reveals that the labeled rANG-IRE binds 3 major IRPTC
nuclear proteins (Iabeled bands A, B and C). Nuclear proteins in ail three
bands are completely displaced by 100 X fold-excess of unlabeled rANG-IRE.
The addition of rabbit anti-hnRNP F induced a supershift of rANG-IRE binding
with nuclear proteins in band A but not band B and C. No supershift bands
were observed with rabbit non-immune immunoglobulin G (lgG). These
resuits demonstrate that rANG-IRE binds to endogenous nuclear hnRNP F in
1RPTCs as well as with two unidentifled nuclear proteins.
Effect of hnRNP F on ANG mRNA Exrression in 1RPTCs
HnRNP F expression (Figure SA) from IRPTCs transiently transfected
with pcDNA 3.1/hnRNP F (+) was significantiy higher (p<0.05) than in IRPTCs
transientiy transfected with empty vector, pcDNA 3.1 or pcDNA 3.1/hnRNP F
(-), as analyzed by Western blolling. it is apparent, however, that basal ANG
mRNA levels in IRPTCs transiently transfected with pcDNA 3.1/hnRNP F (+)
were signiflcantiy lower (50% decrease, p.<0.05) than those in non-transfected
IRPTCs (Figure 8B). In contrast, ANG mRNA levels were significantly higher
(200% increase, p<0.01) in IRPTCs transientiy transfected with pcDNA
3.1/hnRNF (-) than those in non-transfected IRPTCs (Figure 8B). These
resuits demonstrate that transfected sense and antisense hnRNP F cDNA
80
respectively suppressed and enhanced the expresssion 0f endogenous ANG
mRNA in IRPTCs.
Effect of hnRNP F on rANG Gene Promoter Activity
Figure 9 indicates that co-transfection with hnRNP F significantly
suppresses rANG gene promoter activity. However, co-transfection with
hnRNP F had no inhibitory effect on mutant rANG gene promoter activity.
These studies support the notion that hnRNP F modulates ANG gene
expression at the transcriptional level via binding to the IRE.
Effect of High Glucose and lnsulin on hnRNP F Expression in IRPTCs
Figure JOA shows the Southwestern blot analysis of hnRNP F
expression in IRPTC nuclear extract by employing the labeled rANG-IRE.
After Southwestern blot analysis, the same menbrane was blofted with the
polyclonal antibodies against the hnRNP F (Figure lOB). Southwestern
blolling analysis reveals that high glucose levels (25 mM) enhanced and
insulin suppressed the expression of 48- and 70-kDa molecular species from
IRPTCs. The polyclonal antibodies against the hnRNP F interacted with a
predomïnant molecular species of 48-kDa and a minor specîes of 46-kDa.
The 48-kDa molecular species detected by Southwestern blotting (Figure
I OA) is superimposed or corresponding to the 48-kDa species detected by
Western blotting (Figure lOB). These data demonstrate that the 70 kDa IRE
BP is immunologically different from the hnRNP F. The expression of HnRNP
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F and unidentified 70 kDa IRE-BP is regulated by high glucose and insulin in
I RPTCs.
Tissue Distrïbution of hnRNP F in Rat Tissues
Figure 1f illustrates the tissue distribution of the hnRNP F protein in
various rat tissues by Western blotting. It is apparent that the hnRNP protein
is present in the nuclear extracts of kidney, liver, testis, lung and brain but not
in the spleen.
DISCUSSION
The present studies employed a combination cf Southwestern blolling
and proteomics and identified hnRNP F as one of the nuclear ptoteins that
binds ta IRE of the rat ANG gene promoter and inhibits ANG gene
expression in IRPTCs.
We have previously demonstrated that high glucose enhances the
expression of bath 48 and 70 kDa nuclear proteins in IRPTCs, and insulin
inhibits this increment, suggesting that 48 and 70 kDa nuclear proteins may
mediate the effect of high glucose and insulin on ANG gene expression in
IRPTCs. Since the molecular structure of the 48 and 70 kDa IRE-binding
proteins is unknown, the present studies aimed to identify their molecular
structure. lt is apparent that multiple IRPTC proteins are resolved by 2-D
electrophoresis. A second gel run simultaneously with the first gel for
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Southwestern bloUing demonstrated 2 positive spots with an apparent
molecular weight of 46-48 kDa, and pi cf 5.0 te 6.0 that closely matched the
stained protein spots on the first gel. After tryptic digestion and MALDI-MS,
these two spots were found to have matching the partial amine acid
sequence deduced from RIKEN cDNA (Accession number 4833420120, gi
19527048 and NM 133834). The cDNA sequence of RIKEN is identical to the
hnRNP F sequence as reported by Yoshida et aI (34) (Accession number
BAA 37095). Using specific rabbit antiserum against hnRNP F, we confirmed
the identity cf hnRNP F on the membrane from Southwestern blet. Western
blotting revealed positive signais superimposed on the positions cf the 2
spots detected by Southwestern blolling. The reasons why hnRNP F is
present in 2 different forms (same apparent molecular weight but different pi)
is presently unclear. One possibiiity is that these proteins might be variants
with different phosphorylated forms.
A broad spot with an apparent molecular weight cf 68 te 70 kDa
(denoted by broken rectangle in Figure 1) was detected by Southwestern
blotting. Subsequent MALDI-MS analysis of this spot, however, couid flot
yieid a definite peptide with a significant high Masscot score. These data
suggest that the positive broad spot detected by Southwestern biolling is a
ciuster cf several different proteins.
Te demonstrate that hnRNP F interacts with rANG-IRE, we cioned
hnRNP F from IRPTCs by conventional RT-PCR and expressed it in a
bacterial system fer use in GMSAs. Our GMSAs revealed that iabeied rANG
iRE DNA interacted with GST-hnRNP F fusion protein(s), but net GST
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proteins. The addition cf unlabeled rANG-IRE DNA effectively displaced
Iabeled ANG-IRE at or greater than a 100-fold molar excess of unlabeled
DNA, whereas unlabeled hGAPDH-IRE, rat glucagon-IRE, SPi consensus
sequence, and mutants Ml and M2 of rANG-IRE were not effective in
displacing Iabeled rANG-IRE. In contrast, M3 and M4 were effective in
competing with Iabeled ANG-IRE. These studies demonstrate that
nucleotides N-878 to N-864 represent the rANG-IRE motif, which is essential
for binding to hnRNP F fusion proteins.
Most convincingly, the addition cf specific rabbit polyclonal antibodies
against hnRNP F yielded a supershift of Iabeled rANG-IRE binding with
hnRNP F fusion proteins in a dose-dependent manner. Moreover, the
addition cf rabbit polyclonal antibodies against hnRNP F also yielded a
supershift of Iabeled rANG-IRE binding with IRPTC nuclear proteins but not
with rabbit immunoglobulin G. Taken together, these data demonstrate
unequivocally that hnRNP F binds to rANG-IRE.
There are at Ieast 20-30 independent hnRNP species in mammalian
cells (45, 46). Since antibodies against hnRNPs affect splicing (47-49), and
hnRNPs are associated with poly (A)-containing RNA, i.e., pre-mRNA and
mRNA, and found to be constituents of the splicesome (47), they are believed
to be important in splicing events. HnRNP F is a member of a subfamily of
hnRNP proteins which includes at Ieast F, H and HEproteins (33, 50). These
proteins are highly related; hnRNP H and H are 96% identical and 78 and
75% identical te hnRNP F, respectively (33, 50). HnRNP F has the unique
nucleotide binding property of bindïng to (G/C)-stretch cf double-stranded
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DNA and RNA sequences via its GY-rich motif and RNA-binding domains,
respectively (34). Studies on hnRNP F and H/H:ihave revealed that these
proteins participate at various steps in the processing of cellular mRNA, i.e.,
in alternating spiicing of the c-src gene (51), the J3-tropomyosin gene (52), and
the thyroid hormone receptor gene (53). Furthermore, Veraldi KL et al. (54)
have demonstrated that differential changes in expression levels of hnRNP F
and H/Hzare involved in controlling the synthesis of membrane-bound versus
secreted antibodies during the development of memory B ceils into plasma
celis. Most interestingly, studies by Yoshida et aI (55) and Gamberi et al. (56)
have demonstrated that hnRNP F could bind to TATA-binding protein,
associates with RNA polymerase II and interacts directly with nuclear cap
binding protein (CBP) complex, suggesting that hnRNP F could modulate
gene expression at the transcriptional and post-transcriptional levels. Thus,
these data strongly indicate that the members of this subfamily are important
for the control of gene expression at both the transcriptional and post
transcriptional levels in various ceils.
Surprisingly, over-expression and down-expression of hnRNP F
inhibits and augments ANG mRNA expression and ANG gene promoter
activity in IRPTCs, respectively. To the best of our knowledge, the present
report is the flrst to demonstrate that hnRNP F can modulate ANG gene
expression in kidney proximal tubular ceNs in vitro. At present, the molecular
mechanism(s) of hnRNP F action on ANG gene expression is flot known. One
possibility is that hnRNP F behaves like a negative transacting protein and
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inhibits the binding 0f other positive transacting factor(s) (i.e., the p70 kDa
IRE-BPs) to TBP and RNA polymerase II, subsequently attenuating ANG
gene expression. The second possibility is that hnRNP F overexpression
exhausts the availability of nuclear CBPs for capping pre-mRNAs, which
would subsequently allenuate the formation of mature ANG mRNA in the
cytoplasm. The third possibility is that hnRNP F could bind to unidentified
spiicing silencer(s) in ANG pre-mRNA and subsequently alter the normal
splicing of ANG pre-mRNA in the nucleus. Finally, it is possible that hnRNP F
is a negative regulatory protein, but its negative effect is normally neutralized
by interaction (heterodimerization) with the unidentified 70 kDa IRE-BP (an
hypothetical positive regulatory transacting factor that binds to rANG-IRE) in
cells. HnRNP F overexpression will then exceed the neutralization ability of
the unidentified 70 kDa IRE-BP and subsequently attenuate ANG mRNA
expression. More studies are definitely needed along these lines to elucidate
the mechanism(s) of action of hnRNP F on ANG gene expression in IRPTCs.
Finally, our studies reveal that high glucose stimulated and insulin
inhibited the expression of hnRNP F in IRPTCs. To the best of our knowledge,
this is the first report that hnRNP F could be modulated by high glucose and
insulin in kidney proximal tubular cells in vitro. Our tissue distribution analysis
revealed that the hnRNP F protein is detectable in the nuclear extracts of rat
liver, kidney, testis, brain and lung but flot in the spleen. Rat liver, kidney,
testis (epididymis), brain and lung are known to express ANG mRNA (57, 58).
These observations raise the possibility that the expression of hnRNP F might
have a role in regulating ANG gene expression in these tissues.
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In summary, we have identified a nuclear protein that binds to rANG
IRE by a combination of Southwestern blolling and proteomics. This IRE
binding protein is identified as hnRNP F. hnRNP F modulates ANG gene
expression in IRPTCs. Finally, it appears that high glucose and insulin
regulate hnRNP F expression in IRPTCs and hnRNP F is detected in various
rat tissues that express ANG mRNA. The present studies raise the possibility
that the expression of hnRNP and the unidentified 70 kDa IRE-BP(s) may
play an important role in regulating local intrarenal RAS activation.
Dysregulation of the expression of hnRNP F and unidentified 70 kDa IRE-BPs
may contribute to renal injury in diabetes via altering local intrarenal RAS
activation.
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APPENDIX
Abbreviations used in this article: ACE, angiotensin-converting enzyme;
ANG, angïotensinogen; Ang Il, angiotensin Il; BPB, bromophenol blue; CBP,
CAP-binding protein; CREB, cAMP-responsive element-binding protein;
DMEM, DulbeccoLs modified Eagle medium; DN, diabetic nephropathy; EDTA,
ethylenediaminetetraacetic acid; FBS, fetal bovine serum; GMSA, gel
mobility shift assay; hGAPDH, human glyceraldehyde phosphate
dehydogenase; hnRNP F, heterogenous nuclear ribonucleoprotein F; IPTG,
isopropylthïogalactosidase; IRE, insulin-responsive element; I RE-BP, IRE
binding protein; IRPTCs, immortalized renal proximal tubular ceils; kDa,
kiloDalton; MALDI, Matrix assisted laser desorption/ionization technique; MS,
mass spectrometry; PCR, polymerase chain reaction; RAS, renin-angiotensin
system; RT-PCR, reverse transcriptase-polymerase chain reaction; SDS
PAGE, sodium dodecyl sulfate-polyacrylamide gel electrophoresis; 2-D, 2
dimensional
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LEGENDS
Figure J: Rat ANG IRE-BPs detected by 2-dimensional (2-D)
electrophoresis, Southwestern and Western bloftings. A, rat
IRPTC nuclear extracts were subjected to 2-D electrophoresis
and then stained with Coomassie Brilliant Blue R-250. M:
Amersham Pharmacia Biotech[s rainbow molecular mass
markers. N.E.: rat IRPTC nuclear extracts without
isoelectrofocusing. B, Southwestern blolling analysis of ANG
IRE-BPs from IRPTC nuclear proteins after 2-D electrophoresis.
After 2-D electrophoresis, the nuclear proteins were transferred
onto a Hybond C-extra membrane, hybridized with radioactively
labeled ANG-IRE (N-878/N-864), washed, and subjected to
autoradiography. The arrow heads indicate the proteins that
were determined to be hnRNP F by later mass spectrometry.
The broken box denotes the proteins that were subjected to
mass spectrometry, but their identities could not be determined.
C, Western blolling analysis of the 2-D electrophoresis
membrane from panel B using anti-hnRNP F antibody (obtained
from Dr. Christine Milcarek, Univ. of Pittsburg School of
Medicine, Pittsburg, PA, USA).
Figure 2: Mass spectrometry analysis of proteins dectected by
Southwestern bloffing. Spot I was isolated from 2-D gel and
then subjected to tryptic digestion and MALDI-MS analysis. A, a
100
typical MALDI-MS peptide fingerprint of spot 1. B, peptide
sequence homology with hnRNP F identifïed by MALD-MS and
database search (BOLD letter). The sequence coverage cf
hnRNP F reached 32%. Similar results were obtained from spot
2 (flot shown).
Figure 3: Sodium dodecyl sulfate-10% polyacrylamide gel electrophoresis
(SDS- PAGE) and Western bloffing analysis of glutathione S
transferase (GST)-rat hnRNP F (GST-hnRNP F) fusion proteins
from bacterial culture. A, Bacterial extracts were subjected to
10% SDS-PAGE and then stained with Coomassie Brilliant Blue
R-250. B, Western blotting analysis of GST-hnRNP F fusion
proteins from bacterial culture with rabbit anti-hnRNP F
antiserum. Lane 1 (Amersham-Pharmacia Biotechs rainbow
markers), lanes 2 and 3 [30 j.tg, crude bacterial extract (E. Cou
transformed with control plasmid, pGex 4T-3 without and with
0.5 M isopropylthiogalactoside (IPTG) induction, respectively],
lanes 4 and 5 [30 j.ig, crude bacterial extract (E. Cou
transformed with the plasmid, pGex 4T-3 containing hnRNP F
cDNA) without and with 0.5 M IPTG induction, respectively],
lane 6 (10 j.tg, purified GST protein after the GST affinity column
chromatography) and lane 7 (10 .tg, purified GST-hnRNP F
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fusion protein after the GST affinity column chromatography).
Similar resuits were obtained in 2 additional experiments.
Figure 4: Gel mobility shift assay of the radioactively-Iabeled rANG-IRE
DNA fragment with GST-hnRNP F fusion protein(s). (A) The
labeled DNA probe (0.1 pmol) was incubated with GST (5 tg) or
GST-hnRNP F fusion protein(s) (0.1 to 2. 0 tg each) in the
presence of 0.3 units of poly dI-dC. (B) Competition with 100-
and 300-fold molar excess of unlabeled hGAPDH-IRE (N-4731-
446), rGlucagon-IRE (N-2661-242), concensus SPi sequence,
and rANG-IRE motif is shown in lanes 4 to 5, lanes 6 to 7, lanes
8 to 9, and lanes 10 to 11, respectively. Similar observations
were made in 2 other experiments.
Figure 5: Autoradiography in gel mobility shift assay of the radioactively
labeled rANG-IRE DNA fragment with GST-hnRNP F fusion
protein(s). The Iabeled DNA probe (0.1 pmol) was incubated
with GST (5 fig, lane 2) or GST-hnRNP F fusion protein(s) (1 g
each; lanes 3 to 13) in the presence of 0.3 units of poly dI-dC.
Competition with 100- and 300-folU excess of unlabeled ANG
IRE motif and mutants of rANG N-882/-854 (Mi, M2, M3 and
M4) is shown in lanes 4 to 5, lanes 6 to 7, lanes 8 to 9, lanes 10
102
to 11, and lanes 12 to 13, respectively. Similar observations
were made from 2 other experiments.
Figure 6: Super-shift gel mobility shift assay of the radioactively-labeled
rANG-IRE DNA fragment with GST-hnRNP F fusion protein(s).
The Iabeled DNA probe (0.1 pmol) was incubated with GST (5
jig) or GST-hnRNP F fusion protein(s) (1 jig each, lanes 3-9) in
the presence of 0.3 units of poly Ul-UC. Rabbit anti-hnRNP F
antiserum (0.5 to 2 tI, lanes 4 to 6) or rabbit lgG (0.5 to 2 jig,
lanes 7 and 9) were added the reaction mixture and incubated
for 30 min on ice before incubation with the labeled probe.
Similar observations were made from 2 other experiments.
Figure 7: Super-shift gel mobility shift assay of the radioactively-labeled
rANG-IRE with IRPTC nuclear protein(s). The labeled DNA
probe (0.1 pmol) was incubated with BSA (5 jtg) or IRPTC
nuclear protein(s) (5 jig each, lanes 2-7) in the presence of 0.3
units of poly dl-dC. Excessive rat ANG-IRE (100-fold) was
added for competition with the labeled probe (lane 3). Rabbit
lgG (10 and 5 jig, lanes 4 and 5, respectively) or rabbit anti
hnRNP F antiserum (obtained from Dr. T. Tamura, Chiba, Japan)
(1.0 and 0.5 jd, lanes 6 and 7, respectively) were added the
reaction mixture and incubated for 30 min on ice before
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incubation with the Iabeled probe. Similar observations were
made from 2 other experiments. (55, supershift band)
Figure 8: Expression cf hnRNP F and ANG mRNA in IRPTCs transiently
tranfected with pcDNA 3.1, pcDNA 3.1/hnRNP F (+) or pcDNA
3.1/hnRNP F (-). A, Western blolling analysis cf hnRNP F and
p-actin expression in IRPTCs. 24 h after gene transfecticn, the
ceNs were incubated for 24 h in 5 mM DMEM containing 5%
FBS. Then, ceils were collected, extracted and assayed for
hnRNP F and J3-actin by Western blolling. The relative densities
cf the hnRNP F band were compared with the 13-actin band. The
hnRNP F level in pcDNA 3.1-transfected celis represents the
control level (100%). B, Reverse transcriptase-polymerase chain
reacticn (RT-PCR) analysis cf endcgencus rat ANG and 3-actin
mRNA expression in IRPTCs. 24 h after gene transfection, the
celis were cultured for 24 h in 5 mM DMEM containing 5% FBS.
Then, ceils were harvested and assayed for rat ANG mRNA by
RT-PCR as described in Matenals and Methods. The relative
densities cf the PCR band of ANG mRNA were ccmpared with
the r3-actin band. The ANG mRNA level in pcDNA 3.1-
transfected ceNs represents the control level (100%). Results
were expressed as the means ± SD cf 3 determinaticns (*p
104
0.05, p 0.01). Similar resuits were obtained in 3 othet
experiments.
Figure 9: Effect of hnRNP F on rANG gene promoter activity in IRPTCs. 48
h after transfection, celis were harvested and assayed for CAT
activity. The relative activity in ceNs transfected with 1 ug of
pOCATIrANG N-14981+18 or mutant pOCATIrANG N-1498/+18
was given relative value cf 100% (control). Each point represents
the mean ± S.D. of three independent experiments (N.S., flot
significant; *p 0.05; **p 0.01).
Figure 10: Effect cf high glucose and insulin on hnRNP F expression in
IRPTCs. (A) Southwestern blot analysis. Ceils were incubated in
5 mM plus 20 mM D-Mannitol, 25 mM D-glucose or 25 mM D-
glucose plus insulin (10v M) and 5% FBS for 24 h. Then, celis
were harvested and nuclear proteins (100 pg) were subjected to
Southwestern blolling as described in Materials and Methods.
(B) Western blet analysis. After Southwestern blet analysis, the
same membrane was blottted with rabbit polyclonal antibodies
against hnRNP F (obtained from Dr. Christine Milcarek, Univ. cf
Pittsburg School of Medicine, Piftsburg, PA, USA) and 3-actin
control and ECL-chemiluminescent developing reagent. The
relative densities cf hnRNP F bands were compared with the F3-
105
actin control. The level of hnRNP F expressed in IRPTCs in 5
mM glucose medium was considered to be the control (100%).
Each bar represents the mean ± SD of three independent
experiments (*p< 0.05, **p 0.01).
Figure 1 1: Distribution of the hnRNP F protein in various rat tissues as
analyzed by Western blot analysis. Nuclear proteins (100 Jg)
were subjected to Western bloffing as described in Materials
and Methods with rabbit polyclonal antibodies against hnRNP F
(obtained from Dt. Christine Milcarek, Univ. cf Pittsburg School
cf Medicine, Pillsburg, PA, USA) and 3-actin and ECL
chemiluminescent developing reagent. The relative densities cf
hnRNP F bands were compared with the Ç3-actin control. Ihe
level cf hnRNP F expressed in IRPTCs was ccnsidered te be
the contrcl (100%). Each bar represents the mean ± SD cf three
independent experiments (**p< 0.01).
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Heterogeneous nuclear ribonucleoprotein K
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kidney ceils.
118
HETEROGENOUS NUCLEAR RIBONUCLEOPROTEIN K MODULÂTES
ANGIOTENSINOGEN GENE EXPRESSION IN KIDNEY CELLS
Publïshed on The Journal of Biological Chemistry Vol. 281: 25344-25355,
2006
Chih-Chang Wei*, Shao-Ling Zhang*, Yun-Wen Chen*, Deng-Fu Guo*,
Julie R. lngelfinger**, Karol Bomsztyk*** and John S.D. Chan*
(Relative contribution: Wei, 80%; Zhang, 3%; Chen, 2 %, Guo, 2%;
Ingelfinger, 2%; Bomsztyk, 1%; Chan, 10%)
* Centre de recherche
Centre hospitalier de l’Université de Montréal (CHUM)-Hôtel-Dieu
Pavillon Masson
3850 Saint Urbain Street
Montreal, Quebec
Canada H2W 1T8
** Pediatric Nephrology Unit
Massachusetts General Hospital
Harvard Medical School
15 Parkman Street, WAC 709
Boston, MA 02114-3117
USA
***Depament of Medicine
University of Washington
Box 356523
Seaille, WA 98195
USA
*To whom correspondence should be addressed
Telephone: (514) 890-8000 extension 15080
Fax: (514) 412-7204
Short Title: Heterogenous nuclear ribonucleoprotein K and angiotensinogen
gene
Keywords: Heterogeneous nuclear ribonucleoprotein K, angiotensinogen,
kidney
Abstract: 173 words; Text: 4,839
119
ABSTRACT
The present studies aimed to identify the 70-kiloDalton nuclear protein that
binds to an insulin-responsive element in the rat angiotensinogen gene
promoter and to define its action on angiotensinogen gene expression.
Nuclear proteins were isolated from rat kidney proximal tubular celis and
subjected to 2-dimensional electrophoresis. The 70-kiloDalton nuclear protein
was detected by Southwestern blolling and subsequently identifled by mass
spectrometry, which revealed that it was identical to 65-kDa heterogenous
nuclear ribonucleoprotein K (hnRNP K). HnRNP K bound to insulin
responsive element of rat angiotensinogen gene was revealed by gel mobility
shift assay and chromatin immunoprecipitation assay. HnRNP K inhibited
angiotensinogen mRNA expression and promoter activity. In contrast, hnRNP
K down-expression by small interference RNA enhanced angiotensinogen
mRNA expression. Finally, in vitro and in vivo studies demonstrated that high
glucose increases and insulin inhibits hnRNP K expression in rat kidney
proximal tubular ceils. In conclusion, our experiments revealed that hnRNP K
is a nuclear protein that binds to the insulin-responsive element of the rat
angiotensinogen gene promoter and modulates angiotensinogen gene
transcription in the kidney.
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INTRODUCTION
Diabetic nephropathy (DN) is a leading cause o! end-stage renai
disease (ESRD), accounting for 30-50 ¾ of ail new ESRD cases in North
America (1-3). Both clinical and animal studies indicate that intensive insuiin
therapy and proionged treatment with angiotensin-converting enzyme (ACE)
inhibitors or angiotensin il (Ang li)-AT1 receptor biockers delay the
progression of nephropathy in diabetes, but neither strategy cures
nephropathy (4-12). While such resuits support the concept that
hyperglycemia and the renin-angiotensin system (RAS) are invoived in the
deveiopment and progression of DN, the molecular mechanism(s) linking
hypergiycemia to RAS activation remain largely undefined.
Angiotensinogen (ANG), is a glycoprotein consisting of 452 amino acid
residues with an apparent molecular weight (MVV) of 62-65 kiloDaiton (kDa),
is the sole substrate in the RAS cascade (13, 14). ANG is principaily
produced by the liver and cieaved by renin from the kidney to form
angiotensin I (Ang i), which is then further processed by ACE to form Ang li.
However, physioiogical, biochemical and molecular studies have provided
convincing evidence for other pathways of Ang il production. Among these,
the existence of an intrarenai RAS is of special interest and is now generaliy
accepted (15, 16). Renai proximal tubuies (RPTs) contain ail components of
the RAS, including messenger RNAs and proteins, such as ANG, renin, ACEs,
and Ang li receptors (AT1 and AT2 subtypes) (17-23). We have reported that
ANG protein is synthesized and secreted from rat immortaiized renal proximal
tubular ceils (IRPTCs) (24), providing evidence that intrarenal Ang il is
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probably derived from ANG synthesized within renal proximal tubular ceNs
(RPTCs) in vivo. Thus, the local formation of Ang Il may play an important
role in the development of nephropathy in diabetes.
We have established that high glucose (i.e., 25 mM) stimulates ANG
gene expression via reactive oxygen species generation, activation of protein
kinase C (PKC), p38 mitogen-activated protein kinase (p38 MAPK) and
hexosamine biosynthesis pathway (HBP) signalling in IRPTCs (25-28). RAS
blockers and stable transfer of antisense rat ANG cDNA into IRPTCs inhibit
transforming growth factor-beta J (TGF-f31) gene expression and cellular
hypertrophy in high glucose (29, 30). These investigations strongly indicate
that ANG and TGF-f31 gene expression are essential for the high-glucose
effect on RPTC hypertrophy and kidney injury. We have also established that
insulin inhibits the stimulatory effect of high glucose levels on ANG gene
expression and the induction of hypertrophy in IRPTCs (31-33). Moreover, a
putative insulin-responsive element (IRE) containing nucleotides N-878 to N-
864 (5’ CCT TCC CGC CCT TCA 3’) upstream of the transcription start site of
the rat ANG gene promoter has been identified, and it binds to 2 major
nuclear proteins with apparent MW of approximately 48 and 70 kDa from
IRPTCs, as revealed by Southwestern bloffing (33). We recently reported
that the 48-kDa nuclear protein is identical to 46-kDa heterogenous nuclear
ribonucleoprotein F (hnRNP F) (34). Furthermore, transient transfer of sense
and antisense hnRNP F cDNA respectively inhibits and enhances ANG gene
expression in IRPTCs (34).
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The ptesent studies aimed to identify the 70-kDa nuclear protein and to
investigate its action on ANG gene expression. We identified the 70-kDa
nuclear protein as 65-kDa heterogenous nuclear ribonucleoprotein K (hnRNP
K) by 2-dimensional (2-D) electrophoresis and mass spectrometry (MS).
Recombinant hnRNP K bound to ANG-IRE, as shown by gel mobility shift
assay (GMSA) and chromatin immunoprecipitation assays. Over-expression
and down-expression of hnRNP K inhibited and enhanced ANG gene
expression in IRPTCs, respectively. Finally, in vitro and in vivo studies
revealed that high glucose or hyperglycemia increased and insulin inhibited
hnRNP K expression in rat kidney proximal tubular ceils. These experiments
demonstrated that 65-kDa hnRNP K is a nuclear protein that binds to the rat
ANG gene promoter and modulates ANG gene expression in the kidneys.
MATERIALS AND METHODS
D(÷)-glucose, D-mannitol and insulin were purchased from Sigma
Aldrich Canada Ltd. (Oakville, ON, Canada). Insulin implant ((Linplant) and
gamma-[32P-ATP] (3,000 Ci/mol) were obtained from Linshin Ltd.
(Scarborough, ON, Canada) and Amersham-Pharmacia Biotech (Baie d’Urfé,
QC, Canada), respectively. Plasmid containing full-Iength hnRNP K cDNA
(pcDNA 3/hnRNP K) and rabbit polyclonal antiserum (#54) recognizing
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hnRNP K (QNSVKQYADVEGF corresponding to amino acids 452 to 464 of
human hnRNP K) were generated in Karol Bomsztyk’s Iaboratory as
described previously (35). Mouse monoclonal antibody against human
hnRNP KIL (clone 3C2), a gift from Dr. Gideon Dreyfuss (Department of
Biochemistry and Biophysics, University of Pennsylvania School of Medicine,
Philadephia, PA, USA), has been reported elsewhere (36). The bacterial
expression vector pGex 4T-3 and mammalian expression vectors, pcDNA 3.1
and pRC/RSV were purchased from Amersham-Pharmacia Biotech and
InVitrogen Inc. (Buriington, ON, Canada), respectively. Restriction modifled
enzymes were acquired from either InVitrogen Inc., Amersham-Pharmacia
Biotech or Roche Diagnostics (Lavai, QC, Canada).
Oligonucleotides for rat ANG-IRE N-882 to N-855 (5’ CCT CCC TTC
CCG CCC TTC ACT TTC TAG T 3’) (33), mutants of ANG N-882 to N-885
(Ml, 5’ CCT CCC TIC CAT_TAC TTC ACT TTC TAG T 3’; M2, 5 CCT CCC
TTA AAT AAG ACC ACT TIC TAG T 3; M3, 5 CCI CCC TIC CCI 1CC
TTC ACT TIC TAG T 3; M4, 5 CCT CCC TIC CCI CCC TTC ACT TTC
TAG T 3), IRE of human glyceraidehyde phosphate dehydrogenase gene
(hGAPDH-IRE, N-473 to N-477, 5’ CCA ACT TIC CCG CCI CTC AGC CII
TGA A 3) (37), and IRE of rat glucagon gene (N-267 to N-242, 5’ AGI ITT
CAC GCC TGA CIG AGA 11G A 3’) (38) were synthesized by InVitrogen Inc.
The oiigonucleotide containing the consensus Spi-binding site (5-TCG CCC
CGC CCC CGA ICG AAT-3) (39) was purchased from Promega (Fisher
Scientific Inc., Montreai, QC, Canada).
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Cellular Nuclear Extract Preparation
IRPTCs from passages 12 to 18 were tested. The characteristics of
IRPTCs, which express the mRNA and protein of ANG, renin, ACE, and Ang
Il receptors, have been described previously (40). IRPTC nuclear extracts
were prepared from 20 plates (150 x 20 mm), each containing confluent
IRPTCs previously incubated in Dulbecco’s modified Eagle medium (DMEM)
with 5 mM glucose plus 20 mM D-mannitol, 25 mM glucose, or 25 mM
glucose plus insulin (1OE7 M) for 24 h according to the method of
Henninghausen and Lubon (41) with slight modifications (33, 34).
2-D Electrophoresis
2-D electrophoresis was carried out with the lPGphor Isoelectric
Focusing Unit (Amersham-Pharmacia Biotech) (34). For isoelectrofocusing
(IEF), precast 13-cm IPG strips (pH 3-10, non-linear, Immobiline DryStrips,
Amersham-Pharmacia Biotech) were pre-equilibrated with 750 .ig of nuclear
extracts in 250 jil rehydration buffer (8 M urea, 1 M thiourea, 4% CHAPS, 2%
IPG buffer, 1% NP-40, 0.1 M DIT, and 0.0001% bromophenol blue (BPB)) for
more than 12 h according to the supplier’s manual. IEF was run for 90
kilovolt-h at 25°C. After IEF separation, the IPG strips were immediately
equilibrated for 15 min with a buffer containing 50 mM Tris-HCI, pH 6.8, 6 M
urea, 30% glycerol, 2% SDS, 2% DIT and 0.0001% BPB. Then, the strips
were re-equilibrated with another buffer containing 50 mM Tris-HCI, pH 6.8, 6
M urea, 30% glycerol, 2% SDS, 2% iodoacetamide and 0.0001% BPB for an
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additional 15 min. For 2-D separation, the IPG strips wete placed above 10%
polyacrylamide gel containing SDS and electrophoresed (SDS-PAGE).
Amersham’s rainbow markers served as MW markers. IRPIC nuclear
extracts (100 jig) were run on the same 10% SDS-PAGE as the controls.
Each sample was divided into 2 strips for 2-D electrophoresis. One gel was
stained with Coomassie Brilliant Blue R-250 (Amresco Inc., Salon, OH, USA)
to visualize proteins. The other was electrotransferred to a Hybond C-extra
membrane (Amersham-Pharmacia Biotech) for Southwestern blolling.
Southwestern Bloftinq
Southwestern blolling was performed according to the procedure of
Kwast-Welfeld et al. (42) with slight modifications (33, 34). Briefly, IRPTC
nuclear proteins (200 jig) were resolved on a 4 to 20% SDS-PAGE gradient
or on 10% SDS-PAGE (43), then electrotransferred to a Hybond C-extra
membrane, which was incubated with 10% (WN) non-fat milk proteins in a
binding buffet containing 10 mM Hepes, pH 7.0, 10 mM MgCI2, 50 mM NaCI,
0.25 mM EDTA and 2.5% glycerol (VN) for 24 h at 4°C. The membrane was
washed at Ieast twice with binding buffet containing 0.25% non-fat mllk
proteins. Subsequently, it was hybridized overnight with 32P-labelled ANG
IRE motif DNA (approximately 1.0 to 2.0 pmol; 106 cpm/mI) in binding buffer
containing 0.25% non-fat milk proteins and 300 tg/mI non-denatured herring
sperm DNA at 4°C. The membrane was finally washed, air-dried and
exposed for autoradiography.
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Matrix-assisted Laser Desorptionhlonization-Mass Spectrometrv (MALD1-MS)
Spots on the gel corresponding to positive signais of the Southwestern
biot membrane were picked up for MALD1-MS. Ail MALDI-MS analyses were
performed at the Quebec Genome Centre (McGiil University, Montreai, QC,
Canada). Briefly, protein sampies were first cleaved by trypsin and then
subjected to MALD1-MS. MALDI-MS analysis was conducted at 20-kV
accelerating voltage and 23-kV reflecting voltage. For protein identification,
peptide mass fingerprints were searched by the Mascot program developed
by Matrix Science Ltd. (freely accessible on http:\\www.matrixscience.com).
Expression of Recombinant hnRNP K
Rat hnRNP K cDNA (35), with the Not 1 enzyme restriction site added
on the 5 and 3 ends of sense and antisense primers, respectively, was
subcloned at the polycionai site (Not 1) cf the bacteriai expression vector
pGex 41-3 by conventional methodology. E. Cou BL-21 cells (Amersham
Pharmacia Biotech) were transformed by pGex 41-3 containing rat hnRNP K
cDNA. Expression of the fusion protein [GST fused with hnRNP K (GST
hnRNP K)] in BL-21 celis was induced by the addition cf 1 mM
isopropylthiogalactoside (1PTG) in the culture medium with incubation for 4 h
at 3TC. The bacteria were then harvested, and GST-hnRNP K fusion
proteins were purified from the bacterial extracts by GST affinity column
chromatography according to the manufacturers protocol (Amersham
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Pharmacia Biotech). The purifled GST-hnRNP K fusion proteins were tested
in GMSAs.
GMSAs
These assays were performed according ta the methodology described
elsewhere (33, 34), employing labeled monomeric ANG-IRE motif DNA as
probe. Briefly, the ANG-IRE DNA fragment was 5’ end labeled with [y-32PJ-
ATP by 14 polynucleotide kinase. Purifed GST-hnRNP K fusion proteins (0.1
jig) or GST (5 jig) in the presence 0f 1 pg of poly(dl/dC) in 20 mM Hepes (pH
7.6), 1 mM EDTA, 50 mM KCI, 2 mM spermidine, 1 mM DTT, 0.5 mM PMSF
and 10% glycerol (VN) were sonicated for 30 min and then incubated for 30
min on ice. Subsequently, the 5’-Iabelled probe (—0.1 pmol) was added and
further incubated for 30 min at room temperature. After being chilled on ice,
the mixture was run on 5% (WN) non-denaturing PAGE and exposed for
autoradiography.
In competition assays, 100-fold molar excess of unlabeled DNA
fragments was added to the reaction mixture and incubated for 30 min at
room temperature before incubation with the Iabeled probe.
Chromatin immunoprecipitation (ChiP)
ChIP analysis was performed according to the methodology of Kuo
and Allis (44) with slight modifications (45). Briefly, 0.4 mi of 37%
formaldehyde was added to 10 mi of overlaying media of IRPTC culture for 15
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min at 4°C. After cross-linking, the celis were harvested, washed twice with 1
mi of PBS in Eppendorf tubes, and then iysed with 0.5 ml of
immunoprecipitation (1P) buffer (150 mM NaCI, 5 mM EDTA, 1% Triton X-100,
0.5% NP-40, 50 mM Tris-HCI, pH 7.5, 0.5 mM DTT) containing the following
inhibitors: 10 pg/ml leupeptin, 0.5 mM PMSF, 30 mM p-nitrophenol phosphate,
10 mM NaF, 0.1 mM Na3VO4 and 10 mM 3-glycerophosphate. After 1 wash
with IP buffer, the peilet was suspended in I ml IP buffer and sheared in a
Bronson sonicator with two 10-s cycles, 1 pulsed and 1 continuous, at an
output 3 and 80% duty cycle. Pull-downs were done using anti-K protein
antibody with or without blocking peptide (100 pM) and protein A beads
(Amersham-Pharmacia Biotech). The beads were washed 5 times with 1 mi
of IP buffer without inhibitors. DNA was eluted twice from the beads with 250
pi of elution buffer (1% SDS, 0.1 M NaHCO3) for 15 min with periodic
vortexing (at room temperature). Cross-linking was reversed by adding 20 pI
of 5 M NaCI and incubating the eluate overnight at 65°C. After adding 5 pg cf
linear acrylamide, DNA was precipitated with 1.0 ml cf 100% ethanol. The
peilet was precipitated with 1.0 ml of 70% ethanol, and dissolved in 100 pI cf
Tris-EDTA (TE) buffer, pH 8.0. Then, 11 pI cf JOX protein K buffer (0.1 M Tris,
pH 7.8, 50 mM EDTA, 5% SDS) and 1 pI cf 20 pglpl prcteinase K were added
and incubated at 50°C for 30 min. DNA was extracted with phenol/chlcrcfcrm,
precipitated with ethanci, and the final DNA pellet was disscived in 20 pI of
TE buffer.
Polymerase chain reacticn (PCR) amplications were done in 50 pI cf
1X PCR buffer containing DNA, 0.5 pM primers (forward primer: 5 CCT TGA
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TGC CTC CAA CAA CI 3 and backward primer: 5 GGT GGG AGC TGA
GAA GAC AG 3 corresponding to nucleotides N-1043 to N-1026 and N-718
to N-698 of the rat ANG gene promoter (46), respectively), 40 pM of each
deoxynucleotide triphosphate, 1.5 mM MgCI2 and 1 unit of Tag DNA
polymerase (In Vitrogen Inc.). The PCR products were resolved on 2%
agarose gel and transferred onto a Hybond XL nylon membrane (Amersham
Pharmacia Biotech). Digoxigenin-labeled oligonucleotide 5’ CCT CCC TTC
CCG CCC TIC ACT TTC TAG T 3’), corresponding to nucleotide N-882 to
NI-855 of the rANG gene promoter (46) prepared with a digoxigenin
oligonucleotide 3’ end labeling kit (Roche Diagnostics), served to hybridize the
PCR products on the membrane. After stringentwashing, the membrane was
detected with a digoxigenin luminescence kit (Roche Diagnostics) and
exposed to Kodak BMR film (Eastman Kodak Cc., Rochester, NY, USA).
Mammalian Expression of Recombinant hnRNP K
Rat hnRNP K cDNA with flag-tag at the N-terminal in mammalian
expression vector pcRCIRSV (35) was transfected into IRPTCs with
Lipofectamine according to the instruction manual provided by the supplier
(InVitrogen Inc.). We optimized the DNA concentration for gene transfection
at 2 pg per 0.5 to 1 x 106 cells. Forty-eight h after transfection, total RNAs and
nuclear proteins were isolated from IRPTCs and assayed for ANG mRNA by
RT-PCR (33, 34) or for flag-hnRNP K protein by Western blolling,
respectively.
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SmaII Interfering RNA (siRNA) cf hnRNP K
IRPTCs were transfected with 40 nM scrambled Silencer® Negative
Control # 1 siRNA (Ambion Inc., Austin, TX, USA) or 40 nM siRNA for hnRNP
K fSense 5 CCA GAU GUA AUG UUU UAG Uft 3 and antisense 5 ACU
AAA ACA UUA CAU CUG Gtg 3. Hnrpk siRNA ID 195920, Ambion Inc.) or
40 nM siRNA for hnRNP F (sense 5 GCA UGG GAC ACC GGU AUA Uft 3
and antisense 5 AUA UAC CGG UGU CCC AUG CII 3. HnRNP F siRNA ID
192101, Ambion Inc.). Transfections were accomplished by using siPORT
Amine (Ambion Inc.) according to the manufacturers instructions. Total
cellular RNA and protein were harvested at 48 h post-transfection and then
analyzed for ANG and 13-actin mRNA, and hnRNP K protein expression by
RT-PCR (34) and Western blolling, respectively.
Western Bloftinq for hnRNP K
Briefly, the ceil pellets were Iysed in 100 jil RIPA buffer [50 mM Tris
HCI, pH 7.4, 150 mM NaCI, 0.1% (WN) SDS, 1% Triton X-100, 1% sodium
deoxycholate, 1 mM EDTA, 1 mM PMSF, I jig/mI leupeptin and 1 p.gImI
aprotinin], then incubated on ice for 30 min. The ceil lysates were centrifuged
at 12000 x g for 15 min and the supernatants transferred to new tubes. Thirty
ig of the supernatants were subjected to 10% SDS-PAGE, then transferred
onto a polyvinylidene difluoride membrane f Hybond-P, Amersham-Pharmacia
Biotech). The membrane was initially blofted for anti-flag or anti-hnRNP K
antibody (1:4,000 dilutions) and then re-blofted for anti-3-actin antibody
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(1:10,000 dilutions) and chemiluminescent developing teagent (Roche
Diagnostics). The relative densities of the hnRNP K and 13-actin bands were
quantified by computerized laser densitometry (ImageQuant software (version
5.1), Molecular Dynamics, Amersham-Pharmacia Biotech).
Chloramphenicol Acetyl Transferase (CAT) Assay
The method of construction of the rANG-CAT fusion gene,
pOCATIrANG N-14981+18 (fusion gene containing 1,498 nucleotides
upstream of the transcription start site and 18 nucleotides of exon I fused with
CAl reporter gene) and mutant pOCATIrANG N-14981+18 with mutated IRE
has been described previously (32, 34). Control plasmid or fusion gene was
ttansfected into IRPTCs using lipofectamine (InVitrogen Inc.) according to
methods described previously (32, 34). 48 h after transfection, the ceils were
harvested and assayed for CAT activity (32, 34).
To normalize the efficiency of transfection, 0.5 tg of pRSV/3-GaI [a
vector with the Rous Sarcoma Vital enhancer/promoter fused to the bacterial
3-galactosidase gene] was co-transfected with pOCATIrANG N-1 4981+18 (32,
34). The plasmid pRSV/CAT [a vector with the Rous Sarcoma Viral
enhancer/promoter fused to the CAT reporter gene] served as a positive
control to monitor the efflciency of transfection of rANG-CAT fusion gene.
The level of transfection efficiency for pRSV/CAT in IRPTCs ranged from 60
to 90%, i.e., the percentage of conversion of C chloramphenicol to mono
and di-acetyl chloramphenicol. The transfection efficiency of pOCAT/rANG N-
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14981÷18 in 1RPTCs ranged from 25% to 35% compared with pRSV-CAT.
The inter- and intra-assay coefficient variations cf transfection for
pOCATIrANG N-14981+18 in 1RPTCs were 25% and 12% (N = 10),
respectively.
Animais
The streptozotocin (STZ)-induced diabetic Wistar rat model has been
described previousiy (47). Briefly, aduit maie Wistar rats (200-250 g) obtained
from Charles River i. (St-Constant, QC, Canada) were divided into 3
groups: 1. Vehicie-injected controis (10 mM sodium citrate buffer, pH 4.0); 2.
Untreated STZ-induced diabetics (65 mg/kg cf STZ dissoived in 10 mM
sodium citrate buffer administered i.p. after overnight fasting); and 3. Treated
STZ-induced diabetics (subcutaneous insulin implant 48 heurs after STZ
induction). Untreated and treated diabetic rats with blood glucose >25 mM
and <7 mM, respectively, were studied. Blood glucose was monitored with a
glucose analyzer (Accu-Check Compact, Roche Diagnostics, Lavai, QC,
Canada).
Ail animais were allowed free access to rat chow and water. Ail
methods cf animal care and sacrifice were approved by the Animai Care
Commiftee of the CHUM.
Isolation of Rat RPTs
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Two weeks after the induction 0f diabetes, the rats were anesthetized
and euthanized [Control and treated rats were euthanized at the same time
point]. Kidneys were removed immediately for proximal tubule isolation. The
renal cortex was separated from the medulla and minced under sterile
conditions. Proximal tubules were isolated by Percoli gradient (48) with slight
modifications (47). Proximal tubular celis were characterized by their
histological appearance (48). A highly-purified preparation of proximal tubules
(>97% by microscopy) with >95% viability (determined by trypan blue
exclusion) was obtained. Aliquots of freshly-isolated proximal tubules from
individual rats were immediately used for total RNA and protein isolation.
Statistical analysis
Three to 5 separate independent experiments were performed per
protocol, and each treatment group was run in duplicate. The data were
analyzed by 1-way ANOVA and the Bonferroni test. A probability level of
pO.05 was regarded as statistically significant.
RESULTS
Identification of 70-kDa IRE-binding proteins (BPs) in IRPTCs
Figure lA shows the staining of nuclear proteins after 2-D
electrophoresis. Southwestern blotting of IRE-BPs after 2-D electrophoresis is
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displayed in Figure 18. Positive spots with apparent MW of 70 and 48 kDa
were cut out and subjected to MALDI-MS. The MS resuits of 70-kDa proteins
are displayed in Figure 2. The 2 spots with an apparent MW of 70 kDa were
identifled as a common protein (Accession number NM_057141). Database
analysis reveaied that they are identical to the rat hnRNP K cDNA sequence
reported by Ito et aI. (49). The 2 spots with an apparent MW of 48 kDa were
identified as 46 kDa hnRNP F (34).
b confirm the authencity of rat hnRNP K revealed by Southwestern
bloffing, we stripped the radioactivity from the membrane and re-biotted it with
rabbit polyclonal antiserum against hnRNP K, as shown in Figure IC. It is
apparent that the proteins interacting with anti-hnRNP K were
superimposable, with positive signais detected by Southwestern blotting, as
seen in Figure lB. These data confirm that the 70-kDa proteins that interact
with ANG-IRE are identical to hnRNP K.
GMSA
Bacterially-expressed recombinant hnRNP K proteins were employed
to study the interaction of rANG-IRE with hnRNP K. One major band
appeared with retarded mobility with Iabelled rANG-IRE by employing GST
hnRNP K fusion protein (Figure 3). No slowiy-migrating band was observed
when the Iabeled DNA was incubated with GST (bacteriai extract of empty
vector pGex 41-3). The addition of an unlabeled rANG-IRE was effective in
competing with the binding of Iabeied rANG-IRE DNA to the fusion proteins(s)
(100-fold molar excess of uniabeled DNA fragment), but not the mutant of
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rANG-IRE and the unlabeled DNA fragment of hGAPDH-IRE, rat glucagon
IRE, and the Spi consensus sequence (data flot shown).
ChIP Analysis of HnRNP K Interactions with Gene Loci
ChIP assays were used to test if hnRNP K interacts with the IRE of the
ANG gene promoter in vivo. Figure 4 displays the PCR product of pulled
down DNA with primers specific to the rANG gene promoter. A -300-bp DNA
fragment was apparent in ceils that were treated with the cross-Iinking agent
and without blocking peptide (lane 4). In contrast, no PCR product was
generated in cells without treatment with hnRNP K antibody (lane 3) or in the
presence of blocking peptide (lane 5). These results validate the interaction
of hnRPN K with rANG gene Ioci in vivo.
Effect of hnRNP K on ANG mRNA expression in IRPTCs
It is apparent that hnRNP K protein levels in IRPTCs transiently
transfected with pRSR/hnRNP K were signiflcantly higher (p<O.Ol) than those
in control pRC/RSV-transfected IRPTCs (Figure 5A) by Western blouing. In
contrast, ANG mRNA expression was significantly lower in pRSV/hnRNP K
transfected celis than those in pRC/RSV-transfected ceils analyzed by RI
PCR (Figure 5B). These resuits demonstrated that hnRNP K inhibits ANG
mRNA expression in IRPTCs. Most interestingly, hnRNP K overexpression
prevented the stimulatory effect of high glucose on ANG mRNA expression in
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IRPTCs (Figure 6). These data suggest that hnRNP K modulates high
glucose stimulation ofANG gene expression in IRPTCs.
Effect cf siRNA of hnRNP K on ANG mRNA expression in IRPTCs
Transient transfer of siRNA of hnRNPK and hnRNP F suppressed
respective hnRNP K and hnRNP F expression but enhanced ANG mRNA
expression in IRPTCs (Figure 7). In contrast, transient transfer of negative
scrambled silencer had no effect on hnRNP K or hnRNP F protein and ANG
mRNA expression in IRPTCs. These data further demonstrate that, like
hnNRP F, hnRNP K modulates ANG mRNA expression in IRPTCs.
Effect cf hnRNP K on rANG Gene Promoter Activity
Like hnRNP F, co-transfection with hnRNP K significantly suppressed
pOCAT-rANG fusion gene promoter activity (Figure 8). lt appears that
hnRNP K is more effective in inhibiting ANG gene promoter activity than
hnRNP F. These studies confirm the notion that hnRNP K modulates ANG
gene expression at the transcriptional level via binding to IRE.
Effect of Hiqh Glucose and Insulin on hnRNP K Expression In Vitro and In
Vivo
Figures 9A and 9B show the resuits of respective Southwestern and
Western blot analysis of IRPTC nuclear extracts for hnRNP K incubated in
normal glucose (5 mM D-glucose plus 20 mM D-Mannitol) or high glucose (25
mM D-glucose) medium in the absence or ptesence of insulin (10v M). lt is
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apparent that high glucose levels enhanced and insulin suppressed hnRNP K
expression in IRPTCs in vitro. Similarly, studies in vivo revealed that
hyperglycemia upregulated hnRNP K expression in diabetic rat RPT5, and
insulin treatment normalized hnRNP K to non-diabetic levels (Figure 10).
These data demonstrate that hyperglycemia and insulin regulate hnRNP K
expression in diabetic rat RPTs.
DISCUSSION
The present studies identified hnRNP K as one of the nuclear proteins
that binds to IRE of the rat ANG gene promoter and inhibits ANG gene
expression in IRPTCs.
We reported recently that by employing a combination of proteomics
and Southwestern blolling, 46-kDa hnRNP F was identified as the 48-kDa
nuclear protein that binds to IRE of the rat ANG gene promoter and inhibits
ANG gene expression in IRPTCs (34).
The present studies aimed to identify the molecular structure of the 70-
kDa nuclear protein with the same approach as with 46 kDa hnRNP F. It is
apparent that multiple IRPTC proteins are resolved by 2-D electrophoresis. A
second gel run simultaneously with the first gel for Southwestern bloffing
demonstrated 2 positive spots with an apparent MW of 70 kDa, and pI of 5.0
to 6.0 closely matched the stained protein spots on the flrst gel. After tryptic
digestion and MALDI-MS, these 2 spots were found to match the partial
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amino acid sequence deduced from the hnRNP K sequence as reported by
ito et ai. (49) (Accession number NM_057141). Using specific rabbit
antiserum against hnRNP K, we confirmed the identity cf hnRNP K on the
membrane by Southwestern blotting. Western blotting reveaied positive
signais superimposed on the positions of the 2 spots detected by
Southwestern blolling. The reason why hnRNP K is present in 2 different
forms (same apparent MW but different pi) is presentiy unclear. One
possibility is that these proteins might be isoforms or variants with different
phosphoryiated forms. We have further conflrmed that the 48-kDa species by
MALDI-MS analysis is 46-kDa hnRNP F as we have reported previously (34,
data not shown).
HnRNP K was identïfied as one of these hnRNPs that binds cytidine
rich elements (50-52). HnRNP K is encoded by 1 gene and can be
aiternatively spiiced to at ieast 4 isoforms with deduced MW in the range of
50-51 kDa but in SDS-PAGE, hnRNP K has an apparent MW of 65 kDa (53).
HnRNP K has been Iocaiized in the nucleus, cytoplasm and mitochondria,
and implicated in chromatin remodeling, transcription, spiicing and translation
processes (see review by Bomsztyk et ai. (54, 55)). HnRNP K binds single
stranded (ss) and double-stranded (ds) DNA motifs (CT element, 5 d-TCCC)
within the promoter of c-myc, c-src and c-fos gene, and complexes with Spi
and TATA-binding protein (TBP) to stimulate gene transcription (56-59).
HnRNP K also represses the transcription of thymidine kinase (60), the
neuronal nicotinic acetylcholine receptor 34 subunit (61), and osteocalcin (62).
Thus, hnRNP K is a multifunctional protein that interacts with DNA, RNA,
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transcriptional and transiational molecules to alter the in vivo rate of gene
transcription and translation (either stimulation or repression).
b demonstrate that hnRNP K interacts with rANG-IRE, we expressed
hnRNP K in a bacterial system. Dur GMSAs revealed that labeled rANG-IRE
binds ta GST-hnRNP K fusion protein and IRPIC nuclear proteins. The
addition of unlabeled rANG-IRE DNA effectively displaced labeled ANG-IRE
at or greater than a 100-fold molar excess of unlabeled DNA, whereas mutant
rANG-IRE was not effective. Similarly, unlabeled hGAPDH-IRE, rat glucagon
IRE, and the Spi consensus sequence were flot effective in displacing
Iabeled rANG-IRE (data flot shown). These studies indicate that rANG-IRE
binds to hnRNP K. Most convincingly, anti-hnRNP K antibodies yielded a
supershift of Iabeled rANG-IRE binding with hnRNP K fusion protein. Most
convincingly, our ChIP assays revealed that hnRNP K interacts with rANG
gene promoter loci. Taken together, these data unequivocally demonstrate
that hnRNP K binds to rANG-IRE.
lnterestingly, over-expression and down-expression of hnRNP K
inhibits and enhances ANG gene expression in IRPTCs, respectively. Ta the
best of OUt knowledge, this is the first report that hnRNP K could modulate
ANG gene expression in kidney proximal tubular cells in vitro. The negative
effect of hnRNP K is similar ta that of hnRNP F on ANG gene expression (34).
At present, the molecular mechanism(s) of hnRNP K action on ANG mRNA
expression is not known. One possibility is that hnRNP K behaves like a
negative transacting protein and inhibits the binding of other positive
transacting factor(s) to TBP and RNA polymerase II, subsequently
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allenuating ANG gene expression. This possibility is supported by the
findings that the hnRNP K molecule binds directly to TBP and, therefore, may
inhibit the basal transcription machinery (36, 51). The second possibility is
that hnRNP K over-expression inhibits the formation cf an activating
transcriptional complex on the promoter and subsequently represses ANG
gene expression. This possibility is supported by the studies of Du et al. (61)
and Da Silva et al. (63), showing that hnRNP K inhibits Spi binding to the
promoter of the gene encoding the 34 subunit cf the nicotinic acetylcholine
receptor and CD 43 gene promoter, respectively. The third possibility is that
hnRNP K could recruit unidentifled repressor molecules and subsequently
repress ANG gene expression. This possibility is supported by previeus
studies demonstrating that hnRNP K could bind the murine repressor Ziki
(64). Finally, it is also possible that hnRNP K could form an heterodimer with
hnRNP F (a hypothetical stable complex) and then bind to rANG-IRE and
subsequently allenuate ANG gene expression. This possibility is supported
by the findings that hnRNP K could form an heterodimer or trimer with hnRNP
Aller hnRNP C te inhibit human thymidine kinase promoter (60). Clearly,
more work is needed along these unes to elucidate the mechanism(s) of
action cf hnRNP K on ANG gene expression in IRPTCs.
Finally, eut studies revealed that high glucose stimulated and insulin
inhibited hnRNP K expression in IRPTCs in vitro and in diabetic rat kidneys in
vivo. Te the best cf eut knowledge, this is the fitst report that hnRNP K could
be modulated by high glucose and insulin in kidney proximal tubular cells in
vitro and in vivo. The exact physiological tole(s) cf hnRNP K on renal ANG
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gene expression is unknown. Studies are ongoing in our laboratory along this
une.
In summary, we have established, by a combination of Southwestern
bloffing and proteomics, that hnRNP K is a nuclear protein that binds to
rANG-IRE and inhibits ANG gene expression in IRPTCs. It appears that high
glucose and insulin regulate hnRNP K expression in kidney proximal tubular
ceils. Our studies raise the possibility that hnRNP K expression may play an
important role in counter-balancing high glucose stimulation of ANG gene
expression and in modulating local intrarenal RAS activation. Dysregulation of
hnRNP K expression may contribute to renal injury in diabetes via altered
local intrarenal RAS activation.
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APPENDIX
Abbreviations used in this article: ACE, angiotensin-converting enzyme:
ANG, angiotensinogen; Ang Il, angiotensin Il; CAT, chloramphenicol acetyl
transferase: ChIP, chromatin immunoprecipitation; DN, diabetic nephropathy:
ESRD, end-stage renal disease: GMSA, gel mobility shift assay; hnRNP F,
heterogenous nuclear ribonucleoprotein F; hnRNP K, heterogenous nuclear
ribonucleoprotein K: IP, immunoprecipitation: I EF, isoelectrofocusing: IRE,
insulin-responsive element; I RE-BP, I RE-binding protein; I RPTCs,
immortalized renal proximal tubular cells; kDa, kiloDalton; MALDI, matrix
assisted laser desorptionhionization technique; MS, mass spectrometry: MW,
molecular weight; PCR, polymerase chain reaction; RAS, renin-angiotensin
system: RPTCs, renal proxîmal tubular cells; RT-PCR, reverse transcriptase
polymerase chain reaction; RPTs, renal proximal tubules; SDS-PAGE,
sodium dodecyl sulfate-polyacrylamide gel electrophoresis; ss, single
stranded; siRNA, small interfering RNA; STZ, streptozotocin; 2-D, 2
dimensional; TBP, TATA-binding protein; TGF-131, transforming growth factor
beta 1.
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LEGENDS
Figure 1: Rat ANG IRE-BPs detected by 2-D electrophoresis,
Southwestern and Western bloftings. (A) Rat IRPTC nuclear
extracts were subjected to 2-D electrophoresis and then stained
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with Coomassie Brilliant Blue R-250. M: Amersham-Pharmacia
Biotech’s rainbow molecular mass markers. N.E.: Rat IRPTC
nuclear extracts without IEF. (B) Southwestern bloffing analysis
of ANG IRE-BPs from IRPIC nuclear proteins after 2-D
electrophoresis. After 2-D electrophoresis, the nuclear proteins
were ttansferred onto a Hybond C-extra membrane, hybridized
with radioactively-labeled concanmeric ANG-IRE (N-878/N-864),
washed, and subjected to autoradiography. The arrow heads
indicate the proteins that were determined to be hnRNP K by
later MS. The rectangle denotes the 70-kDa proteins that were
subjected to MS, their identifies were determined as 65-kDa
hnRNP K. (C) Western blolling of the 2-D electrophoresis
membrane from panel B using anti-hnRNP K antibody.
Figure 2: MS analysis of proteïns detected by Southwestern blolling. Spot
1 was isolated from 2-D gel and then subjected to trypsin
digestion and MALDI-MS analysis. Figure 2A shows a typical
MALDI-MS peptide fingerprint of spot 1. Figure 2B shows the
peptide sequence homology with hnRNP K identifled by MALDI
MS and database search (BOLD lellers). The sequence
coverage of hnRNP K reached 32%. Similar resuits were
obtained from spot 2 (flot shown).
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Figure 3: GMSA of radioactively-labeled rANG-IRE DNA fragment with
GST-hnRNP K fusion protein(s). The labeled DNA probe (0.1
pmol) was incubated with GST (5 I.tg) or GST-hnRNP K fusion
protein(s) (0.1 tg) in the presence of 1 tg of poiy di-dC.
Competition with 100-fold molar excess of unlabeled rANG-IRE
is shown in lane 4. Anti-hnRNPK antibody yielded a supershift
band shown in lane 5.
Figure 4. ChIP analysis with anti-hnRNP K antibody. The celis were Iysed,
and nuclei were isolated and then sonicated. HnRNP K was
immunoprecipitated with (+, iane 4) or without (-, lane 3) anti
hnRNP K antibody or in the presence of blocking peptide (iane
5). Complexes were eluted, cross-Iinking was reversed, and
purified DNA was used as a tempiate in PCR with primers
specific to the rat ANG gene promoter. DNA was separated by
agarose gel electrophoresis and visualized. Then, the DNA was
transferred onto a Hybond XL nylon membrane and hybridized
with a D1G-labeied internai DNA probe.
Figure 5: Effect of hnRNP K on ANG mRNA expression in IRPTCs. A.
Western blolling of hnRNP K protein in IRPTCs transiently
transfected with pRC/RSV or pRSV/hnRNP K. B. RT-PCR
analysis of endogenous rANG and 3-actin mRNA expression in
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IRPTCs transiently tranfected with pRC/RSV or pRSV/hnRNP K.
Twenty-four h after gene transfection, the celis were cultured for
24 h in 5 mM DMEM containing 5% FBS. Then, the ceils were
harvested and assayed for hnRNP K and rANG mRNA by
Western blotting and RT-PCR assay, respectively. The relative
levels of hnRNP K protein and ANG mRNA were compared with
J3-actin protein and J3-actin mRNA, respectively. The hnRNP K
and ANG mRNA level in pRCIRSV-transfected celis represents
the control level (100%). The results were expressed as means
± SD of 3 determinations (**p 0.01). Similar results were
obtained in 3 other experiments.
Figure 6: Over-expression of hnRNP K prevented the high glucose effect
on ANG mRNA expression in IRPTCs. RT-PCR analysis of
endogenous rANG mRNA expression in IRPTCs stably
tranfected with control plasmid pRC/RSV (A) or pRSV/hnRNP K
(B). Twenty-four h after synchronization, the celis were cultured
for 24 h in 5 mM DMEM plus 20 mM D-glucose, 25 mM D
glucose in the absence or presence or insulin (10v M)
containing 1% depleted FBS. Then, the ceils were harvested
and assayed for rANG mRNA by RT-PCR. The relative levels of
ANG mRNA were compared with 13-actin mRNA. The ANG
mRNA level in 5 mM D-glucose medium represents the control
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level (100%). The results were expressed as means ± SD of 3
determinations (**p 0.01, NS, flot significant). Similar results
were obtained in 3 other experiments.
Figure 7: Effect of siRNA of hnRNP F and hnRNP K on rANG mRNA
expression in IRPTCs. 48 h after transfection, the ceils were
harvested and assayed for hnRNP F or hnRNP K protein and
ANG mRNA expression by Western blouing and RT-PCR,
respectively. The level of hnRNP F or hnRNP K and ANG
mRNA expression was compared with 3-actin protein and
mRNA, respectively.
Figure 8: Effect of hnRNP K on rANG gene promoter activity in IRPTCs. 48
h after transfection, the ceils were harvested and assayed for
CAT activity. Relative activity in ceils transfected with 1 ig of
rANG N-1498/+18 was given a relative value of 700% (control).
Each point represents the mean ± S.D. of 3 independent
experiments (N.S., not significant; *p 0.05; **p 0.01).
Figure 9: Effect of high glucose and insulin on hnRNP K expression in
IRPTCs analyzed by Southwestern and Western blolling. The
cells were incubated in 5 mM plus 20 mM D-mannitol, 25 mM D
glucose or 25 mM D-glucose plus insulin (i0 M) and 5% FBS
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for 24 h. Then, the ceils were harvested and nuclear proteins
(100 pg) were electrophoresed on SDS-PAGE [(4-20% (WN)
gradient gel], transferred onto a polyvinylidene difluoride
membrane, analyzed by Southwestern bloffing with radioactive
rANG-IRE probe (A) and then by Western blotting with rabbit
polyclonal antibodies against hnRNP K (B) and ECL
chemiluminescent developing reagent. The same membrane
was also hybridized with antibodies against j3-actin contrai. The
relative densities of the hnRNP K bands were compared with
the J3-actin control. The hnRNP K level expressed in IRPTCs in
5 mM glucose medium was considered ta be the control (100%).
Each bar represents the mean ± SD of 3 independent
experiments (*p< 0.05, **p 0.01).
Figure 10: HnRNP K expression in non-diabetic and diabetic rat RPTs.
After 2 weeks of STZ-induced diabetes with or without insulin
suppiementation, RPTs were collected, extracted for proteins
and assayed for hnRNP K and f3-actin levels by Western blotting.
The relative leveis of hnRNP K were normalized with !3-actin.
HnRNP K levels in non-diabetic rats were considered as 100%.
Each point represents the mean ± SD of 5 rat RPTs. p
0.001.
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Abstract
To investigate whether heterogenous nuclear ribonucleoprotein F (hnRNP
F) couid suppress angiotensinogen (AGT) gene expression and subsequently
allenuate renal proximal tubular ceil (RPTC) hypertrophy in a high-glucose
milieu, rat immortalized RPTCs were stably transfected with control plasmid or
plasmid containing hnRNP F cDNA and cultured in normal-glucose (5 mM
D-glucose plus 20 mM D-mannitol) or high glucose (25 mM D-glucose)
medium. HnRNP F overexpression prevented the high-glucose stimulation of
AGT, transforming growth factor-betal (TGF-31), and TGF-31 receptor type li
(TGF-F31 Rll) mRNA expression in RPTC5 as weIl as cellular hypertrophy (i.e.
total cellular protein content, [3H]-leucine incorporation and 27kIP1 protein
expression) in vitro. Transgenic mice specifically overexpressing hnRNP F in
their RPTCs displayed attenuation of AGT, TGF-131 RIl and collagen la (type
IV) mRNA and protein expression with decreased protein/DNA ratio, cellular
and nuclear volume, 27k1 protein expression after streptozotocin-induced
diabetes. Our observations demonstrate that hnRNP F plays a negative
modulatory role in preventing RPTC hypertrophy in diabetes, and its underlying
mechanism is mediated, at Ieast in part, via attenuation of intrarenal AGT and
TGF-l RIl expression in vitro and in vivo.
INTRODUCTION
Diabetic nephropathy (DN), a major cause of end-stage renai disease
(ESRD), presently accounts for 30-50% of ail new ESRD cases in North
America (l-3). While intensive insulin therapy and chronic treatment with
renin-angiotensin system (RAS) biockers retard the progression of DN, neither
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of them cures or prevents it (4-6). However, the partial success of such
therapies suggests that hyperglycemia and RAS activation are major risk
factors for DN initiation and progression.
In addition to the circulating RAS, the existence of a local intrarenal RAS
has been well-established (9). High glucose and angiotensin Il (Ang Il) may
directly or indirectly induce renal proximal tubular celI (RPTC) hypertrophy and
tubulointerstitial fibrosis (10-12). Our laboratory has established that high
glucose (25 mM) stimulates rat angiotensinogen (rAGT, the sole substrate in
the RAS) gene expression in rat immortalized RPTCs (13,14). RAS blockers
and stable transfer of antisense rAGT cDNA prevent high-glucose stimulation
of transforming growth factor-betal (TGF-31) and fibrotic gene expression as
well as RPTC hypertrophy (10,15). We recently reported that RAS blockers
attenuate hypertension, proteinuria, and renal injury in transgenic (Tg) mice
overexpressing rAGT in their RPTCs (4,8). Taken together, these data support
a crucial role for intrarenal RAS activation in the progression cf DN.
We have also demonstrated that insulin inhibits both high-glucose
stimulation cf rAGT gene expression and RPTC hypertrophy (16,17). A
putative insulin-responsive element (IRE), identified in the rAGT gene promoter,
modulates rAGT gene transcription through binding with 2 nuclear proteins,
heterogencus nuclear ribonucleoprotein F (hnRNP F) and hnRNP K (18-20).
The physiological roles of hnRNP F and K in RPTCs in vivo, however, remain
undefined.
The hnRNPs are a family cf more than 20 different proteins that share
common structural domains, and extensive research has shown that they play
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central roles flot only in mRNA processing, metabolism and transport but also
in DNA repair, telomere biogenesis, celi signaling and the regulation of gene
expression at both the transcriptional and translational levels (21). Through
these key cellular functions, individual hnRNPs have a variety of potential roles
in disease development and progression.
In the present studies, we investigated whether hnRNP F overexpression
could inhibit AGI gene expression and allenuate RPTC hypertrophy in high
glucose both in vitro and in vivo. Our studies revealed that hnRNP F
overexpression indeed attenuates AGT and fibrotic gene expression, RPTC
hypertrophy and tubulointerstitial fibrosis under these conditions.
MATERIALS AND METHODS
Reagents
D(+)-glucose, D-mannitol, and monoclonal antibodies against -actin were
purchased from Sigma-Aldrich Canada Ltd. (Oakville, ON, Canada).
Full-length hnRNP F cDNA was cloned in our (JSDC’s) Iaboratory (19) and
inserted into pEGFP Cl plasmid (Invitrogen, Inc., Burlington, ON, Canada).
Rabbit polyclonal antibodies specific for hnRNP F (CTARRYIGIVKQAGLER
corresponding to amino acids 215 to 230 of human hnRNP F) (19) and
polyclonal antibodies against rat AGI were generated in our Iaboratory (22).
Anti-p27 antibody and anti-green fluorescence protein (GFP) antibody were
obtained from BD Biosciences (Mississauga, ON, Canada) and Zymed (South
San Francisco, CA, USA), respectively. Polyclonal anti-TGF-131 receptor Il
(TGF-31 Ru) antibody and monoclonal anti-collagen la (type IV) antibody
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were procured from Santa Cruz Biotechnology (Santa Cruz, CA, USA) and
Chemicon International, Inc. (Temecula, CA, USA), respectively. The plasmid
pKAP2 containing the kidney-specific androgen-regulated protein (KAP)
promoter has been described elsewhere (23). It was a gift from Dr. Curt D.
Sigmund (University of lowa, iowa, lA, USA). Placebo pellets or pellets
containing 5 mg testosterone with a 21-day release schedule (Cat. #A-121)
were purchased from Innovative Research cf America (Sarasota, FL, USA).
Oligonucleotides were synthesized by Invitrogen, Inc. Restriction and
modifying enzymes were from either Invitrogen, Inc., La Roche Biochemicals
(Lavai, QC, Canada), or Amersham-Pharmacia Biotech (Baie d’Urfé, QC,
Canada).
Ceil Culture and Gene Transfection
Rat immortalized RPTCs were cultured as described previously (19,20).
RPTCs from passage 11 were used to establish stable transfectants. The
plasmids pEGFP Cl and pEGFP C1/hnRNP F were stably transfected into
RPTCs with Lipofectamine reagents, selected in the presence of geneticin
(G418, 500 pg/ml), (Invitrogen, Inc.) as described previously (10), and
observed under an ECLIPSE TE2000 fluorescence microscope (Nikon,
Melville, NY, USA).
Western Blolling
Western blotting was performed as described previously (19,20). The
membrane was first blotted with rabbit anti-GFP (1:1,000) or p271 (1:2,000),
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then re-blofted with anti-3-actin antibodies and exposed to HRP color or
chemiluminescent developing reagent (La Roche Biochemicals).
Real Tïme-Quantitative Polymerase Chain Reaction (RT-qPCR)
RT-qPCR assays were performed as described previously (24). Briefly,
cDNAs were synthesized from 2 ig of total RNA isoiated from mouse RPTs
following the manufacturer’s protocol (Invitrogen, Inc.). Aliquots of cDNA (1/50
of reverse transcription reactions) were amplified in a MiniOpticonTM MJ mini
RT-PCR Detector System with iQTM SYBR Green Supermix (Bio-Rad
Laboratories, Hercules, CA, USA) in triplicate in 20-pi reaction volumes. The
primers used in the RT-qPCR assays are described in Table 1.
Ceilular Hypertrophy
RPTC hypertrophy was quantified by total cellular protein content,
[3HJ-leucine incorporation, and cellular p27k1 expression as described
previously (17).
Generation of hnRNP F-Tg Mice
Tg mice overexpressing hnRNP F in their RPTCs were generated as
described previously for 1g mice overexpressing rAGI or catalase in RPTCs
(23,24). Briefly, full-length hnRNP F cDNA fused with HA-tag (which encodes
amino acid residues 98-106 (YPYDVPDYA) of human influenza virus
hemagglutinin) at the carboxyl terminal and Noti restriction enzyme site at both
5- and 3 -termini was inserted into pKAP2 plasmid at the Noti site. The
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isolated 17-kb KAP2-hnRNP F transgene (digested with Ndel and Spel) was
then microinjected into 1-ceIl fertilized mouse embryos obtained from
superovulated C57B16 x C3H mice (performed at the Clinicai Research
Institutes of Montreal, Montreal, QC, Canada). Positive Tg founders (identified
by mouse tau genomic DNA) were then crossed with wild-type (WT) C57Bl6
mice (Charles River, St-Constant, QC, Canada) to obtain the F1 generation and
bred until homozygous F4 mice were produced.
The mice were 17-19 weeks of age at the time of data collection. Non-Tg
and sex-matched lillermates (W) served as controls. Ail animais received
standard mouse chow and water aU libitum. Their care met the standards of
the Canadian Council on Animai Care and the Animai Care Commiftee of the
CHUM.
Induction of Transgene Expression
Placebo pellets or pellets containing 5 mg testosterone with a 21-day
release schedule were implanted in male and female homozygous Tg mice
which were euthanized 2 weeks later. Tissues were harvested and snap-frozen
on dry ice. Total RNA was isolated with TRIzol (lnvitrogen, Inc.), foiiowed by
DNase-l treatment (Invitrogen, Inc.) prior to conventional RT-PCR (23,24).
Table 1, lists the primers used.
Induction of Diabetes
Male WT and Tg mice (11-13 weeks old) were divided into 2 groups (6
mice per group): 1. Vehicle-injected controls; and 2. Streptozotocin
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(STZ)-induced diabetic animais injected i.p. after 6 hours 0f fasting with 50
mglkg of STZ dissoived in 10 mM sodium citrate buffer (pH 4.0). STZ injections
were repeated once daiiy for 5 consecutive days. Forty-eight h after the last
injection, blood glucose levels were determined with a Side-Kick Glucose
Analyzer (Modei 1500, interscience, Markham, ON, Canada). Oniy mice with
biood glucose leveis >20 mM were studied. After 4 weeks of diabetes, the
animais were euthanized. Twenty-four hours prior to euthanasia with C02 at 4
weeks post-STZ administration, they were housed individuaiiy in metaboiic
cages to coilect urine samples iater assayed for glucose and ketone leveis
(Keto-Diastix, Bayer inc., Heaithcare Division, Toronto, ON, Canada), and
aibuminuria (ELiSA, Aibuweli and Creatinine Companion, Exoceii, mc.,
Phiiadeiphia, PA, USA) (23,25). Body weight and biood glucose were
measured. Serum creatinine was determined by Beckman Creatinine Anaiyzer
il as described by ichimura et ai. (26). Left kidneys were processed for
histoiogy, and the right kidneys were harvested for isolation of renai proximai
tubuies (RPT5) by Percoii gradient (23,24,27). Aiiquots offreshIy-isolated RPT5
from individuai animais were used immediateiy for quantitation of the
protein/DNA ratio, Western biofting and total RNA isolation.
ProteinlDNA Ratio in mRPTs
DNA was quantified in quadrupiicate (28,29). Briefly, mRPTs were
homogenized in 3 mi coid PBS, and aiiquots (100 pI) were distributed in
96-weii plates at 37°C. Then, 10 pi of 10 pg/mi 4’,6-diamidino-2-phenyiindoie
(DAPI) (La Roche Biochemicais) was added to each weii. After incubation at
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room temperature for 30 mm, DNA concentration was read at À360 nm
excitation and À460 nm emission (CytoFluor Il spectrofluorometer, PerSeptive
Biosystems, Cambridge, MA, USA. Protein concentration was measured in
quadruplicate in the same samples by DC protein assay (Bio-Rad
Laboratories). Once protein (pg)/DNA ratios were calculated, the data were
presented as percentages of increase in comparison to WT controls (1 00%).
RPTC and Nuclear Volumes
Kidneys were collected in Tissue-Tek cassettes (VWR Canlab, Montreal,
QC, Canada), dipped immediately in ice-cold 4% paraformaldehyde and fixed
for 24 h at 4°C. The cassettes were processed by the CHUM Pathology
Department. Tissue sections were counterstained with hematoxylin and eosin
(H/E). Four to 5 tissue sections per kidney from 6 animaIs per group were
analyzed by light microscopy by 2 investigators blinded to treatment. RPTC
and nuclear volumes were measured by image analysis software (Motic Image
Plus 2.0, Motic Instruments Inc., Richmond, BC, Canada). Outer cortical RPTs
with similar cross-sectional views (equal diameter and clear nuclear structure)
were selected.
Mean celi volume was estimated by the Nucleator method (30,31), an
unbiased stereological technique estimating the volume of 3-dimensional
structures on 2-dimensional sections. Briefly, a cell profile was sampled if its
nucleus was visible and if typical nuclear size and the ceil centre were ‘hit’. The
Iength of a random ceil ([f and t) through the hit point was ascertained by
image analysis software. The measurement was repeated 3 times in different
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directions i, 12, 12, 13 and 13) per ceIl. The mean intercept of each
direction was assessed by the equation I = % (I + + I ). Mean intercept length in
the third power per celI (I) was then determined by the equation io = 1/3 (I
+ I2 + I3). Mean ceIl volume (Vo) (100 cells were counted per animal) was
quantified by the equation Vo = 4/3 iT
Mean nuclear volume (VN) was estimated (200 nuclei were counted per
animal) by the Selector method (28, 29) according to the equation VN u/3 x
310
lmm unohistochem istry
Immunostaining was performed on 3-pm renal sections by the standard
avidin-biotin-peroxidase complex method (ABC Staining System, Santa Cruz
Biotechnology) (23,24) with either polyclonal anti-hnRNP F (C1004, 1:100
dilution) (19), rAGI (R-16, 1:100 dilution) (23), TGF-131 RIl (1:100), or control
rabbit pre-immune serum (1:100 dilution). AIl sections were counterstained
with hematoxylin, dehydrated, and covered with glass slips.
Statistical Analysis
Statistical significance between the experimental groups was analyzed
initially by Student’s t-test or 1-way ANOVA (analysis of variance) and the
Bonferroni test as appropriate. The data are expressed as means ± SD.
p<0.05 values were considered to be statistically significant.
RESU LTS
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HnRNP F Overexpression Prevents High Glucose-induced AGT, TGF-1
and TGF-1 Ru mRNA Expression in RPTCs in vitro
To study the effect of hnRNP F on AGT mRNA expression in RPTCs, we
stably transfected immortalized rat RPTCs, which express ail RAS components
(32), with rat hnRNP F cDNA fused to GFP as a tag. GFP-hnRNP F stable
clones are shown in Figure fA. In pEGFP Cl empty vector (GFP-EV) stable
transfectants, fluorescence was predominantly cytoplasmic, but was
exclusively nuclear in GFP-hnRNP F transfectants. Figure lB displays the
Western blotting of GFP-EV and GFP-hnRNP F stable transfectants.
GFP-hnRNP F fusion protein was expressed as ptedicted at 72 kDa (the
apparent molecular weights 0f GFP and hnRNP F were 26 and 46 kDa,
respectively). Thus, hnRNP F is a nuclear protein. Stable GFP-EV and
GFP-hnRNP F transfectants were used in subsequent studies.
To examine the effect of hnRNP F on AGT TGF-131 and TGF-131 RIl gene
expression, we quantified AG1 TGF-F31 and TGF-131 Ru mRNA expression in
GFP-EV and GFP-hnRNP F stable transfectants in normal- and high-glucose
medium. After 24 h of high-glucose stimulation, AGT mRNA (Figure 2A),
TGF-131 mRNA (Figure 2B) and TGF-31 RIl mRNA (Figure 2C) were
significantly increased (>2-fold) in GFP-EV stable transfectants as compared to
normal glucose. HnRNP F overexpression abolished the high-glucose effect on
AGT TGF-131 and TGF-F31 RIl mRNA expression in GFP-hnRNP F stable
transfectants.
HnRNP F Overexpression Prevents High Glucose-induced RPTC
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Hypertrophy
To demonstrate whether hnRNP F overexpression could prevent RPTC
hypertrophy in high glucose via suppression of AGT expression, we
determined the cellular hypertrophy index (i.e., total protein content,
[3HJ-Ieucine incorporation, and p27k1P1 protein expression) in stable
transfectants cultured in normal- or high-glucose medium. High glucose
induced a significant increase in total cellular protein content (Figure 3A),
[3HJ-leucine incorporation (Figure 3B) and cellular 27kui expression (Figure
3C) in GFP-EV stable transfectans. HnRNP F overexpression in GFP-hnRNP
F stable transfectants prevented the stimulatory effect of high glucose.
Generation of Kïdney-specific hnRNP F-1g Mice
Ta confirm our in vitro data, hnRNP F-1g mice were generated to
produce specific and inducible hnRNP F expression in RPTCs by inserting
hnRNP F cDNA into a construct containing the KAP promoter and non-coding
DNA, including exons 3 to 5 of human AGT gene (Figure 4A). Founders were
screened by Southem bloffing, whereas F1, F2, and F3 mice were screened by
PCR for the hnRNP F-HA transgene (Figure 4B). Tissue-specific expression of
the hnRNP F-HA transgene was studied under 2-week testosterone
implantation in 1g mice. Testosterone pellets (but not placebo) induced hnRNP
F-HA transgene expression in the kidneys of female 1g mice (Line 937)
(Figure 4C). The hnRNP F-HA transgene was expressed in the kidneys of
male Tg mice, and exogenous testosterone administration further enhanced its
expression in the kidneys but flot in other tissues (Figure 4C). Renal sections
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from male WT and Tg mice were immunostained with anti-hnRNP F antibody.
HnRNP F protein expression was significantly higher in RPTs from Tg male
mice compared to male WT control Jittermates (Figure 4D).
Taken together, these data demonstrate that the KAP2 promoter directs
rat hnRNP F transgene expression in RPTCs and is testosterone-inducible. In
subsequent experiments, we used male Tg mice without exogenous
testosterone induction since endogenous testosterone was efficient in
stimulating transgene expression in RPTC5.
HnRNP F Overexpression Attenuates ProteinlDNA Ratios and p27’(’Pl
Expression in RPTs of Diabetic Tg mRPTs
To ascertain the functional role of hnRNP F in vivo, diabetes was induced
as described in Materials and Methods. Four groups of mice were compared:
non-diabetic WT, STZ-induced diabetic WT, non-diabetic Tg, and STZ-induced
diabetic Tg. The physical parameters are shown in Table Il. Both diabetic ‘NT
and hnRNP F-1g mice exhibited marked hyperglycemia on the day they were
sacrificed as weII as higher kidney weighUbody weight ratio as compared to
their non-diabetic counterparts. There were no significant differences in blood
glucose, kidney weighUbody weight ratio or serum creatinine between
non-diabetic WT and non-diabetic hnRNP F-Tg mice as well as between
diabetic ‘NT and diabetic hnRNP F-1g mice. An increase in the
albumin/creatinine ratio (ACR) was observed in non-diabetic hnRNP F-1g mice
as compared to non-diabetic ‘NT mice (Table Il), but did flot reach statistical
significance.
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Tubular hypertrophy is a well-known characteristic in diabetes induced by
STZ (30,33). We quantified biochemical markers cf tubular hypertrophy:
protein/DNA ratio, celiular and nuclear volume, and p27<P expression, in
RPTCs ofWF and hnRNP F-Tg mice (31). The protein/DNA ratio (Figure 5A),
cellular volume (Figure 5B) and nuclear volume (Figure 5C) were significantly
higher in RPTCs of diabetic WT and diabetic hnRNP F-Tg mice compared to
non-diabetic mice. Simiiariy, 27KIP1 protein expression was significantly
stimuiated in RPTs of diabetic WT mice compared to non-diabetic ‘NT mice
(Figure 5D). However, the increased protein/DNA ratio (Figure 5A), cellular
volume (Figure 5B), nuclear volume (Figure 5C), and heightened p271
expression (Figure 5D) were significantly attenuated in RPTs of diabetic
hnRNP F-Tg mice as compared to non-diabetic hnRNP F-1g mice. Most
importantly, the percent increase of these parameters in RPTCs of diabetic
hnRNP F-Tg mice was significantly lower in comparison to diabetic WT mice.
HnRNP F Overexpression Aftenuates AGT, TGF-pl RIl and Collagen la
(type IV) Protein Expression in RPTs of Diabetic 1g mice
Since we observed that hnRNP F overexpression inhibits rat AGT mRNA
expression in GFP-hnRNP F stable transfectants in vitro, we investigated
whether hnRNP F overexpression downregulates AGT expression in vivo.
STZ-induced diabetes increased AGT expression in RPTs of both WT (Figure
6A, b) and diabetic hnRNP F-Tg mice (Figure 6A, d) as compared to
non-diabetic animais (Figure 6A, a and c). The increment of AGI expression
in RPTs of diabetic hnRNP-Tg mice (Figure 6A, d), however, was significantly
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attenuated in comparison to diabetic non-1g mice (Figure 6A, b).
Semi-quantitative analysis revealed significantly Iess AGT-positive, stained
tubules in diabetic hnRNP F-Tg mice than in diabetic WT mice (Figure GB).
It was apparent that STZ-induced diabetes increased TGF-j31 Ru
expression in RPTs of both diabetic ‘Arr (Figure 7A, b) and hnRNP F-Tg mice
(Figure 7A, d) compared to their non-diabetic counterparts (Figure 7A, a and
c). Again, the increment of TGF-1 Ru expression in RPTs of diabetic
hnRNP-fg mice (Figure 7A, d) was signiflcantly aftenuated in comparison to
diabetic non-1g mice (Figure 7A, b). Semi-quantitative analysis after 4 weeks
ofdiabetes also revealed significantly Iess TGF-1 Ru-positive, stained tubules
in diabetic hnRNP F-Tg mice than in diabetic WT mice (Figure 7B). The
experiments confirmed that hnRNP F overexpression aftenuatesdrenal AGI
and IGF-31 Ru expression in diabetes.
HnRNP F Overexpression Attenuates Fibrotic Gene Expression in RPTs
of Diabetic 1g mice
AGT mRNA (Figure 8A), TGF-131 Ru mRNA (Figure 8B), fibronectin mRNA
(Figure 8C) and collagen al (type IV) mRNA (Figure 80) were significantly
elevated (2- to 6-fold, p<O.005) in RPTs of diabetic wr compared to
non-diabetic WT mice. However, the heightened expression of these fibrotic
genes was signiflcantly attenuated in RPTs of diabetic hnRNP F-1g mice.
DISCUSSION
This report demonstrates that hnRNP F overexpression in RPTCs
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allenuates the high-glucose stimulation 0f AGT and TGF-31 Ru expression,
cellular hypertrophy and fibrosis, bath in vitro and in vivo, suggesting that
hnRNP F expression suppresses RPTC hypertrophy and tubulointerstitial
fibrosis in diabetes by dampening AGT gene expression and intrarenal RAS
activation.
HnRNPs are pre-mRNA-binding proteins involved in mRNA processing,
and appraximately 20 of them have been identified (34,35). Accumulating
evidence indicates that hnRNP F may regulate gene expression at bath the
transcriptional and post-transcriptional levels. lndeed, reports suggest that
hnRNP F engages in alternative splicing of c-src (36), 3-tropomyosin gene (37),
thyroid hormone receptor gene (38), and Bd-x gene (39), as well as in the
3 -end processing of pre-mRNA in B-celI differentiation (40). HnRNP F
associates with TATA-binding protein (TBP), RNA polymerase Il (Poly Il), and
even with nuclear cap-binding protein complex (41,42). The molecular
mechanism of hnRNP F action on gene transcription, however, is not
welI-defined.
We previously reported that hnRNP F binds ta the IRE of rat AGT gene
promoter and inhibits AGT promoter transcriptional activity (19). We also
demonstrated that hnRNP F interacts with hnRNP K (another nuclear protein
that binds ta the same IRE in rat AGT gene promoter) and further inhibits AGT
expression in RPTCs in vitra (20). More recently, Chen et al. (43) observed
that hnRNP F interacts with the asmoregulatary transcription factor,
TonEBP/OREBP, and modulates Hsp9O and PARP-1 gene expression. These
findings indicate that hnRNP F may act alone or interact with ather
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transcriptional factors to modulate specific gene transcription.
The present evidence suggests that the intrarenal RAS plays a key role in
hyperglycemia-induced celi hypertrophy via the activation of TGF-131 signaling
(10,44). Our studies in stable transfectants overexpressing hnRNP F indicate
that hnRNP F is localized predominantly in the nucleus. HnRNP F
overexpression in stable transfectants prevents the high-glucose stimulation of
AGT TGF-31 and TGF-431 RIl mRNA expression, and circumvents high
glucose-induced cellular hypertrophy, as determined by total protein content,
[3HJ-leucine incorporation, and 27kIP1 protein expression in RPTCs. These
data are consistent with our previous observations that hnRNP F suppresses
AGT gene transcription in RPTCs (19) and decreases AGT gene expression
preventing cellular hypertrophy in high glucose (10).
In Tg mice overexpressing hnRNP F in their RPTCs, we showed that
hnRNP F overexpression fails to prevent the increase in blood glucose and
kidney/body weight ratio in diabetic Tg mice (N.B.: The kidney/body weight
ratio in hnRNP F-Tg mice tends to decrease as compared to non-Tg controls
but the change is not statistically significant). However, hnRNP F
overexpression clearly prevented attenuation of the protein/DNA ratio, cellular
and nuclear volume, and 27kIP1 protein expression in RPTCs of diabetic
hnRNP F-Tg mice as compared to diabetic non-1g controls. Moreover, the
expression of AGT TGF-31 RIl, fibronectin and collagen al (type IV) mRNA
was also significantly reduced in RPTs of diabetic Tg-hnRNP F mice as
compared to diabetic non-Tg controls.
The exact reason why hnRNP F-Tg mice had a higherACR (although flot
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statistically significant) as compared to WT was flot clear in the present studies.
Urinary albumin is considered to be the unbalance between glomerular
filtration rate and tubular reabsorption (45). It raises the possibility the hnRNP
F overexpression may affect the expression or function of some genes
associated with tubular reabsorption of albumin, such as megalin and cubilin
(46,47). Clearly, more studies along these unes are required.
The present report provides novel observations that hnRNP F
overexpression can prevent high glucose-induced RPTC hypertrophy both in
vitro and in vivo. The molecular mechanism(s) of hnRNP F action on AGT gene
expression remain undefined. One possibility is that hnRNP F behaves as a
negative transacting factor and competes with other positive transacting
factor(s) (i.e., cAMP-response element-binding protein (CREB) and activating
transcription factor-7 (AIE-1)) for binding to TBP and RNA PoIy II,
subsequently allenuating AGT gene expression. This possibility is supported
by our previous report that CREB and ATF-1 expression is enhanced in RPTC5
in high glucose (13), and CREB overexpression augments AGT gene
transcription (48). A second possibility is that hnRNP F overexpression may
exhaust the availability of nuclear CAP-binding proteins for capping
pre-mRNAs, which might then attenuate the formation of mature AGT mRNA in
the cytoplasm. Finally, it is also possible that hnRNP F could form a
heterodimer with hnRNP K that effectively binds with other positive
transcriptional factors to prevent their interaction with the initiation complex.
The physiological importance of attenuation of RPTC hypertrophy in
diabetes by hnRNP F overexpression remains to be elucidated. Since studies
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have reported that targeting disruption of the p271 gene attenuates kidney
hypertrophy and progression of nephropathy in STZ-induced diabetic mice
(49,50), we propose that RPTC hypertrophy may be an initial mechanism
leading to nephropathy in diabetes.
In summary, we have demonstrated that hnRNP F overexpression
suppresses AGT gene expression and subsequently allenuates high
glucose-induced cellular hypertrophy in vitro and in vivo, implying that
dysregulation of hnRNP F expression may contribute to renal injury in diabetes
via altered local intrarenal RAS activation.
APPENDIX
Abbreviations used in this article: ACR, albumin-creatinine ratio; AGT,
angiotensinogen; ATF-1, activating transcription factor-1; CREB,
cAMP-response element-binding protein; DAPI, 4 ,6-diamidino-2-phenylindole;
DN, diabetic nephropathy; ESRD, end-stage renal disease; GFP green
fluorescent protein; GFP-EV, pEGFP Cl empty vector; hnRNP F,
heterogenous nuclear ribonucleoprotein F; IRE, insulin-responsive element;
KAP, kidney-specific androgen-regulated protein promoter; PoIy II, RNA
polymerase Il; RAS, renin-angiotensin system; RPTCs, renal proximal tubular
celis; RPTs, renal proximal tubules; RT-PCR, reverse transcription-polymerase
chain reaction; RT-qPCR, real time-quantitative polymerase chain reaction;
SDS-PAGE, sodium dodecyl sulfate-polyacrylamide gel electrophoresis; STZ,
streptozotocin; TBP, TATA-binding protein; Tg, transgenic mice; TGF-131,
transforming growth factor-betal; TGF-131 RlI, TGF-3l receptor II; WT, wild
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type.
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Table I. Primer sequences
Table Il. Physical parameters ofdiabetic mice
LEGENDS
F igure 1. Generation of rat hnRNP F stable transfectants. RPTCs were stably
transfected with plasmid DNA, pEGFP Cl empty vector (GFP-EV) or pEGFP-hnRNP
F (GFP-hnRNP F). Nuclei were shown by DAPI staining. GfP fusion protein
expressions of G418-resistant transfectants were identified by fluorescence
microscopy, magnification x 600. (A) and Western blotting (3) as described in
Materials and Methods.
Figure 2. Expression ofAGT, TGF-431 and TGF-1 Ru mRNA in stable transfectants.
Real time-quantitative PCR (RT-qPCR) analysis ofrAGT mRNA (A), TGF-f31 mRNA
(B) and TGF-131 Ru mRNA (C) expression in stable transfectants. CelIs were
incubated with 5 mM D-glucose plus 20 mM D-mannitol or 25 mM D-glucose for 24
h. Then. they were harvested and assayed for gene expression by RT-qPCR as
described in Materials and Methods. (*p<O.O5; **p<OOl; ***p<O.005: n.s.,
non-significant).
Figure 3. Cellular hypertrophy in stable transfectants. (A) Total cellular protein
content per million ceils, (B) [3H]-leucine incorporation, and (C) p27’”1 protein
expression in RPTCs stably transfected with pEGFP-EV or pEGfP-hnRNP f. The
cells were incubated with 5 mM D-glucose plus 20 mM D-mannitol or 25 mM
D-glucose for 24 h. (**p<o.ol; ***p<o.00s; n.s.., non-significant).
Figure 4. Generation of Tg mice. (A) Schematic map of the kidney
androgen-regulated promoter (KAP2)-rat hnRNP F construct. (B) Southern blotting of
genomic DNA for founders with radioactive hnRNP f probe. Heterozygous and
homozygous f
,
f2 and f3 were screened by PCR with specific primers (Table I). (C)
RT-PCR product showing tissue expression of hnRNP f-HA mRNA in female and
male 1g mice un-induced or induced with testosterone. -actin and hnRNP F-HA
fragments are indicated. Transgenic (line #937) mice were induced with placebo or
testosterone for 2 weeks prior to RNA isolation. Br, brain; Hr, heart; Lu, lung; Li, liver;
Ki, kidney; Sp, spleen; Ts, testis. (D) Immunohistochemistiy of hnRNP F in kidneys
of male WT and 1g mice at 20 weeks (magnification, x 200 and 600).
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Figure 5. RPIC proteinfDNA ratio, cellular and nuclear volume, and p27u3l protein
expression in mouse kidneys. RPTs were isolated, extracted and assayed as described
in Materials and Methods. RPT protein/DNA ratio (A), cellular volume (B), nuclear
volume (C) and p27’ protein expression (D) are shown in RPIs of diabetic and
non-diabetes WT and hnRNP F-1g mice. The relative densities ofthe p27KuT)l band (D)
were normalized with the f3-actin band. The protein/DNA ratio, celluÏar and nuclear
volume, or 27KIP1 level in non-diabetic W1 mice RPTs represents the control level
(100%) (*p<o.o5; **p<O.Ol; ‘“p<O.OO5; n.s., non-significant).
Figure 6. AGT expression in mice kidneys. (A) Immunohistochemistry of AGI
protein expression in kidneys from non-diabetic WT mice (a), STZ-induced diabetic
WT mice (b), non-diabetic 1g mice (c), and S1Z-induced diabetic 1g mice (d).
Magnification x 600. (B) Semi-quantitative analysis of AGI-positive tubules from
kidneys of non-diabetic and diabetic WT and hnRNP F-1g mice (N6, **p<o.oI;
***p<o.005; n.s., non-significant)..
Figure 7. TGF-f31 RIT expression in mice kidneys. (A) Immunohistochemistiy of
1GF-3l RI! protein expression in kidneys ftom non-diabetic WT mice (a),
STZ-induced diabetic W1 mice (b), non-diabetic 1g mice (c), and SIZ-induced
diabetic 1g mice (d). Magnification x 600. (B) Semi-quantitative analysis of TGF-3l
RIT-positive tubules from kidneys of non-diabetic and diabetic WT and hnRNP F-Tg
mice (N6, ***p<O.005; n.s., non-significant).
Figure 8. R1-qPCR of AGI, 1GF-I Ru, fibronectin and collagen ul (type IV)
mRNA expression in RPIs. AGI, TGF-1 RIT, fibronectin and collagen IV mRNA
levels in RPTs of non-diabetic and diabetic WT and 1g mice are shown in (A), (B), (C)
and (D), respectively. Values are expressed as means + SD, N6 (*p<O.O5; **p.<0•0T,
***p<o.005; n.s., non-significant).
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Table 1. Primers used for conventional RT-PCR or RT-qPCR
Gene Primer sequences
hnRNP F-HA S: 5’-AGA GTG ACC GGA GAA GCT GA-3’
(BCO 97275) AS: 5’-GGC GTA GTC AGG CAC GTC GT-3’
Angiotensinogen (rat) S: 5’-CCT CGC TCT CTG GAC flA TC-3’
(BC087679) AS: 5’-CAGACAJrGAGGTGCTGTTG-3’
Angiotensinogen (mous e) S: 5’-CCA CGC TCT CTG GAT fiA TC-3’
(14M_007428) AS: 5’-ACA GAC ACC GAG ATG CTG fi-3’
TGF-fi 1(rat and mouse) S: 5’-CCAAÀC TAA GGC TCG CCA GTC-3’
(BC076380) AS: 5’-GGC ACT GCT TCC CGAATG TC-3’
TGF-fi I RU (rat and mouse) S. 5’-TCC TTC AAG CAG ACG GAT GT-3’
(11M_031 132) AS: 5’-ATC fiC TCC TGG GAG CAG CT-3’
fi -actin (rat and mouse) S: 5’-CGT GCG TGA CAT CAA AGA GAA-3’
(14M_031 144) AS: 5’ -GCT CGT TGC CAA TAG TGA TGA-3’
Fibronectin (mouse) S: S’-TAG CAG GCTACC GAC TGA CCG-3’
(14M 010233) AS: 5’-CAC CCA GCT TGA AGC CAA TCC-3’
S: 5’-TGC CGG GTC CAC AAG Gfl CAC-3’
AS: 5’ -GTC CAG GAG GGC CGA TGT CT-3’
Collagen IV A (mouse)
(11M_009931)
S, sense; AS, antisense.
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Table 2. The physical parameters of the animais at eithanization.
WT hnRNP F-Tg
C:onnol STZ Control STZ
Body we:ght t!) 29.52±2.1 22.83±i.8a 31.32±2.6
Biood iuce tmM) 7z1.Z 1.6±3.2b 8.2±12 3096b
Kidnevwejht (z) 0.36±0.08 042±0.11 0.34±0.10 0.40±0.16
Rauo’fKidneywt. bodvwt 0.012±0.002 0.01$±0.003 0.011±0.002 0.016±0.003
Urine a1bumrne(iz.mi) 13.6±4.1 18.35.9 33.7±10.6 21.4±8.2
Uiine creatinrne (mg,dl) 44.9±8.7 1 .2z0.5 16.4z6.1 1.5±0.7
Urine AC’R 29.8z3.5 163e 141918j
Senimcreannine(mg) 0.18±0.02 0.19±0.01 0.2±0.02 0.18±0.02
ACR = AlbunuaCreatinine Ratio
a. p:0.001 when STZ (Diabètes) compared with Control (Non-diabètes) n6 for cadi group.
b. p::O.00l when STZ (Diabètes) compared with Control (Non-diabetes) : u6 for each group.
c. p<O.05 when STZ (Diabètes) compared wirh Control (Non-diabètes) : n=6 for cadi group.
d. p:.0.01 elien SIZ (Diabètes) cornpared with Control (Non-diabètes): n=6 for each group.
e. p::0.05 wien STZ (Diabètes) cornpared with Control tNon-diabetes) : n=6 for cadi group.
f. non-sigruficant wlien hnR_NP F-Tg control cornpared witli WT Control: n6 for each group.
g. p<O.Oi when STZ (Diabetesi cornpared with Control (Non-diabètes) : n=6 for cadi group.
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Chapter 5: Discussion
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DN is the leading cause cf ESRD. RAS activation and hyperglycemia
are 2 major risk factors for the development cf DN. Previous studies in Dr.
Chan’s lab have demonstrated that the intrarenal RAS might play an
important role in DN development. Since AGT is the sole precursor cf the
RAS and its regulation is net well-deflned, elucidation cf the regulation of
AGI expression in the kidneys is a major research topic in our lab. We
have published several studies on the effects cf hyperglycemia and insulin
on rAGI gene regulation (35; 131; 132; 165). Our group has identified a
novel IRE in the promoter region cf the rAGI gene, and showed that 2
nuclear proteins could bind to the IRE. Ihese nuclear proteins could be
regulated by glucose and insulin (207). Howevet, their identification has not
been completed. Therefore, my Ph.D. studies concentrated on the 2
nuclear proteins, to elaborate their functions in rAGI gene expression and
their influence on RPTC hypertrophy in high glucose in vitro and in vivo.
5.1 Protein-DNA interactions
Proteins often interact with each other, forming transient or stable
complexes to exert their biological activities. Some proteins interact
specifically or non-specifically with non-protein molecules, such as DNA,
RNA, or metabolites. These interactions are critical for cellular functions,
especially in gene regulation. Ihus, defining the composition cf protein
complexes and understanding how they are assembled and regulated may
yield invaluable insights into protein function.
Proteins that bind DNA have been found to have common folding
patterns known as DNA-binding motifs. Each DNA-binding motif is
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composed of recognition and stabilization regions (275). A significant
number of DNA-binding protein structures have been postulated, along
with several structures of their binding site complexes. The a-helix may be
best suited to bind major grooves for specific recognition (276). The major
classes of binding motifs that have been described are helix-turn-helix,
leucine zippers, zinc fingers (ZF), and 3-structures (277). Some proteins
even indirectly bind to DNA by binding to other proteins before interacting
with DNA (278; 279).
5.1.1 General Prospecting Technologies to Elucidate Protein-DNA
Interactions
Several methods are commonly used to analyze protein-DNA
interactions, including DNase I footprînting, gel mobility shift assay (GMSA),
chromatin immunoprecipitation (ChIP), and Southwestern blotting (280;
281). Each ofthese methods has specific capabilities and limitations.
DNase I footprinting identifies the DNA sequence to which a protein
binds. First, a target DNA fragment of about 100-300 bp in Iength is either
PCR-generated or cut from a vector, and then Iabeled with an isotope
before incubation with nuclear proteins. This is followed by controlled
digestion with DNase I, which randomly cuts the probe once. The digested
DNA is recovered from the reaction and resolved on polyacrylamide gel
with a sequencing reaction that employs the same probe as template. The
regions bound by proteins are protected from digestion and show up as a
blank area on the gel track. The exact protein-bound sequence can be read
by comparing the location of the blanks with the sequencing reaction (282;
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283). By varying the concentration of DNA-binding protein, binding affinity
can be estimated according to the minimum concentration of protein at
which a footprint is observed. The disadvantages of this technique are that
it is tedious and technically demanding, and DNase I can only be deployed
under specific conditions (i.e., in the presence of Mg and Ca ions) (281).
GMSA is based on the observation that protein-DNA complexes
migrate through non-denaturing polyacrylamide gel more slowly than free
DNA fragments or double-stranded oligonucleotides (280; 281; 284).
GMSA is performed by incubating a purified protein or a complex mixture of
proteins (i.e., a nuclear extract) with a labeled DNA fragment containing the
putative protein-binding site. The reaction products are then analyzed by
electrophoresis on non-denaturing polyacrylamide gel. The specificity of
the DNA-binding protein for the putative binding site is established in
competition experiments with DNA fragments or oligonucleotides
containing a bïnding site either for the protein of interest or for other
unrelated DNA sequences. Supershift-GMSA is undertaken by incubating
proteins with a Iabeled DNA fragment containing the putative
protein-binding site and an antibody to the putative protein (280; 281). A
“super-complex” of DNA-protein antibody has signiflcantly reduced mobility
compared to a DNA-protein complex when it is subjected to
electrophoresis in non-denaturing gel. This method provides information on
the mass of the bound protein, and the resuits are easier to see than those
of footprint assay. Although useful for basic research, gel-shift and
supershift assays have low sensitivity, so that a large number of controls
are required. Furthermore, gel-shift and supershift assays are not
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quantitative. They can detect the presence or absence of a particular
DNA-binding protein, but they cannot localize the binding site or predict the
molecular size of the binding proteins.
ChIP is typically performed to test whether a protein binds to a
candidate promoter in living ceils. The principle behind this assay is that
DNA-bound proteins in living ceils can be cross-linked to the chromatin with
which they interact. This is usually accomplished by gentle formaldehyde
fixation. After fixation, the cells are lysed, and DNA is broken by sonication
into pieces 0.2-1 kb in length (280; 281). Once the proteins are immobilized
on the chromatin and the chromatin is fragmented, whole protein-DNA
complexes can be immunoprecipitated with an antibody specific for the
protein in question. DNA from the isolated protein/DNA fraction can then be
purified. The identity of the DNA fragments isolated in a complex with the
protein of interest can then be determined by PCR, using primers specific
for the DNA regions hypothetically bound by the protein.
ChIP has the advantage of measuring protein-DNA interactions in their
natural genomic state. Moreover, ChIP can provide direct information on
the histone acetylase status of specific chromatin regions. It also minimizes
the chances of chromatin rearrangements during preparation and
precipitation. Its disadvantages are that a large number of celis are usually
required, and the data may represent an average of multiple functional
states in the cell population. In addition, specific antibodies are needed for
each protein, and negative results do flot necessarily mean that a given
factor is flot associated with the site (285).
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Southwestern bloffing was first described by Bowen and colleagues as
a method of identifying and characterizing DNA-binding proteins by their
ability to bind to a specific oligonucleotide probe (286). Nuclear protein
extracts are typically separated electrophoretically on sodium dodecyl
sulphate (SDS)-polyacrylamide gel and then transferred to nitrocellulose
for screening with a probe. The disadvantages of this technique are that it
requires relatively large amounts of nuclear protein, there are problems
with protein degradation during isolation, and it is difficuit to achieve
efficient electrophoretic separation and transfer of a wide range of proteins
of different molecular sizes (287).
During the first year of my Ph.D. studies, I tried to clone nuclear
proteins that bind to the IRE of rAGT from a cDNA library constructed from
IRPTCs. I constructed several cDNA libraries ranging from 300 to 1.5 kbp.
Unfortunately, I did flot obtain any candidate clones in the second
screening (unpublished resuits). We changed our strategy by flrst
separating nuclear proteins by 2D gel electrophoresis, and then identifying
candidate proteins by Southwestern blotting employing radioactive
rAGT-IRE as a probe. After we identified positive spots, we sequenced
them by matrix-assisted laser desorption ionization-mass spectrometry
(MALDI-MS). This powerful proteomics technology has provided us with
very good data, and we have been able to identify the 2 nuclear proteins as
hnRNP F and hnRNP K (Chapters 2 and 3).
5.1.2 Advantages and Disadvantages of 2D Gel Electrophoresis Combined
with MS
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2D gel electrophoresis is a technique by which proteins are separated
according to their isoelectric point (pi) and mass. It is used as a component
of proteomics and is the initial step in the isolation of proteins for further
characterization by MS (288). The technique separates proteins in 2 steps:
1) isoelectric focusing fIEF), which separates proteins according to their pi,
and 2) SDS-polyacrylamide gel electrophoresis (PAGE), which separates
proteins according to their MW. In this way, complex mixtures consisting of
thousands of proteins can be resolved, and the relative amount of each
protein determined.
The procedure involves placing the sample in a gel with a pH gradient
and applying a potential difference across it. In the electrical field, the
protein migrates along the pH gradient until it carnes no overali charge. The
location of the protein in the gel indicates its pi.
There are 2 methods for creating the pH gradient: carrier amphoiites
and immobilized pH gradient (IPG) gels. In our Iab, IEF is performed with
commercial 1PGs for highly-reproducible results. IEF is the most critical
step in the 2D electrophoresis process. The proteins must be solubilized in
a buffer without charged detergents, usually a highly-concentrated urea
solution that splits the proteins into individual components, but also
denatures them, which ensures reliable running in IEF. To obtain high
quality data, it is essential to achieve low ionic strength conditions before
IEF. Since different types of samples vary in their ion content, it is
necessary to adjust the IEF buffer and the electnical profile for each type of
sample.
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Voltage volume is another problem in running IEF. It appears that
higher voltage yields bettet resuits. The correct voltage for running strips
depends on the length cf the strip; Bio-Rad recommends 600 V/cm. This
means that for running an 18-cm strip, a maximum of arcund 10,000 V is
required. However, tests of several conditions are recommended to find the
best resolution. In this study, we had to run 2 gels under the same
condition at the same time to get an identical protein profile, which
faci Iitated comparison with Southwestern blotting.
In recent years, MS has emerged as a powerful tool to quickly and
efficiently identify proteins in biological samples (289; 290). However, the
application of MS to large biomolecules and synthetic polymers has been
limited because of the high volatility and thermal instability of the materials
(291). These problems have been overcome to a great extent through the
development cf soft ionization techniques, such as MALDI-MS (292-294).
Coupled with an isolation technique (i.e., 2D electrophoresis) to purify a
specific protein of interest, MS can rapidly and reliably identify the structure
of a protein.
MALDI is based on an ultraviolet-absorbing matrix pioneered by
Hillenkamp et al. (293). The matrix and polymer are mixed at a molecular
level in an appropriate solvent with -104 molar excess of the matrix. The
solvent prevents aggregaticn cf the polymer. The matrix mixture is placed
on a sample probe tip. The solvent is removed in vacuum, leaving
co-crystallized polymer molecules homogeneously dispersed with matrix
molecules. When the pulsed laser beam is tuned to the appropriate
frequency, energy is transferred to the matrix, which is partially vaporized,
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carrying intact polymers into the vapor phase and charging the polymer
chains (294). Multiple laser shots improve the signal-to-noise ratio and
peak shapes, increasing the accuracy of molar mass determination. In a
linear time-of-flying (10F) analyzer, the distributions cf molecules
emanating from a sample are imparted to identical transiational kinetic
energies after being subjected te the same electrical potential energy
difference. The digitized data generated from successive laser shots are
summed, yielding a TOF mass spectrum, which is a recording of the
detector signal as a function cf time. The time cf flight for a molecule cf
mass (m) and charge (z) to travel is proporticnal to (m/z)112. This
relationship can serve to calculate ion mass, through which conversion cf
the 10F mass spectrum te a ccnventional mass spectrum cf
mass-te-charge axis can be achieved (295).
The prctein te be analyzed must be purified by an apprcpriate
apprcach, which cften includes an affinity chrcmatography step. In this
study, I isclated the nuclear prcteins frcm high gluccse-stimulated IRPTCs,
as cur previous resuits showed that high glucose enhances the binding
profile cf IREBPs te the rAGT IRE. Then, I separated the prcteins by 2D gel
electrophcresis.
5.2 Advantages and Disadvantages cf IRPTCs
The prcximal tubule cf the mammalian kidney is ccmpcsed cf
polarized epithelial cells endcwed with specific ion transport capacities and
biochemical functicns distinct frcm thcse cf cells in the more distal
segments of the renal tubule (296-298). Primary cultures of proximal cells
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retain most of their properties during the first 2 or 3 weeks in culture, but
usually Iose their differentiated functions when they are sub-cultured (299;
300). Renal proximai tubule (RPT)-Iike established celi unes, such as
LLC-PKJ and OK celis, have been used to analyze glucose and ion
transport regulation (301; 302) as weB as intrarenal AGT expression (303;
304), and to study processes controlling membrane protein sorting (305).
However, the precise origin of these ceils remains unclear, since LLC-PK1
celis, for exampie, have both proximal and distal tubule celi functions (297;
302; 306).
The IRPTCs in this study were established by Ingelflnger’s group. The
IRPIC 93-p-2-1 celi une was derived from 4- to 6-week-old WKY male rats
with an origin-defective SV4O plasmid (307; 308). IRPTC 93-p-2-1 is a
rapidiy-growing and stable PTC une, which makes it useful in experiments
requiring a large amount of material. This IRPTC une polarizes and
expresses enzymes and proteins that are normally present in PiCs, thus
displaying a highly-differentiated phenotype. Celi une 93-p-2-1 aiso
expresses ail components of the RAS: AGT, renin, ACE, and Ail and Ai2
receptors (308).
One of the disadvantages of the IRPTC 93-p-2-1 celi une is that it
cannot be 100% identical to PiCs in vivo. For exampie, renai AGi mRNA
expression varies in comparison to that of rat RPTCs in vivo. ihere are
differences in AGT steady-state mRNA ieveisand regulation by sodium diet
in SHR compared to normotensive WKY rats in vivo (307; 309).
212
5.3 MoecuIar Mechanisms of hnRNP F and hnRNP K on AGT Gene
Expression
Accumulating evidence strongly suggests molecular Iinkage between
transcription by RNA poly II and pre-mRNA processing (310; 311). hnRNPs
associated with RNA poly II transcripts in the nucleus have important roles
in mRNA biogenesis (312-316). hnRNP F, H/H’, and the 2H9 family are a
subgroup of hnRNPs (317; 318). This family shares almost 75% sequence
homology (319). Rat and human hnRNP F cDNAs encode 415 amino acids
and exhibit 99% homology (317). The structure of hnRNP F/H/H’ contains 3
RBDs and a GY-rich region between RBD-II and RBD-IJI. The GY-rich
region has been suggested to bind to double-stranded DNA (320). By
analyzing its structure in the EMBL-EBI database, we found a ZF in this
region (Figure 9). The ZF is a —26-amino-acid residue peptide forming a
structure that binds to specific sequences in DNA (321; 322). The ZF motif
consists of an a-helix followed by a turn and 2 short F3-strands. The
f3-strands form a small Ioop resembling a finger, and the fold sandwiches a
zinc ion (323; 324). The a-helix and the first 3-strand contain conserved
cysteine and histidine residues that coordinate the zinc metal ion, which is
important for stabilizing the protein fold (325). Whether this motif is
responsible for hnRNP F-binding to the rAGT IRE is stili not weII-deflned.
Further experiments should be performed to demonstrate the role of this
region in DNA-binding ability (see Chapter 6 on Research Perspectives).
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Figure 9. Structure of hnRNP F.
hnRNP F co-immunoprecipitates with TBP and RNA poly Il, forming
complexes with nuclear cap-binding protein complex (CBC) (320; 326; 327),
suggesting that hnRNP F participates in gene regulation. Studies have also
shown that hnRNP F/H/H’ engages in alternative spiicing of c-src (237),
3-tropomyosin gene (232), thyroid hormone receptor gene (328), and Bd-x
gene (231) as well as in the 3 -end processing of pre-mRNA in B-cell
differentiation (329). Thus, evidence indicates that the hnRNP F/H/H’ family
plays an important role in both gene transcription and spiicing.
Input
rGST
- +
-
Beads’
LGST-hnRNPK
-
- +
kDa
160
105
75 p
50
Anti-113?
-
(W.B.) 35
1 2 3
Figure 10. Interaction of hnRNP K with TATA-Box
Binding Protein (TBP).
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hnRNP K was first discovered as a hnRNP particle (330). It has an
apparent MW of 65 kDa in SDS-PAGE (331). hnRNP K, localized in the
nucleus, cytoplasm and mitochondria, has been implicated in
chromatin-remodeling, transcription, splicing, and translation processes
(332). Indeed, it has been suggested that hnRNP K binds to RNA via
highly-conserved KH domains (333). K binds both double- and
single-stranded DNA motifs (CT element, 5 d-ICCC) within the promoter of
c-myc (334), c-src (253), c-fos, and elongation initiation factor 4E gene
(335), forming complexes with Spi and TBP to enhance gene transcription
(217; 246; 251). This evidence suggests that hnRNP K may also be
involved in transcription. In fact, hnRNP K expression can both activate and
repress RNA poly Il promoters (246; 254). hnRNP K has been found to play
the role cf a transcriptional repressor in suppressing the transcription of
thymidine kinase (336), the neuronal nicotinic acetylcholine receptor 34
subunit (247), and osteocalcin (337). We have discovered that hnRNP K
suppresses AGI gene transcription and binds with IBP (see Chapter 4
and Figure 10), supporting the notion that it isa suppressor protein. hnRNP
K also participates in the alternative splicing of p-tropomyosin (338),
stabilizes renin mRNA via binding to the 3 -untranslated region of renin
mRNA (339), and regulates 15-lipoxygenase gene translation via binding
with elongation factor-lo (249; 250). Ihus, hnRNP K is a multifunctional
protein that interacts with DNA, RNA, and transcriptional and translational
molecules to alter the in vivo rates of gene transcription and translation
(332).
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Studies in our lab have demonstrated that high glucose activates PKC
and p38 MAPK signaling and phosphorylates CREB and AIF-2 (35; 132).
The phosphorylated CREB and AIF-2 form a heterodimer, bind to CRE in
the rAGI promoter, recruit p300/CREB-binding protein (p300/CBP), and
stimulate rAGI gene expression. To counterbalance the action of
CREB/AIF-2, high glucose also stimulates hnRNP F and K gene
transcription, subsequently suppressing AGI gene transcription via protein
phosphorylation and transiocation into the nucleus. Studies have shown that
insulin alters hnRNP K-binding to DNA and RNA through phosphorylation
(340). ERK phosphorylation also drives the cytoplasmic accumulation of
hnRNP K and inhibition of mRNA translation in HeLa cells (341). These
resuits raise several possibilities concerning the mechanism(s) of hnRNP F
and hnRNP K action on the inhibition of AGT gene expression. First,
phosphorylated hnRNP K may interact with phosphorylated hnRNP F ta form
a heterodimer, and then bind with single-stranded AGT-IRE. The bound
heterodimer competes with CREB/ATF-2 heterodimer for binding with IBP
and RNA poly Il, which attenuates AGI gene expression. Ihis notion is
supported by the data in my second article and unpublished resuits (as
shown in Figure 10) that co-transfection of hnRNP F and hnRNP K into
IRPICs further suppresses AGI mRNA expression. Second, the
phosphorylated hnRNP F/K heterodimer may interact directly with
p300ICBP, altering the conformation of p300ICBP to release bound
CREB/AIF-2, and subsequently suppress AGT gene transcription. Finally,
the bound hnRNP KIF heterodimer could exhaust the availability of other
unidentified nuclear transcriptional activating factors via protein-protein
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interactions, thus attenuating AGT gene transcription. Clearly, more
studies are needed along these unes.
Taken together, our data demonstrate that hnRNP F and hnRNP K
could both bind to rAGI-IRE and TBP as weII as suppress rAGT
transcription. Ihe inhibitory effect of hnRNP F and hnRNP K may be
mediated directly or via protein-protein interactions with transcriptional
factors.
5.4 Renopathological Significance of Suppressing AGI Gene Expression
via hnRNP F or hnRNP K in Hyperglycemia
Renal hypertrophy and matrix protein synthesis are associated with
the upregulation of TGF-31 gene expression in diabetic rats and mice
(342-344). There is compelling evidence that Ang II-induced RPTC
hypertrophy and the stimulated synthesis of collagen type IV are mediated
by increased IGF-131 transcription and production (345-351). This was
demonstrated by the elegant studies of WoIf et aI. (350) and Sharma et al.
(344), who reported that neutralizing anti-IGF-31 antibodies significantly
reduced Ang II-stimulated collagen production and hypertrophy in murine
PTCs in vitro and in vivo, respectively.
Previous investigations in our lab have shown that both basal TGF43
and collagen al (type IV) mRNA levels in IRPICs stably transfected with
pRSV/rAGI antisense are lower than in non-transfected IRPICs and
IRPTCs stably transfected with pRC/RSV or pRSV/rAGI sense (352).
Ihese data suggest that TGF-r31 and collagen al (type IV) mRNA
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expression in IRPTCs depends, at least in part, on the presence of
endogenous Ang Il. Thus, renal Ang II acts in an autocrine manner to
stimulate TGF-31 expression and, subsequently, IGF-31 enhances cellular
hypertrophy and collagen al (type IV) expression in RPTCs. Iherefore, we
hypothesized that either hnRNP F or hnRNP K regulates AGI expression,
and subsequently attenuates RAS activation and the progression of
renopathology in hyperglycemia, that is, RPIC hypertrophy.
Evidence suggests that the intrarenal RAS plays a key role in
hyperglycemia-induced celi hypertrophy via the activation of IGF-131
signaling (350; 353). Our data have revealed that stable transfectants
overexpressing hnRNP F or hnRNP K prevent the high-glucose stimulation
of AGI, IGF-13l and IGF-3l Ru mRNA expression, and circumvent high
glucose-induced cellular hypertrophy, as determined by total protein
content, [3HJ-leucine incorporation, and 27kIP1 protein expression in
RPICs (Chapter 4 and unpublished data in Figure 1 1). These findings are
consistent with our previous observations that hnRNP F and hnRNP K
suppress AGI gene transcription in RPTCs (354; 355) and that decreased
AGT gene expression prevents cellular hypertrophy in high glucose (352).
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Figure 11. hnRNP K overexpression prevents ceUutar hype,traphy in high glucose.
Since I did flot prove per se that the effects on TGF-3 and TGF-3 Ru
expression, protein/DNA ratios, ceflular volume and 27k1P1 protein
expression are mediated uniquely by the intrarenal RAS, further
experiments in kidney-specific AGT knockout mice are required. To obtain
tissue-specific gene knockout, the Cre recombinase/IoxP (Cre/loxP)
system is most widely utilized, for which 2 different mouse unes have to be
produced separately. In 1 of these 2 unes, exon 2 of mAGT is flanked by 2
loxP sites by homologous recombination techniques in embryonic stem
celis. The IoxP sites are short-sequence elements (34 bp) containing 2
13-bp inverted repeats flanking an 8-bp asymmetric spacer. In the second
mouse une, generated by standard oocyte injection, Cre recombinase
expression is driven by the core promoter of a kidney-specific gene,
choosing KAP2 or Sglt2 (sodium-glucose transporter 2) promoter. Mating
of these 2 different mouse unes wiIl yield offspring where Cre recombinase
is solely expressed in the targeted tissue or ceil type in which it wilI excise
the floxed AGT fragment. Analyzing the TGF-3 signal pathway and PTC
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r 1
r I 5mM
l.l 25mM
mi fl.ï
Emptyvecwr hnRNP K
219
hypertrophy after diabetes induction, we speculate that the TGF-13 signal
pathway and PTC hypertrophy wiIl be aftenuated or completely blocked in
diabetic AGI knockout compared to diabetic wild type mice. Thus, we can
validate that the intrarenal RAS is partly or uniquely mediating the TGF-13
signal pathway and PIC hypertrophy.
In hnRNP F-1g mice, we showed that hnRNP F fails to prevent the
increased blood glucose and kidney/body weight ratio occurring in diabetic
Tg mice. (N.B.: The kidney/body weight ratio in hnRNP F-1g mice tends to
be Iower than in non-1g controls, but the difference is not statistically
significant.) However, hnRNP F overexpression clearly prevents
attenuation of the protein/DNA ratio, cellular and nuclear volumes, and
p27k1P1 protein expression in RPICs of diabetic hnRNP F-1g mice
compared to diabetic non-Tg contrais. In addition, although DN has
traditionally been considered ta be primarily a glomerular disease, it is now
widely accepted that the diabetic kidney fails not only as a result of
glomerular lesions but aiso because of tubulointerstitial changes, whereas
diabetic glomeruiosclerosis alone does not Iead ta chronic renal failure
(356; 357). These observations suggest that although glomerular injury
plays a primary role in patients with proteinuria, the Iong-term autcame is
determined by events in the renal interstitium. In this study, we alsa
demonstrated that AGT, TGF-1 Ru, fibranectin, and callagen al mRNAs
are significantly elevated in vivo and in vitro. However, the heightened
expression of these mRNAs is significantly aftenuated when hnRNP F is
overexpressed (see results in Chapter 4).
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Taken together, the present experiments make novel observations
that AGI suppression in the RAS through hnRNP F or K can prevent high
glucose-induced RPIC hypertrophy both in vitro and in vivo.
5.5 Physiological Significance of Suppressing Local RAS Gene
Expression via hnRNP F and hnRNP K in Diabetes
Our lab has reported previously that AGI mRNA expression is increased
at Ieast 3-fold in RPIs of SIZ-induced diabetic mice. b avoid the
nephrotoxicity’ induced by STZ (358) and to demonstrate the physiological
roles of hnRNP F and hnRNP K in vivo, we used spontaneously diabetic
Akita mice, an optimal model for type 1 diabetes, and dbldb mice, an optimal
model for type 2 diabetes. The Akita mouse model has a mutated insulin
gene2, which is inherited by an autosomal dominant trait and confers a
decrease in the number of 3-cells of the pancreatic islets (271).
Our preliminary data disclosed that Akita mice (10 weeks old) develop
hyperglycemia and an increase (>3-fold, P< 0.01) of AGT mRNA expression
in RPTCs compared to wild-type controls (see unpublished data in Figure
12A). In contrast, hnRNP F and K mRNA expression is signiflcantly
decreased (>20% Iower, P < 0.05) in RPTs of diabetic Akita mice compared
to wild-type controls. Furthermore, we found that AGI mRNA is increased at
least 5-folU (P < 0.005) in RPIs of db/db diabetic mice, whereas hnRNP F
and hnRNP K mRNA levels are reduced at least 25% in comparison to
heterozygous db/m (P < 0.05) (see unpublished data in Figure 12B).
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Figure 12. Endogenous hnRNP F and K mRNA expression in diabetic animal models.
High glucose stimulated and insulin suppressed hnRNP F and K
expression in PTCs. Interestingly, hnRNP F and K overexpression
prevented the high-glucose effect on AGT mRNA expression in IRPICs
(354; 355). In contrast, hnRNP F and K downexpression by siRNA
enhanced the high-glucose stimulation of AGT mRNA expression in
IRPTCs (355). This, combined with preliminary results, showed that
hnRNP F and K expression is significantly lower in RPTs of Akita and db/db
mice (Figures 12A and 125). These data demonstrated that hnRNP F and
K proteins may be pivotai in counterbalancing the high-glucose stimulation
of AGT and TGF-F31 gene expression in diabetic kidneys. Dysregulation of
hnRNP F and/or K expression could enhance high-glucose stimulation of
intrarenal AGI gene expression and subsequent kidney injury in diabetes.
Thus, it is conceivable that hnRNP F and K proteins may be regulated
differently in humans predisposed to DN than in those who are less
r * 1
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susceptible to nephropathy. Clearly, more research is needed to define the
physiological role(s) of hnRPN F and hnRNP K proteins on ANG gene
expression in the diabetic kidney.
Figure 13. PAS staining of kidneys.
To elucidate the potential implications of hnRNP F and K on renal
function and development of histological changes of diabetic nephropathy
we have performed PAS staining to analyze the changes in glomerular
morphology (Figure 13). We also measured serum creatinine concentration
as a marker of renal function (Table Il in Chapter 4). There was no
significant change in glomerular morphology and serum creatinine in the 4
groups of mice. Since the animais were studied under 4 weeks of diabetes,
it is conceivable that we may not see latent effects on the progression of
nephropathy, i.e. decreased renal function, glomerular changes, and
glomerular homeostasis. b address this question, longterm experiments
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are needed, i.e. at least 12 weeks of diabetes. Given that hnRNP F
overexpression suppresses AGI gene expression and tubular hypertrophy
in diabetes, we anticipate that tubular damage might be attenuated and
subsequently ameliorate glomerular damage in diabetic hnRNP F-1g mice.
Nevertheless, more studies are needed to confirm this possibility. Tubular
hypertrophy is a good predictor of DN. Awazu et aI. (359) and Wolf et al.
(360) have reported that albuminuria, glomerular scierosis and mesangial,
endothelial, podocyte and PIC hypertrophy are aftenuated by 27kIPl
knockout in STZ-diabetic mice. Ihese studies provide an in vivo link
between renal hypertrophy and the progression of DN.
Our flndings support the notion that the suppressive action of hnRNP F
and hnRNP K on AGT expression in RPTs may play an important role in DN
in animal models. They also raise the possibility that hnRNP F or hnRNP K
dysregulation in the RPTs cf Akita or dbldb mice could be a major risk factor
in kidney injury in diabetes.
5.6 Conclusions
Ihe following conclusions can be drawn from our studies:
• Iwo nuclear proteins that bind to rAGI-IRE have been identified as
hnRNP F and hnRNP K by a combination of Southwestern blotting
and proteomics. Both proteins negatively modulate AGT gene
expression in IRPTCs. High glucose upregulates and insulin
downregulates hnRNP F and hnRNP K expression in IRPTCs.
hnRNP F and hnRNP K are detected in various rat tissues that
express AGI mRNA.
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• hnRNP K interacts with hnRNP F and TBP. Overexpression of
both hnRNP F and hnRNP K in IRPICs suppresses AGI
expression.
• hnRNP F overexpression attenuates high giucose-induced RPIC
hypertrophy via AGI inhibition in RPICs both in vitro and in vivo.
• Ihe expression of endogenous hnRNP F and hnRNP K in RPTs of
diabetic animais is iower than in nondiabetic animais, suggesting
that hnRNP F and hnRNP K dysreguiation may constitute risk
factors in the progression of nephropathy in diabetic animais.
Chapter 6: Perspectives of Research
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To clearly understand the mechanism of AGI gene regulation under
glucose and insulin stimulation via hnRNP F and hnRNP K, several
additional experiments shouid be performed.
6.1 Correlation between hnRNP F/hnRNP K and RAS Gene Expression in
Diabetic AnimaIs in vivo
The spontaneously diabetic Akita mouse modei has an insulin gene2
mutation that is inherited by an autosomal dominant trait with a decrease in
the number of 3-cells of the pancreatic islets (361). Our preliminary data
reveal increased AGT mRNA expression in RPTCs of diabetic Akita mice,
dbldb mice and BB rats compared to wild-type controls. In contrast, hnRNP
F and K mRNA expression is signiflcantly lower in RPTs of diabetic animais.
We postulate that AGI mRNA overexpression is due to decreased hnRNP
F or K expression in diabetic Akita mice. b test the hypothesis that
re-introduction of hnRNP F in RPTs couid rescue or prevent renal injury,
maie heterozygous Akita mice wiil be crossbred with homozygous femaie
hnRNP F-1g mice to produce hybrid 1g mice. The hybrids wili be identified
by Southern blotting of genomic DNA for KAP-hnRNP F transgene
expression and by PCR of mutated insuiin gene2.
Briefly, non-1g Akita lillermates and 1g Akita (KAP-hnRNP F) mica wiil
be divided into 4 subgroups: 1. non-treated diabetic group; 2. insuiin-treated
diabetic group; 3. perindopril/iosartan-treated diabetic group; 4.
perindopril/losartan/insulin-treated diabetic group. Ail females but flot maies
wiil aiso receive a testosterone peilet. At 2 and 6 months after treatment, the
animais wili be sacrificed after measurement 0f BP, biood glucose, GFR, and
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the urinary albumin/creatinine ratio. Body and kidney weights wiII be recorded.
Irunk blood wiII be collected for plasma AGI and Ang Il analysis. The left
kidney of each mouse will be removed and processed immediately by
histology and immunohistochemistry of hnRNP F, hnRNP K, AGI, TGF-131,
collagen la (type IV) protein and cellular hypertrophy, as described in
Chapter 4. The right kidney wiIl be harvested for RPI isolation, total RNA
extraction, and quantitative RT-PCR for AGT, TGF-J31, and collagen la
(type IV) mRNA expression (see Chapter 4 for details).
Ihe functional role 0f hnRNP F and K will also be tested by conditional
knockout or siRNA technologies. Ihese experiments will demonstrate
whether hnRNP F is important in regulating ANG gene expression, RAS
activation and subsequent renal injury in diabetes in vivo.
6.2 Identification of Transcriptional Factors Interacting or Associating with
hnRNP F and hnRNP K in vitro
Experiments have shown that hnRNP F and K bind to TBP, associate
with RNA poly Il, and interact directly with nuclear CBC (320; 326; 327),
suggesting that hnRNP F and K could modulate gene transcription via
interaction with basal transcription factors. In Chapter 5, our preliminary data
from pull-down assay have revealed that hnRNP K interacts with IBP. b
confirm whether hnRNP F and K interact directly with IBP, RNA poly Il and
CBC as welI as with other unidentified transcription factors in IRPICs, we wiIl
incubate cellular nuclear proteins from hnRNP F and K stable clones with an
equal amount of proteins of GST-hnRNP F or GST-hnRNP K or a
combination of both in the absence or presence of ribonucleases in pull-down
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assays. The immunoprecipitates will be subjected to Western bloffing with
antibodies against TBP, RNA poly Il, and p20/80 CBC.
As some other factors could interact with hnRNP F or K, we wiII perform
MALDI-MS. We will sequence the peptide in immunoprecipitates from
GST-hnRNP F and GST-hnRNP K or from ChIP. Then, we wiII clearly know
which other proteins are involved in transcription in association with hnRNP F
and K in vitro. Ihese data should discern details of AGI transcription
mechanisms.
Meanwhile, we do not know the exact mechanisms whereby high
glucose stimulates AGI expression through hnRNP F or K. We hypothesize
that high glucose stimulates hnRNP F and K nuclear translocation via
phosphorylation in RPTCs (Chapter 5).
6.3 Gene Chip Microarrays to ldentify Downstream Genes that are
Differentially Regulated by hnRNP F and hnRNP K in RPTCs
Both hnRNP F and hnRNP K could be involved in different cellular
roles. It is not known whether other genes regulated by hnRNP F and K
also have functions in AGI expression. b establish whether other genes
besides AGI could be modulated by hnRNP F or K, we will isolate RNA
from stable transfectants of hnRNP F and hnRNP K, or RPTCs from
hnRNP F-1g mice for gene chip microarray assay. Gene chip microarray is
widely used to screen gene expression profiles under different conditions.
Ihrough microarray technology, we can acquire valuable information about
229
other genes reguiated by hnRNP F and hnRNP K, which should help us
know more about hnRNP F and hnRNP K functions.
6.4 Potential Gene Iherapy with hnRNP F and hnRNP K
As mentioned above, AGI mRNA overexpression might be due to
decreased hnRNP F or K expression in diabetic animais. Ihe introduction
of hnRNP F or K couid prevent or attenuate hypergiycemic or other effects
in diabetes, raising the possibiiity of deveioping gene therapy of the
disease. Since data from clinical triais have disclosed that ARBs and ACEi
are unabie to cure diabetes in patients but significantiy slow disease
progression, combined treatment of RAS blockers and hnRNP F or K
introduction may be successfui. Obviousiy, more studies are needed to
explore these possibiiities.
Data from my studies have opened up a new area of research into renal
RAS reguiation. 2D gel electrophoresis, Southwestern bloffing and MS for
the identification of transcription factors represent powerful toois to clone
unknown functional DNA-binding proteins. The kidney-specific expression of
hnRNP F in Tg mice is an appropriate approach to investigating the
functional roles of hnRNP F in the diabetic kidney in vivo. Our studies shouid
garner novel information on the regulation of intrarenal AGI gene expression
and RAS activation in the pathogenesis of DN.
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